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Abstract 
 
Type 2 Diabetes Mellitus is a serious disease and a cause for growing public health 
concern in both developed and developing countries.  Diabetes is a typical chronic disease 
that demonstrates the need for integrated and multifaceted approaches to achieve good 
control. Poor adherence to the treatment for diabetes results in avoidable suffering for the 
patients and excess costs to the health system.  Poor adherence to recognized standards of 
care is the principal cause of development of complications of diabetes and their associated 
individual, societal and economic costs.   
 
Aim of the study is to determine the prevalence of non-compliance among type 2 diabetes 
patients in Gaza- Strip and associated factors, and to suggest measures for improving 
compliance. 
A cross-sectional study was conducted among diabetic patients from both genders with 
proved type-2 diabetes mellitus from different districts of Gaza Strip who registered at Al-
Rimal Diabetic Central Clinic. A sample of 216 patients was chosen by convenient 
sampling method, Data collection was carried out using retrospective review of medical 
records, structured face to face questionnaire and bio-physiological measures. Compliance 
with the medication regimen was measured by the indirect method which included 
questioning the patient and bio-physiologic markers. 
  
The prevalence of non compliance in the study population was 50.5%, farther more 
compliance to non- pharmacological treatment was poor, 38.9% were found not following 
any diet regimen and was significantly associated with non compliance and 61.6% of 
respondents were found not exercising at all. The result showed that 75.5% of study 
population had  poor glycemic control measured according to HbA1c as an indicator of 
therapeutic outcome.  
Typical reasons cited by patients for non compliance included forgetfulness (66.4%), 
frustration (24.3%), feeling better without treatment(19.6%), polypharmacy (14%), fear 
from drug side-effect (12.1%) and  unavailability of drugs (8.4%).  
Poor knowledge of drug side-effect, Patients' feeling (not to take their medicine or feeling 
in need for a rest period), negative attitude regarding taking a missed dose have  a 
significant relationship with non compliance. 
Polypharmacy, unavailability of drugs, presence of complications of diabetes in general 
and  ophthalmic and diabetic foot complication in particular were  reported to have  
significantly higher rates of  non compliance. 
Socio-demographic factors (age, gender, locality, consanguinity,  marital status, family size 
educational level and income) were found to have no significance effect on compliance 
rates, while low socio-economic status, positive family history regarding the mother, 
associated ischemic heart disease were found to have a negative significant effect on 
compliance. 
The majority of study population had associated risk factors; uncontrolled blood 
pressure(68.5%), hypercholesterolemia(64.8%), hyper triglyceridemia (68.5%), and 
obesity (63%). but hypertriglyceridemia and obesity were significantly increased among 
non compliance. 
 
V 
 
Most of the study population (88%), mentioned that they respect their appointment to the 
diabetic clinic, the proportion who did not omit their appointment related the causes to the 
increasing waiting time or to that doctors did not give them their care or attention.   
Improving compliance could be achieved by identifying the barriers and overcoming 
factors that impede compliance.  Efforts must work in the context of changing patients' self 
awareness of their values, needs, and goals for diabetes care, encouraging and enhancing  
specific training in adherence management for practitioners and staff nurses, and 
increasing efforts by policy makers for creation and adoption of chronic care models of 
service delivery, for improving access to medicines and health care, decreasing waiting 
time and to offer medications for all patients. 
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 ﻤﻠﺨﺹ ﺍﻟﺩﺭﺍﺴﺔ
ﻴﻌﺘﺒﺭ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻤﻥ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺃﺤﺩ ﺍﻷﻤﺭﺍﺽ ﺍﻟﺘﻲ ﺘﺤﺘل ﻤﻜﺎﻨﺔ ﻫﺎﻤﺔ ﻤﻥ ﺒﻴﻥ ﺍﻷﻤﺭﺍﺽ ﺍﻟﻤﺯﻤﻨﺔ 
ﻜﻤﺎ ﻭﺃﻨﻪ ﻤﺸﻜﻠﺔ ﻤﺅﺭﻗﺔ ﻟﻠﺼﺤﺔ ﺍﻟﻤﺠﺘﻤﻌﻴﺔ ﻓﻲ ﻜل ﻤﻥ ﺍﻟﺩﻭل ﺍﻟﻤﺘﻁﻭﺭﺓ ﻭﺍﻟﻨﺎﻤﻴﺔ ﻜﻤﺎ ﻭﺍﻨﻪ ﻴﺤﺘﺎﺝ ﺇﻟـﻲ 
ﻤﻥ ﺠﻬﺎﺕ ﻤﺘﻨﻭﻋﺔ ﻟﻠﺤﺼﻭل ﻋﻠﻰ ﺍﻟﻀﺒﻁ ﺍﻟﻤﻌﻴﺎﺭﻱ ﻭﺍﻟﻤﻁﻠﻭﺏ ﻟﻪ، ﺇﻥ ﻨﻘﺹ ﻤﻁﺎﻭﻋﺔ  ﺠﻬﻭﺩ ﻤﺘﻀﺎﻓﺭﺓ 
ﻟﻠﺨﻁﺔ ﺍﻟﻌﻼﺠﻴﺔ ﻴﺅﺩﻱ ﺇﻟﻲ ﻨﺘﺎﺌﺞ ﻭﺨﻴﻤﺔ ﻋﻠﻰ ﺤﻴﺎﺓ ﺍﻟﻤﺭﻀـﻰ ﻭﻴﺯﻴـﺩ ﻤـﻥ ( ﻋﺩﻡ ﺍﻻﻟﺘﺯﺍﻡ)ﺍﻟﻤﺭﻀﻰ 
ﺇﻥ ﻨﻘﺹ ﻤﻁﺎﻭﻋﺔ ﺍﻟﻤﺭﻀـﻰ ﻟﻠﻤﻌـﺎﻴﻴﺭ ﺍﻟﻘﻴﺎﺴـﻴﺔ . ﺍﻷﻋﺒﺎﺀ ﺍﻟﻤﺎﻟﻴﺔ ﺍﻟﻤﻠﻘﺎﺓ ﻋﻠﻰ ﻜﺎﻫل ﺍﻟﺠﻬﺎﺯ ﺍﻟﺼﺤﻲ
ﻟﺭﺌﻴﺴﻲ ﻟﻅﻬﻭﺭ ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻤﺨﺘﻠﻔﺔ ﻋﻨﺩ ﻤﺭﻀﻰ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ، ﻭﻤﺎ ﻴﻨﺠﻡ ﻋﻨﻬﺎ ﺍﻟﺼﺤﻴﺔ ﻟﻬﻭ ﺍﻟﺴﺒﺏ ﺍ
  .ﻤﻥ ﺯﻴﺎﺩﺓ ﺍﻷﻋﺒﺎﺀ ﺍﻟﻤﺎﻟﻴﺔ ﺍﻟﻔﺭﺩﻴﺔ ﻭﺍﻟﻤﺠﺘﻤﻌﻴﺔ
ﻋﻨـﺩ ( ﻭﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﺭﺍﻓﻘـﺔ ﻟﻬـﺎ ) ﺇﻥ ﻫﺩﻑ ﺍﻟﺩﺭﺍﺴﺔ ﻫﻭ ﻤﻌﺭﻓﺔ ﻤﻌﺩل ﺤﺩﻭﺙ ﻅﺎﻫﺭﺓ ﻋﺩﻡ ﺍﻻﻟﺘﺯﺍﻡ 
ﺍﻟﺩﺭﺍﺴﺔ ﺇﻟـﻲ ﺍﻟﺘﻭﺼـل ﺇﻟـﻲ ﻤﺭﻀﻰ ﺍﺭﺘﻔﺎﻉ ﺴﻜﺭ ﺍﻟﺩﻡ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻓﻲ ﻗﻁﺎﻉ ﻏﺯﺓ، ﻜﻤﺎ ﺘﻬﺩﻑ 
  .ﻤﻌﺎﻴﻴﺭ ﺨﺎﺼﺔ ﺘﺯﻴﺩ ﻤﻥ ﻨﺴﺒﺔ ﺍﻟﺘﺯﺍﻡ ﺍﻟﻤﺭﻀﻰ
ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ  ﻫﻲ ﺩﺭﺍﺴﺔ ﻤﻘﻁﻌﻴﺔ ﻋﻠﻰ ﻤﺭﻀﻰ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻤﻥ ﻜﻼ ﺍﻟﺠﻨﺴﻴﻥ ﻤـﻥ 
ﻤﺨﺘﻠﻑ ﺍﻟﻤﻨﺎﻁﻕ ﻓﻲ ﻗﻁﺎﻉ ﻏﺯﺓ ﻭﺍﻟﻤﺴﺠﻠﻴﻥ ﻀﻤﻥ ﻋﻴﺎﺩﺓ ﺍﻟﺭﻤﺎل ﺍﻟﻤﺭﻜﺯﻴﺔ،  ﻟﻘﺩ ﺘﻡ ﺠﻤﻊ ﻋﻴﻨـﺔ ﻤـﻥ 
ﻤﺭﻴﺽ، ﻭﻗﺩ ﺠﻤﻌﺕ ﺍﻟﻤﻌﻠﻭﻤـﺎﺕ ﻭ ﺍﻟﻤﻘـﺎﻴﻴﺱ  612ﻠﻎ ﻋﺩﺩ ﻫﺫﻩ ﺍﻟﻌﻴﻨﺔ ﺍﻟﻤﺭﻀﻰ ﺒﻁﺭﻴﻘﺔ ﺘﻭﺍﻓﻘﻴﺔ ﻭﻴﺒ
ﺍﻟﺒﻴﻭﻓﺴﻴﻭﻟﻭﺠﻴﺔ ﺒﺎﻟﺘﺤﻠﻴل ﺍﻟﺭﺍﺠﻊ ﻟﻠﺴﺠﻼﺕ ﺍﻟﻁﺒﻴﺔ ﻭﺃﻴﻀﺎﹰ ﻤﻥ ﺨﻼل ﺍﻻﺴﺘﺒﻴﺎﻨﺎﺕ ﺍﻟﺘﻲ ﺘﻡ ﺠﻤﻌﻬـﺎ ﻤـﻥ 
  .ﺨﻼل ﺍﻟﻤﻘﺎﺒﻼﺕ ﺍﻟﻤﺒﺎﺸﺭﺓ ﻤﻊ ﺍﻟﻤﺭﻀﻰ
ﺍﻻﻟﺘـﺯﺍﻡ  ، ﻭﺃﻜﺜﺭ ﻤﻥ ﺫﻟـﻙ ﻓـﺈﻥ %5.05ﻭﻗﺩ ﻭﺠﺩ ﺃﻥ ﻤﻌﺩل ﻅﺎﻫﺭﺓ ﻋﺩﻡ ﺍﻻﻟﺘﺯﺍﻡ ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ 
ﻤﻥ ﺍﻟﻌﻴﻨﺔ ﻻ ﻴﺘﺒﻌﻭﻥ ﺃﻱ ﺒﺭﺍﻤﺞ ﺼﺤﻴﺔ ﻏﺫﺍﺌﻴـﺔ % 9.83ﺒﺎﻟﻌﻼﺝ ﻏﻴﺭ ﺍﻟﺩﻭﺍﺌﻲ ﻜﺎﻥ ﺴﻴﺌﺎ،ﻓﻘﺩ ﺘﺒﻴﻥ ﺃﻥ 
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ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﺍﻟﻤﺩﺭﻭﺴـﺔ ﻻ ﻴﺘﺒﻌـﻭﻥ ﺃﻱ ﺘﻤـﺎﺭﻴﻥ % 6.16ﻭﻭﺠﺩ ﺃﻥ  ,ﻭﻟﻜل ﻤﻥ ﺫﻟﻙ ﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ
ﺴـﺔ ﻤﻥ ﺍﻟﺤـﺎﻻﺕ ﺍﻟﻤﺩﺭﻭ % 5.57ﺭﻴﺎﻀﻴﺔ، ﻭﻭﺠﺩ ﺃﻥ ﻀﺒﻁ ﻤﺴﺘﻭﻯ ﺍﻟﺴﻜﺭ ﻓﻲ ﺍﻟﺩﻡ ﻜﺎﻥ ﺴﻴﺌﺎﹰ ﻋﻨﺩ 
ﻜﻤﺸـﻌﺭ ﺒﻴﻭﻓﺴـﻴﻭﻟﻭﺠﻲ ( c1AbH)ﻭﺫﻟﻙ ﻋﻨﺩ ﻗﻴﺎﺱ ﻫﺫﺍ ﺍﻟﻀﺒﻁ ﺒﻤﺴﺘﻭﻯ ﺍﻟﻬﻤﻭﻏﻠﻭﺒﻴﻥ ﺍﻟﺠﻠﻭﻜﻭﺯﻱ 
  . ﻟﻠﺤﺎﻟﺔ ﺍﻟﻌﻼﺠﻴﺔ
ﻤﻨﻬـﺎ  ﺒﺴـﺒﺏ % 4.66ﻥﺇﻥ ﺍﻷﺴﺒﺎﺏ ﺍﻟﺘﻲ ﺘﻡ ﺍﻟﺘﻭﺼل ﺇﻟﻴﻬﺎ ﺒﺎﻟﺩﺍﺭﺴﺔ ﻭﺍﻟﻤﺴﺌﻭﻟﺔ ﻋﻥ ﻋﺩﻡ ﺍﻻﻟﺘﺯﺍﻡ ﻜﺎ
ﺇﺤﺴﺎﺴﻬﻡ ﺒﺎﻟﺘﺤﺴﻥ ﻨﺘﻴﺠﺔ % 6.91ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﺒﺴﺒﺏ ﺍﻟﺸﻌﻭﺭ ﺒﺎﻟﻤﻠل ﻭﺍﻹﺤﺒﺎﻁ، ﻭ% 3.42ﺍﻟﻨﺴﻴﺎﻥ، ﻭ
ﺒﺴﺒﺏ ﺍﻟﺨـﻭﻑ % 1.21ﻭ  ﻨﺘﻴﺠﺔ ﺘﻌﺩﺩ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﻴﺘﻨﺎﻭﻟﻬﺎ ﺍﻟﻤﺭﻴﺽ،% 41ﻋﻨﺩ ﻋﺩﻡ ﺃﺨﺫ ﺍﻟﻌﻼﺝ، ﻭ
  . ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﻻ ﻴﺠﺩﻭﻥ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻭﺼﻭﻓﺔ ﻟﻬﻡ% 4.8ﻭ ,ﻤﻥ ﺍﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻠﻌﻼﺝ
ﻴﻨﻬﺎ ﻭﺒـﻴﻥ ﻜﻤﺎ ﺃﻥ ﻫﻨﺎﻙ ﺠﻤﻠﺔ ﻤﻥ ﺍﻷﺴﺒﺎﺏ ﺍﻟﻤﺘﻨﻭﻋﺔ ﻗﺩ ﻭﺠﺩﺕ ﺒﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻋﻨﺩ ﺩﺭﺍﺴﺔ ﺍﻟﻌﻼﻗﺔ ﺒ
ﻋﺩﻡ ﺍﻟﺭﻏﺒﺔ ﺒﺄﺨـﺫ )ﻗﻠﺔ ﺍﻟﻤﻌﺭﻓﺔ ﺒﺎﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻠﺩﻭﺍﺀ، ﺍﻟﻤﺸﺎﻋﺭ ﺍﻟﻤﺨﺘﻠﻔﺔ ﺘﺠﺎﻩ ﺍﻟﺩﻭﺍﺀ : ﻋﺩﻡ ﺍﻻﻟﺘﺯﺍﻡ
  . ، ﻭﺴﻠﻭﻙ ﺍﻟﻤﺭﻴﺽ ﺍﻟﺴﻠﺒﻲ ﺘﺠﺎﻩ ﺃﺨﺫ ﺍﻟﺠﺭﻋﺔ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﻤﻨﺴﻴﺔ(ﺍﻟﺩﻭﺍﺀ ﺃﻭ ﺍﻟﺭﻏﺒﺔ ﺒﺄﺨﺫ ﻗﺴﻁ ﻤﻥ ﺍﻟﺭﺍﺤﺔ
ﻭﺩ ﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺒﺸـﻜل ﻜﻤﺎ ﺃﻥ ﺘﻌﺩﺩ ﺍﻷﺩﻭﻴﺔ ﺃﻭ ﻋﺩﻡ ﺘﻭﻓﺭﻫﺎ ﻓﻲ ﺍﻟﻤﺭﺍﻜﺯ ﺍﻟﺼﺤﻴﺔ، ﻭﻭﺠ
ﻋﺎﻡ، ﻭﺒﺸﻜل ﺨﺎﺹ ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻨﺎﺠﻤﺔ ﻋﻥ ﺇﺼﺎﺒﺔ ﺍﻟﻌﻴﻥ ﻭﺍﻟﻘﺩﻤﻴﻥ، ﺃﺩﺕ ﺇﻟﻰ ﺯﻴـﺎﺩﺓ ﻨﺴـﺒﺔ ﻋـﺩﻡ 
ﻜﻤـﺎ ﻭﺠـﺩ ﺃﻥ ﺍﻟﻌﻭﺍﻤـل ﺍﻟﺴـﻜﺎﻨﻴﺔ , ﻭﺴﺔ ﻭﻜﺎﻥ ﻟﻬﺎ ﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻫﺎﻤـﺔ ﺍﻻﻟﺘﺯﺍﻡ ﻓﻲ ﺍﻟﻌﻴﻨﺔ ﺍﻟﻤﺩﺭ
ﺍﻻﺠﺘﻤﺎﻋﻴـﺔ ، ﺤﺠـﻡ ﺍﻟﻌﺎﺌﻠـﺔ ،  ﺍﻟﻌﻤﺭ ، ﺍﻟﺠﻨﺱ ، ﺍﻟﻤﻭﺍﻁﻨﺔ ، ﺩﺭﺠﺔ ﺍﻟﻘﺭﺍﺒﺔ ، ﺍﻟﺤﺎﻟـﺔ )ﻭﺍﻻﺠﺘﻤﺎﻋﻴﺔ 
ﻟﻴﺱ ﻟﻬﺎ ﺃﻱ ﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻋﻨﺩ ﺩﺭﺍﺴﺘﻬﺎ ﺒﻨﻘﺹ ﺍﻟﻤﻁﺎﻭﻋﺔ، ﺒﻴﻨﻤﺎ ﺍﻷﻭﻀـﺎﻉ ( ﻤﺴﺘﻭﻯ ﺍﻟﺘﻌﻠﻴﻡ ﻭﺍﻟﺩﺨل
ﻟﻺﺼﺎﺒﺔ ﺒﺎﻟﺩﺍﺀ ﺍﻟﺴـﻜﺭﻱ ﻤـﻥ ﺠﻬـﺔ ﺍﻷﻡ   ﺘﺎﺭﻴﺦ ﻤﺭﺽ ﻟﻠﻌﺎﺌﻠﺔﺍﻻﺠﺘﻤﺎﻋﻴﺔ ﺍﻻﻗﺘﺼﺎﺩﻴﺔ ﻭﻜﺫﻟﻙ ﻭﺠﻭﺩ 
  .ﻋﻠﻰ ﻤﺩﻯ ﺍﻻﻟﺘﺯﺍﻡﻭﺘﺭﺍﻓﻕ ﺃﻤﺭﺍﺽ ﻨﻘﺹ ﺍﻟﺘﺭﻭﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻜﺎﻥ ﻟﻬﺎ ﺍﻷﺜﺭ ﺍﻟﺴﻠﺒﻲ 
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ﺍﺭﺘﻔﺎﻉ ﻀـﻐﻁ : ﻭﻟﻘﺩ ﻭﺠﺩ ﺃﻥ ﻏﺎﻟﺒﻴﺔ ﺍﻟﻌﻴﻨﺔ ﺍﻟﻤﺩﺭﻭﺴﺔ ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﻤﺘﻭﺍﻓﻘﺔ ﻤﻊ ﻋﻭﺍﻤل ﺍﻟﺨﻁﺭ ﺍﻟﺘﺎﻟﻴﺔ
، %(5.86)، ﺍﺭﺘﻔﺎﻉ ﺍﻟـﺩﻫﻭﻥ ﺍﻟﺜﻼﺜﻴـﺔ %(8.46)، ﺍﺭﺘﻔﺎﻉ ﻜﻭﻟﺴﺘﺭﻭل ﺍﻟﺩﻡ %(5.86)ﺍﻟﺩﻡ ﺍﻟﺸﺭﻴﺎﻨﻲ 
ﺩﻻﻟﺔ ﺇﺤﺼﺎﺌﻴﺔ ﻤـﻊ ﻋـﺩﻡ  ﻭﻗﺩ ﻭﺠﺩ ﺃﻥ ﻜل ﻤﻥ ﺍﺭﺘﻔﺎﻉ ﺍﻟﺩﻫﻭﻥ ﺍﻟﺜﻼﺜﻴﺔ ﻭﺍﻟﺴﻤﻨﺔ ﻟﻬﺎ%(.  36)ﺍﻟﺴﻤﻨﺔ 
  . ﺍﻻﻟﺘﺯﺍﻡ
ﻤﻥ ﺍﻟﻌﻴﻨﺔ ﺍﻟﻤﺩﺭﻭﺴﺔ  ﻤﻠﺘﺯﻤﻭﻥ ﺒﺎﻟﺯﻴﺎﺭﺍﺕ ﺍﻟﺩﻭﺭﻴﺔ ﻟﻠﻁﺒﻴﺏ ﺍﻟﻤﺸﺭﻑ ﻋﻠﻰ ﺍﻟﻌـﻼﺝ %88ﻭ ﻗﺩ ﻭﺠﺩ ﺃﻥ
ﺃﻤﺎ ﺍﻟﻤﺘﺒﻘﻲ ﻤﻥ ﺍﻟﻌﻴﻨﺔ ﺍﻟﻤﺩﺭﻭﺴﺔ ﻭﺠﺩ ﺃﻥ ﻋﺩﻡ ﺍﻟﺘﺯﺍﻤﻬﻡ ﺒﺎﻟﻤﺭﺍﺠﻌﺎﺕ ﺍﻟﺩﻭﺭﻴـﺔ ﻟﻌﻴـﺎﺩﺓ .  ﻓﻲ ﺍﻟﻌﻴﺎﺩﺍﺕ
  . ﻤﻥ ﻋﺩﻡ ﺍﻜﺘﺭﺍﺙ ﺍﻟﻁﺒﻴﺏ ﺒﻭﻀﻌﻬﻡ ﺍﻟﺼﺤﻲﺍﻟﺴﻜﺭﻱ ﻴﺭﺠﻊ ﺇﻟﻲ ﺯﻴﺎﺩﺓ ﻭﻗﺕ ﺍﻻﻨﺘﻅﺎﺭ ﺃﻭ ﺍﺴﺘﻴﺎﺌﻬﻡ 
ﻟﺫﻟﻙ ﻴﺠﺏ ﺒﺫل ﻜـل , ﻴﻤﻜﻥ ﺍﻟﺘﻭﺼل ﺇﻟﻰ ﺘﺤﺴﻴﻥ ﺍﻻﻟﺘﺯﺍﻡ ﻋﻥ ﻁﺭﻴﻕ ﺘﺤﺩﻴﺩ ﺍﻟﻤﻌﻴﻘﺎﺕ ﻭ ﺍﻟﺘﻐﻠﺏ ﻋﻠﻴﻬﺎ 
ﺍﻟﺠﻬﻭﺩ ﻨﺤﻭ ﺘﻐﻴﻴﺭ ﺤﺎﻟﺔ ﻭﻋﻲ ﺍﻟﻤﺭﻀﻰ ﺘﺠﺎﻩ ﺍﻷﻫﺩﺍﻑ ﻭ ﺍﻻﺤﺘﻴﺎﺠﺎﺕ ﺍﻟﺼﺤﻴﺔ ﺍﻟﻼﺯﻤﺔ  ﻟﻠﻌﻨﺎﻴﺔ ﺒـﺩﺍﺀ 
ﻟﺘﺯﺍﻡ ﻟﻜل ﻤﻥ ﺍﻷﻁﺒﺎﺀ ﺍﻟﻤﻤﺎﺭﺴـﻴﻥ ﻭ ﺍﻟﻁـﺎﻗﻡ ﻭ ﺘﺸﺠﻴﻊ ﻋﻘﺩ ﺩﻭﺭﺍﺕ ﺘﺩﺭﻴﺒﻴﺔ ﺤﻭل ﻋﺩﻡ ﺍﻻ, ﺍﻟﺴﻜﺭﻱ 
ﻜﻤﺎ ﻭ ﻴﻠﺯﻡ ﺯﻴﺎﺩﺓ ﺍﻟﺠﻬﻭﺩ ﺍﻟﻤﺒﺫﻭﻟﺔ ﻤﻥ ﻗﺒل ﺼﻨﺎﻉ ﺍﻟﻘﺭﺍﺭ ﻟﻌﻤل ﻨﻤﺎﺫﺝ ﺘﺴﻬل ﺍﻟﺤﺼـﻭل , ﺍﻟﺘﻤﺭﻴﻀﻲ 
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Definition 
 
Anti diabetic drug :is a drug used to treat diabetes mellitus (CDC, 2005).  
Blood pressure: is the force of blood on the inside walls of blood vessels, measured by 
analyzing both the systolic blood pressure, the pressure when the heart pushes blood out 
into the arteries, and the diastolic blood pressure, when the heart is at rest (CDC, 2005).  
Body Mass Index (BMI): a bodymass index (the weight in kilograms divided by the 
square of the height in meters), (CDC,2005). 
 
Chronic diseases: Diseases which have one or more of the following characteristics: they 
are 
permanent, leave residual disability, are caused by nonreversible pathological alteration, 
require special training of the patient for rehabilitation, or may be expected to require a 
long period of supervision, observation or care (CDC, 2005). 
 
Compliance: The World Health Organization (WHO) has defined the compliance as “the 
extent to which a person’s behaviour – taking medication, following a diet and/or executing 
lifestyle changes, corresponds with agreed recommendations from a healthcare provider 
(WHO, 2003). 
 
Daonil : an antidiabetic sulfonylurea derivative (CDC, 2005).  
XVII 
 
 
Diabetes Mellitus: is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of 
various organs, especially the eyes, kidneys, nerves, heart, and blood vessels (ADA, 2005). 
Diabetic retinopathy: is diabetic eye disease that results from damage to the small blood 
vessels in the retina, the back part of the eye that contains the cells that respond to light. It 
may lead to loss of eyesight (CDC, 2005).  
Exercise: is a subset of physical activity: planned, structured, and repetitive bodily 
movement performed to improve or maintain one or more components of physical fitness. 
Examples include walking, bicycling, jogging, swimming, water aerobics, and many sports 
(ADA, 2005). 
Glucose intolerance: is a condition in which the body has blood sugar levels higher than 
normal, but not high enough to classify as diabetes. It is diagnosed using an oral glucose 
tolerance test which requires a fasting period of 8 to 12 hours and the blood sugar is 
measured both fasting and 2 hours after drinking a high-sugar drink (CDC, 2005).  
Glycosylated hemoglobin: HbA1c is a derivative of the normal adult hemoglobin, 
hemoglobin A, and is formed in small amounts through the nonenzymatic glycosylation of 
hemoglobin A during periods of elevated plasma glucose (Pawlson, 2000). 
XVIII 
 
Hyperlipidemia: The term hyperlipidemia means high lipid levels. Hyperlipidemia 
includes several conditions, but it usually means that you have high cholesterol and high 
triglyceride levels (SVS, 2006). 
Insulin: is a hormone that is needed to convert sugar, starches, and other food into energy 
needed for daily life (CDC, 2005).  
Metformin: is a medicine pill used to treat type 2 diabetes because it lowers blood sugar 
levels by reducing the amount of sugar produced by the liver and helping the body respond 
better to insulin (CDC, 2005).  
Obesity: is defined as a body mass index (BMI) of =>30 kg/m2. Overweight: is defined as 
a body mass index (BMI) of 25 to 29.9 kg/m2,  (CDC, 2005).  
Physical activity: Physical activity is defined as bodily movement produced by the 
contraction of skeletal muscle that requires energy expenditure in excess of resting energy 
expenditure (ADA, 2005). 
Smoking cessation: is generally defined as complete abstinence from the use of smoked 
tobacco.The duration of the studies varied from 12 weeks to 24 weeks, (CDC, 2005). 
Type 2 diabetes: is a complex metabolic disorder characterized by hyperglycaemia and 
associated with a relative deficiency of insulin secretion, along with a reduced response of 
target tissues to insulin (insulin resistance), (Show, 2003). 
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ist of abbreviation 
ADRs Adverse Drug Reactions
ADA American Diabetes Association
ASCP American Society of Consultant Pharmacist   
BMI Body Mass Index 
CDC Centers for Disease Control and Prevention
CHOs Carbohydrates  
CVD Cardiovascular Disease  
DCCT Diabetes Control and Complications Trial
DM Diabetes Mellitus
FPG Fasting Plasma Glucose 
GS  Gaza Strip
GDM Gestational Diabetes Mellitus  
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GNP Gross National Product
HbA1c Glycated hemoglobin A 
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MODY Maturity-Onset Diabetes of the Young 
MNT Medical Nutrition Therapy  
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MPG Medical Practice Guidelines  
NHS National Health Systyem
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PNA Palestinian National Authority  
PHC Primary Health Care
QIP Quality Improvement Program  
SMBG Self-monitoring of Blood Glucose  
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UPMRC The Union of Palestinian Medical Relief Committee
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 1
Chapter 1 
Introduction 
 
Diabetes mellitus (DM), especially type 2 diabetes is a serious disease and a cause for growing 
public health concern in both developed and developing countries.  In many countries it is now 
a leading cause of death, disability and a high health care cost.  The World Health Report 1997 
paid attention to diabetes: World Health Organization (WHO) warns that diabetes is one of the 
most daunting challenges posed today by virtue of its frequency, and the cost and suffering 
imposed by its complications.  Also, diabetes is no longer a disease of the affluent, it is now a 
third world problem and the developing countries will bear the brunt of the diabetes epidemic 
in the 21st century (MOH, 2002).  There is strong evidence that many patients with chronic 
illnesses including diabetes have difficulty adhering to their recommended regimens.              
A number of rigorous reviews have found that, in developed countries, adherence among 
patients suffering chronic diseases averages only 50%.  The magnitude and impact of poor 
adherence in developing countries is assumed to be even higher given the paucity of health 
resources and inequities in access to health care. 
Poor adherence to treatment of chronic diseases is a worldwide problem of striking magnitude. 
It is undeniable that many patients experience difficulty in following treatment 
recommendations.   
The consequences of poor adherence to long-term therapies are poor health outcomes and 
increased health care costs.  Poor adherence to long-term therapies severely compromises the 
effectiveness of treatment making this a critical issue in population health both from the 
perspective of quality of life and of health economics. Interventions aimed at improving 
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adherence would provide a significant positive return on investment through primary 
prevention (of risk factors) and secondary prevention of adverse health outcomes. 
Diabetes is a typical chronic disease that demonstrates the need for integrated and multifaceted 
approaches to achieve good control ( WHO, 2003). 
Diabetes is a chronic illness that requires continuing medical care and patient self-
management education to prevent acute complications and to reduce the risk of long-term 
complications. Diabetes care is complex and requires that many issues, beyond glycemic 
control, be addressed. A large body of evidence exists that supports a range of interventions to 
improve diabetes outcomes (ADA, 2006). 
Diabetes is one of the foremost health challenges facing the world in the new millennium.  It 
has the potential to overwhelm health budgets. Health administrators and health service 
planners need to heed the warnings as the toll from this serious disease mounts             
(McGill, 2001).  Diabetes is highly prevalent, afflicting approximately 150 million people 
worldwide, and this number is expected to rise to 300 million in the year 2025. Much of this 
increase will occur in developing countries and will result from population ageing, unhealthy 
diet, obesity and a sedentary lifestyle. In developed countries, such as the United States, 
diabetes has been reported as the seventh leading cause of death, and the leading cause of 
lower extremity amputation, end-stage renal disease and blindness among persons aged 18–65 
years.  It has been estimated that diabetes costs the United States economy more than 98 
billion dollars per year in direct and indirect costs. It has also been estimated that low-income 
families in the United States supporting an adult member with diabetes devote 10% of their 
income to his or her care, and that this figure rises to 25% in India (WHO, 2003). 
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This study focus on type 2 diabetes patients who are non complaints which take into 
consideration the factors that lead to non compliance, and suggest measures to improve 
compliance.  
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1.1 Justification of study 
 Diabetes is reaching epidemic proportions in many countries of the world as part of the 
"globalization" process, and the WHO predicts a tripling of the current prevalence rates by 
2025 (McGill, 2001).  According to MOH report, in the year 2000 the prevalence rate of DM 
in Palestine is about 9%, also data reported from Rimal-clinic in the year 2002 showed that out 
of total reported cases about 37,9% was among ages between 50-64 years and 11,5% among 
ages under 30 years (MOH, 2005).  As the care of diabetes is based on self- management by 
the patient, who is helped and advised by those with specialized knowledge. The quest for 
improved glycaemic control has made it clear that whatever the technical expertise applied, 
the outcome depends on welling cooperation by the patient.  If accurate information is not 
supplied, misinformation from friends and other patients will take its place.  For this reason, 
many patients have exaggerated fears of, for example, blindness (less than one patient in 20 is 
blind after 30 years of diabetes), death during hypoglycemia (extremely rare), or the risk of 
passing diabetes on to their children (some 5% of offspring of a person with type-1 DM 
develop the condition, whereas about 15% of children of patients with type-2 DM  develop 
this form of diabetes).  The excess  risk to diabetics compared with the general population 
increases as one moves down the body: Stroke is twice as likely.  Myocardial infarction is 3-5 
times as likely and women with diabetes lose their premenopausal protection from coronary 
artery disease.  Amputation of a foot for gangrene is 50 times as likely (Kumar, 2002). 
The consequences of poor adherence to long-term therapies are poor health outcomes and 
increased health care costs. 
On professional level as I am a physician working in primary health care center, I observed 
that many diabetic patients were non compliant to therapy and exposed to complication of 
diabetes, so the problem is in great need to be studied. 
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Few local studies has been conducted to assess compliance across type 2 DM without using 
biological marker to compare the collected data, where it is an essential and valuable tool in 
the last 5 years world wide. 
 
1.2 Objectives 
 
General objectives 
  
To determine the prevalence and associated factors among non-compliance in type 2 diabetes 
patients. 
Specific objectives 
 
1. To Estimate proportion of controlled and uncontrolled type -2 diabetes patients. 
2. To assess knowledge, attitude and practice of non compliance type -2 diabetes patients 
towards management of diabetes. 
3. To determine factors associated with non – compliance type -2 diabetes patients. 
4. To suggest measures for improving compliance with management of type-2 diabetes 
patients. 
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1.3 Demographic context 
Palestinian National Authority (PNA) territories comprise two geographically separated areas: 
West Bank and Gaza Strip. West Bank lies within an area of 5,800 sq. km2 west of the 
Jordanian river.  
Gaza strip is a narrow piece of land lying on the coast of the Mediterranean Sea.  Gaza Strip is 
very crowded place with an area of 362sq. Km2.  Gaza Strip is composed of five provinces: 
North Gaza, Gaza City, Mid- Zone, Khan Younis and Rafah annex (3).  The main income 
source for Gaza population was working in Israel, in addition to the poor agriculture products 
that have to be exported via Israel (PCBS, 2004).  According to the Palestinian Central Bureau 
of Statistics 2006, the estimated population in the Palestinian Territory reached 3.9 million 
persons in mid year 2006, of which about two millions are males and 1.9 million are females. 
The Palestinians are distributed at 2.5 millions in the West Bank and 1.4 million in Gaza Strip. 
The Palestinian Territory population increased by 39% during the period 1997-2006, 
distributed by 45.0% in Gaza Strip and 36.7% in the West Bank. Despite the decline in the 
natural increase rate to 3.3% in the year 2006 compared with 3.8% in 1997 the population will 
continue increasing  (PCBS, 2006). Ministry of health reported according to PCBS, 2004 that 
42.6% of the population in the Palestinian Territory are refugees, they are estimated to 1.6 
million at the end of 2004,  thereof  686,000 (29.9%) in the West Bank and 892,000 (65.5%) 
in Gaza Strip (MOH, 2005).   
According to the most recent estimation as reported by MOH, 2005, 46.3% of the population 
in Palestine is under 15 years; 44.4% in West Bank and 49.4% in Gaza. The percentage of 
Palestinians who are above 65 years in Palestine is 2%; this figure reached 2.2% in West Bank 
and 1.6% in Gaza (MOH, 2005).  The illiteracy rate reached 7.7% of total persons aged         
15 years and over in the Palestinian Territory in 2005; 3.1% among males and 11.1% among 
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females, moreover 7.5% of the persons aged 15 years and over have bachelor and above; 9.2% 
for males and 5.8% for females, its distributed by 7.0% in the West Bank and 8.4% in Gaza 
Strip (PCBS, 2006).   
The nuclear households increased by 10.9% in 2005 compared with 1997, constituting about 
81.3% of the total households in the Palestinian Territory in 2005, compared with 73.3% in 
1997 (PCBS, 2006).  The average household size in the Palestinian Territory is 5.7 persons 
(MOH, 2005).  The Data indicates that dependency ratio in Palestine dropped from 101.3 in 
1997 to 97.5 in 2004. The ratio declined from 94.7 to 91.7 in West Bank and from 114.5 to 
108.5 in Gaza at the same period. (MOH, 2005).  According to the MOH reporting in 2005 the 
total fertility rate (TFR) in Palestine is high in comparison with other countries in the region. 
This may be due to early marriage especially among females, the desire to have many 
children, and the prevailing traditions of the Palestinian society.  However, indicators show 
that TFR started to decline towards the end of the 20th century (MOH, 2005).  Also as 
published by PCBS, 2006 the trend of fertility rate is declining, fertility rate reached 4.6 births 
per woman in the Palestinian Territory during 2004 , of which 4.1 in the West Bank and 5.8 in 
Gaza Strip. While fertility rate in the Palestinian Territory was 6.0 births per woman in 1997 
(PCBS, 2006).  Infant mortality rate in the Palestinian Territory decreased from 27.7 per 1000 
live births during 1990-1994 to 24.2 per 1000 live births during 1999-2003. The life 
expectancy for 2006 in the Palestinian Territory is 71.7 years for males and 73.2 years for 
females (PCBS, 2006).  The crude death rate in the Palestinian Territory in mid of 2005 is 4.0 
deaths per 1000 population (4.1 deaths  in the West Bank, and  3.9 deaths in Gaza Strip in mid 
of 2005). 
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 1.4 Palestinian economy 
As reported by MOH in 2005, according to the Palestinian Ministry of Finance (MOF), the 
Gross National Product (GNP) in Palestine has been subjected to high fluctuations during the 
last five years.  The Gross National production (GNP) was 5,454 million US$ in 1999 and 
decreased to 3,720 million US$ in 2004. Gross Domestic Production (GDP) was 4,517 million 
US$ in 1999 and decreased to 3,286 million US$ in 2004 (MOH, 2005).  The PCBS reported 
that the number of Palestinian workers in Israel decreased from 135,000 in 1999 to 50,100 in 
2004.  The main income source for Gaza population was working in Israel, in addition to the 
poor agricultural products that have to be exported via Israel.  The workers in Gaza and West 
Bank increased from 453,000 in 1999 to 527,600 in 2004 due to the political situation and 
recurrent crisis (MOH, 2005).  The PCBS reported that the unemployment rate reached 25.3% 
in the Palestinian Territory during the first quarter of 2006, distributed by 21.4% in the West 
bank and 34.1% in Gaza Strip.  The estimated poverty rate among Palestinian households in 
the Palestinian Territory during the 2nd quarter 2006 reached 65.8%, distributed by 87.7% in 
Gaza Strip and 54.65 in the West Bank, Estimates showed that about 55.65 of households are 
suffering deep poverty, distributed by 79.8% in Gaza Strip and 43.2% in the West Bank 
(PCBS, 2006). 
The total cost of antidiabetic drugs in MOH which was used in the governmental health 
centers was 732,561US$ in 2004, out of which 623,436 US$ for insulin and 109,125US$ for 
oral antidiabetic agents.  The annual average cost of antidiabetic drug was 812,933 US $ 
during the last 4 years; equal about 5.6% of total drugs expenditure in MOH (MOH, 2004). 
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1.5 Health context 
Over the past years, the Palestinian health care system has developed side by side along with 
the development of Palestinian society in general. 
The four major health providers of health care services in Palestine are: The Palestinian Health 
Authority represented by Ministry of health (MOH), United Nation Relief and Work Agency 
(UNRWA), Non Governmental Organizations (NGOs), and the private sector (MOH, 2005). 
Primary Health Care (PHC) is considered the backbone of the health system.  It is the basic 
level of care provided equally to everyone.  It addresses the common problem in the 
community by providing preventive, curative, and rehabilitative services to maximize health 
and well being (MOH, 2002).  The total number of registered PHC centers in Palestine is 731 
centers (125 centers in Gaza and 606 centers in West Bank).  Distribution by provider shows 
that, there are 413 centers owned and supervised by the MOH with a high percentage of 
56.5%, 53 centers by the UNRWA with a percentage of 7.3% and NGOs have 265 centers 
with a percentage of 36.3% of the total centers.  In Palestine the average ratio of persons per 
center was 4,976 (10,698 in Gaza and 3,796 in West Bank). 
The UNRWA owns and operates 53 centers in Palestine.  The UNRWA  offers health services 
free of charge for all refugees and plays a noticeable role in the vaccination program in 
cooperation with the MOH, in addition to curative services, antenatal and postnatal care and 
other specialized services.  Furthermore, all refugees in Gaza and West Bank have the right of 
accessibility to the governmental health care services. 
In Gaza: the total number of PHC centers is 125 centers in comparison with 100 centers in 
2000, which indicates an increase of 25% in the last five years.  Although  the PHC system in 
Gaza is unique, well established and functioning well, the high population density and the 
overcrowdness of population were responsible for the high ratio of population per centre.   
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MOH owns and operates 56 PHC centers out of which 29 level (II), 19 level (III) and 7 of 
level (IV).  In general, there are 10 centers working 3 shifts (24 hours, emergency services),    
9 centers working 2 shifts and the rest of centers working only one shift, one of which has       
a delivery unit in Gaza City.  The PHC centers provide special health care services in different 
aspects, 44 centers provide antenatal care and family planning services, in addition to 100 
specialized clinics and 25 dental and oral clinics.  About 34 centers have laboratories and      
12 centers have x-Ray units (MOH, 2005). 
The main central clinic in Gaza Strip are: Al-Rimal central clinic which is present in Gaza 
district.   Jabalya central clinic in the South district, Dear El Balah central clinic in the Mid-
zone, Khan-Younis central clinic in Khan-Younis district, and Rafah central clinic in Rafah 
district.  There is specialized clinics for diabetes in all of them.  
Central clinics provide health services to Palestinian patients and all the governmental health 
services are covered by governmental health insurance.  
 
1.6 Al-Rimal clinic 
 
Al-Rimal clinic is one of the central clinic in Gaza district, it provides  health services such as 
specialized clinics for diabetes, hypertension, dermatology, dental and ophthalmology, as well 
as general health care clinic.   
Central diabetic clinic in Al-Rimal provides health services for diabetic patients.  All the new 
cases that are discovered from another PHC clinics from different districs: South, Gaza, Mid-
zone, Khanyounis and Rafah, and referred to central diabetic clinic in Al-Rimal are re-
evaluated by the specialist.  Old cases are routinely and periodically checked.   
There is a continuous improvement and development of MOH diabetic services through 
supplying medicine, equipment, continuous education of the medical team and establishing 
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clinical guidelines in 2004, through the Quality Improvement Program (QIP) Health System 
Project World Bank.  Also improving the diabetes services through updating patient's hard and 
electronic files, which exists only at Al-Rimal central clinic.  The newly introduced a diabetic 
information system (data base) contributed to the rapid improvement for the diabetic services 
including shortening of waiting time for patients as well as reducing the lost-time for doctors 
through rapid and available full data about the patient where information of the study was 
taken.  
Ministry Of Health (MOH) in 2004 reported that the proportion of diabetic patients with 
obesity (BMI >=30) in Al-Rimal health center was 58.7% (43% in males and 69.5% in 
females) while the proportion of overweight diabetic patient was 27.4% (36.6% in males and 
21.1% in females).   
The distribution of diabetic (type II) cases by management in Al-Rimal health clinic is about 
28.1% of all diabetics were managed by insulin treatment.  About 18.7% were treated with a 
combined therapy (insulin and OHA).  Oral anti-diabetic agents was 42.1%. Diet control 
(exclusively managed by lifestyle modification) was 4.7% (MOH, 2005). 
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Chapter 2 
Literature Review 
Diabetes is a typical chronic disease that demonstrates the need for integrated and multifaceted 
approaches to achieve good control. The control of diabetes requires more than just taking 
medicine.  Patients with diabetes usually have co-morbidities that make their treatment 
regimens even more complex. In particular, other commonly associated diseases such as 
hypertension, obesity and depression are themselves known to be characterized by poor rates 
of adherence and serve to further increase the likelihood of poor treatment outcomes. 
Poor adherence to the treatment for diabetes results in avoidable suffering for the patients and 
excess costs to the health system (WHO, 2003).  
2.1  Definition of Diabetes Mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting 
from defects in insulin secretion, insulin action, or both.  The chronic hyperglycemia of 
diabetes is associated with long-term damage, dysfunction, and failure of various organs, 
especially the eyes, kidneys, nerves, heart, and blood vessels (ADA, 2005). 
2.2 Types of Diabetes Mellitus 
American Diabetes Association (2005), stated that assigning a type of diabetes to an individual 
often depends on the circumstances present at the time of diagnosis, and many diabetic 
individuals do not easily fit into a single class.  For example, a person with gestational 
diabetes mellitus (GDM) may continue to be hyperglycemic after delivery and may be 
determined to have, in fact, type 2 diabetes.  Alternatively, a person who acquires diabetes 
because of large doses of exogenous steroids may become normoglycemic once the 
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glucocorticoids are discontinued, but then may develop diabetes many years later after 
recurrent episodes of pancreatitis.  Thus, for the clinician and patient, it is less important to 
label the particular type of diabetes than it is to understand the pathogenesis of the 
hyperglycemia and to treat it effectively. 
2.2.1 Type 1 diabetes  
It is characterized by ß-cell destruction, usually leading to absolute insulin deficiency) It has 
two forms:  
a-Immune-mediated diabetes which result form of diabetes, which accounts for only 5–10% of  
those with diabetes, previously encompassed by the terms insulin-dependent diabetes, type I 
diabetes, or juvenile-onset diabetes, results from a cellular-mediated autoimmune destruction 
of the ß-cells of the pancreas.  
b- Idiopathic diabetes mellitus which refers to some forms of type 1 diabetes have no known 
etiologies (ADA, 2005). 
2.2.2 Type 2 diabetes  
It is ranging from predominantly insulin resistance with relative insulin deficiency to 
predominantly an insulin secretory defect with insulin resistance).  This form of diabetes, 
which accounts for 90–95% of those with diabetes, previously referred to as non-insulin-
dependent diabetes, type 2 diabetes, or adult-onset diabetes, encompasses individuals who 
have insulin resistance and usually have relative (rather than absolute) insulin deficiency at 
least initially, and often throughout their lifetime, these individuals do not need insulin 
treatment to survive.  There are probably many different causes of this form of diabetes. 
Although the specific etiologies are not known, autoimmune destruction of ß-cells does not 
occur.  Most patients with this form of diabetes are obese, and obesity itself causes some 
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degree of insulin resistance.  Patients who are not obese by traditional weight criteria may 
have an increased percentage of body fat distributed predominantly in the abdominal region. 
This form of diabetes frequently goes undiagnosed for many years because the hyperglycemia 
develops gradually and at earlier stages is often not severe enough for the patient to notice any 
of the classic symptoms of diabetes.  Nevertheless, such patients are at increased risk of 
developing macrovascular and microvascular complications.  Whereas patients with this form 
of diabetes may have insulin levels that appear normal or elevated, the higher blood glucose 
levels in these diabetic patients would be expected to result in even higher insulin values had 
their ß-cell function been normal.  Thus, insulin secretion is defective in these patients and 
insufficient to compensate for insulin resistance.  Insulin resistance may improve with weight 
reduction and/or pharmacological treatment of hyperglycemia but is seldom restored to 
normal.  The risk of developing this form of diabetes increases with age, obesity, and lack of 
physical activity.  It occurs more frequently in women with prior GDM and in individuals with 
hypertension or dyslipidemia, and its frequency varies in different racial/ethnic subgroups.  It 
is often associated with a strong genetic predisposition, more so than is the autoimmune form 
of type 1 diabetes.  However, the genetics of this form of diabetes are complex and not clearly 
defined (CDC, 2005). 
2.2.3 Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) 
They are recognized as an intermediate group of subjects whose glucose levels, although not 
meeting criteria for diabetes, are nevertheless too high to be considered normal. Patients with 
IFG and/or IGT are now referred to as having "pre-diabetes" indicating the relatively high risk 
for development of diabetes in these patients. In the absence of pregnancy, IFG and IGT are 
not clinical entities in their own right but rather risk factors for future diabetes as well as 
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cardiovascular disease.  IFG and IGT are associated with the metabolic syndrome, which 
includes obesity (especially abdominal or visceral obesity), dyslipidemia of the high-
triglyceride and/or low-HDL type, and hypertension.  Note that many individuals with IGT are 
euglycemic in their daily lives. Individuals with IFG or IGT may have normal or near normal 
glycated hemoglobin levels.  Individuals with IGT often manifest hyperglycemia only when 
challenged with the oral glucose load used in the standardized OGTT.  
2.2.4 Gestational Diabetes Mellitus (GDM) 
GDM is defined as any degree of glucose intolerance with onset or first recognition during   
pregnancy (ADA, 2005).  It is more common among obese women and women with a family 
history of diabetes.  During pregnancy, gestational diabetes requires treatment to normalize 
maternal blood glucose levels to avoid complications in the infant.  After pregnancy, 5% to 
10% of women with gestational diabetes are found to have type2 diabetes.  Women who have 
had gestational diabetes have a 20% to 50% chance of developing diabetes in the next 5-10 
years (CDC, 2005). 
2.2.5 Other types of diabetes 
American Diabetes Association (ADA) in 2005 stated other types of diabetes as follow: 
a-Genetic defects of the ß-cell: these forms of diabetes are frequently characterized by onset 
of hyperglycemia at an early age (generally before age 25 years).  They are referred to as 
maturity-onset diabetes of the young (MODY) and are characterized by impaired insulin 
secretion with minimal or no defects in insulin action.  They are inherited in an autosomal 
dominant pattern (for example MODY 1,2,3 ). 
b-Genetic defects in insulin action: there are unusual causes of diabetes that result from 
genetically determined abnormalities of insulin action. 
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c-Diseases of the exocrine pancreas : any process that diffusely injures the pancreas can 
cause diabetes.  Acquired processes include pancreatitis, trauma, infection, pancreatectomy, 
and pancreatic carcinoma. 
d-Endocrinopathies: several hormones (e.g., growth hormone, cortisol, glucagons, 
epinephrine) antagonize insulin action.  Excess amounts of these hormones (e.g., acromegaly, 
Cushing’s syndrome, glucagonoma, pheochromocytoma, respectively). 
e-Drug or chemical-induced diabetes:  many drugs can impair insulin secretion.  These 
drugs may not cause diabetes by themselves, but they may precipitate diabetes in individuals 
with insulin resistance.  There are also many drugs and hormones that can impair insulin 
action.  Examples include nicotinic acid and glucocorticoids. 
f-Infections:  certain viruses have been associated with ß-cell destruction.  Diabetes occurs in 
patients with congenital rubella, coxsackie B, cytomegalovirus, adenovirus, and mumps. 
g- Uncommon forms of immune-mediated diabetes.  
h-Other genetic syndromes sometimes associated with diabetes: these include the 
chromosomal abnormalities of Down’s syndrome, Klinefelter’s syndrome, and Turner’s 
syndrome (ADA, 2005). 
2.3 Pathogenesis:  
The American Society of Consultant Pharmacists (ASCP) in 2001 stated that the pathogenesis 
of DM varies with type, type1 DM may be associated with genetic, autoimmune, or viral 
insult, and it may become manifest at any age.  The net result is a steady decrease in insulin 
secretion until the patient presents with the classic triad of polydipsia, polyphagia, and 
polyuria, usually accompanied by weight loss.  Type 2 DM on the otherhand has several 
stages.  In the first stage, obesity in middle age leads to insulin resistance and compensatory 
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hyperinsulinemia.  Insulin, as well as both hypo- and hyperglycemia, contribute to increased 
appetite and craving of foods, especially carbohydrates (CHOs).  This leads to additional 
weight gain, completing the cycle of gradual obesity, hyperinsulinemia, hyperphagia, and 
excessive weight gain. Increased visceral and, to a lesser extent, peripheral fat contribute to 
hepatic insulin resistance, impaired insulin secretion, and peripheral insulin resistance.  These 
insulin changes, in turn, lead to DM, high blood pressure, hyperlipidemia, arteriosclerosis, and 
increased risks for cardiovascular and cerebrovascular disease.  At some point in the DM 
disease process, the hyperinsulinemic state progresses to a relative insulin deficiency state due 
to beta cell "burnout", and exogenous insulin may be required.  Formerly considered part of 
syndrome X, type 2 DM may indeed represent a complex metabolic syndrome that includes 
hypertension, hyperlipdemia, hyperinsulinemia, and insulin resistance, all of which lead to 
early heart, brain, eye, and kidney damage (ASCP, 2001).  
2.4 Epidemiological picture 
2.4.1 Global: 
The epidemic nature of diabetes continues to affect ever-increasing numbers of people around 
the world and the number of people with diabetes is expected to double between 2000 and 
2030 while public awareness remains low (Wild et al. 2004).  According to International 
Diabetes Federation (IDF, 2003) and a recent study done by Wild et al. in 2004 and 
undertaken by the World Health Organization (WHO), it is estimated that 177 million people 
have diabetes in the adult population in the world in 2001 or about 5.2% in the age bracket 20-
79, this is an increase over the 2000 estimate of 151 million and an increase from the 1995 
global estimation of 135 million people with diabetes which was published in a World Health 
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Organization (WHO) study in 1998.  Also in 2004,  it is estimated that around 194 million 
people have diabetes in the adult population in the world.  
 
2.4.2 In Europe 
 
The rapid increase in diabetes in Europe is a major public health issue.  Diabetes is the fourth 
leading cause of death in Europe, and It carries a 3-4 times higher risk of major cardiovascular 
complications and is now the commonest cause of heart attack and stroke and a major cause of 
peripheral vascular disease and peripheral neuropathy leading to a 20 fold higher risk of 
amputation.  The cost of diabetes complications accounts for 5-10% of total healthcare 
spending in several countries including Belgium, France, Germany, Italy, the Netherlands, 
Spain, Sweden and the UK.  In today’s Europe, the average prevalence rate of diabetes is 
7.5%, and about 60 million people live with diabetes, of whom more than 50% are unaware of 
their condition leaving them exposed to the risks and costly complications associated with 
poor control of the illness.  In addition to those 60 million people who have diabetes, it is 
estimated that a further 120 million have pre-diabetes of which 50% will develop diabetes 
within 5 years.  By 2025, the prevalence of diabetes is expected to double in Europe.  The 
prevalence of Type 2 diabetes in France was 3% in 2000.  In Ireland, there were around 
300,000 people with diagnosed or undiagnosed diabetes.  The South-East Asian Region has 
the highest number of people with diabetes mellitus with some 49 million, and its prevalence 
of 7.5% is the second highest, behind North America (7.8%), and ahead of the Eastern 
Mediterranean and Middle East Regions (6.4%), (IDF, 2004). 
According to WHO in 1998, between 1995 and 2025 the number of the adult population 
affected by diabetes mellitus in developing countries is projected to grow by 170%, from 84 to 
228 million people.  By 2025, these countries will be home to 76% of all persons with 
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diabetes, as compared with 62% in 1995.  In the same period, the developed world will see a 
41% increase, from 51 to 72 million people. This more than twofold global increase will occur 
because of population ageing and growth, as well as from obesity, unhealthy diets and a 
sedentary lifestyle.  These latter factors are closely associated with urbanization and 
industrialization.  As they stated these figures are shocking as they represent only clinically 
diagnosed diabetes, and many more cases of diabetes remain undiagnosed and untreated.  In 
addition, up to one-quarter of western populations have impaired glucose tolerance or the 
dysmetabolic syndrome, which are considered to represent pre-diabetic states (WHO,1998). 
 Type 2 diabetes is appearing increasingly in children and adolescents.  The long-term 
complications associated with type 2 diabetes carries a crushing burden of morbidity and 
mortality, and most type 2 diabetic patients die prematurely from a cardiovascular event 
(Zimmet, 2003). Diabetes is most common among the elderly in many populations, while 
prevalence rates are rising alarmingly quickly among comparatively young and productive 
populations in the developing world.  If the present trends persist and if no action is taken to 
address the problem, by 2025 most people with diabetes in developed countries will be aged 
65 years or more, while the majority of diabetic persons in developing countries will be in the 
45-64 year age group.  This means that some 170 million men and women, who will reside in 
the developing regions of the world in less than 30 years from now, will be suffering from 
diabetes in their most productive years of life (WHO, 1998). 
2.4.3 In United States of America ( USA ) 
Total prevalence of diabetes in the United States of America (USA) in all ages is 7.0%. 
Prevalence of diagnosed diabetes in people aged 20 years or younger in the (USA) is 0.22% of 
all people in this age group.  Although type 2 diabetes can occur in youth, the nationally 
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representative data that would be needed to monitor diabetes trends in youth by type are not 
available.  Total prevalence of diabetes among  people aged  20 years or older in United States 
of America is 9.6% of all people in this age group and is 20.9% among people aged 60 years 
or older.  Men are 10.5% of all men aged 20 years or older and women are 8.8% of all women 
aged 20 years or older have diabetes (CDC, 2005).  Many patients with type 2 diabetes are 
asymptomatic and go undiagnosed for many years.  Studies suggest that the average patient 
with new-onset type 2 diabetes actually has had diabetes for at least 4-7 years before the 
diagnosis.  Of patients with type 2 diabetes, 25% are believed to have retinopathy, 9% 
neuropathy, and 8% nephropathy at the time the diagnosis is made (ADA, 2006).  
2.4.4 Regional 
2.4.4.1 The prevalence of DM in Palestine 
The prevalence of DM in Palestine was examined a study conducted in 2000 in cooperation 
with Al-Quds University and MOH.  The preliminary results indicated that the prevalence of 
DM in Palestine is about 9% in 2000.  
 It is around the reported prevalence rate in Egypt and Tunisia (9%) and less than in Saudi 
Arabia (12%) and Oman (13%), (MOH, 2005). 
In 2001, UPMRC (The Union of Palestinian Medical Relief committee) screened 2,482 people 
through their mobile clinics for obesity, hypertension, diabetes and dyslipidemia.  
The preliminary results showed that, overweight (BMI>25) was present in 77%, obesity (BMI 
> 30) in 47%, hypertension in 31%, diabetes in 18% and dyslipidemia in 49%.  These figures 
should be cautiously considered as the targeted population included men and women between 
35 and 65 of age (MOH, 2005). 
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The prevalence of diabetes and associated factors in a cross-sectional survey of urban 
Palestinian population of 492 men and women aged 30–65 years were studied by Abdul-
Rahim et al. in 2001, who found DM in 12.0% of the surveyed population (including 9.4% 
previously diagnosed).  In 2004, according to the Demographic and Health Survey, which was 
done by the Palestinian Central Bureau of Statistics (PCBS), 2.2% of reported persons cases 
suffered from DM, this increased to 21.1% among elderly aged 65 years while it was 11.1% 
among age group of 40- 64years, and 0.4% among age group of 18-39 years (PCBS, 2004).  
Also they indicated that the gap between the expected prevalence rates of DM and cases under 
supervision reflects under registration and underreporting, and requires special efforts to 
accelerate early case-finding activities in order to avoid high cost of treating the complications 
and disability consequences of the disease.  This will give more realistic estimation of the 
prevalence for appropriate evaluation of the problem. 
According to Ministry of Health annual report 2005, in 2004, out of total 623 new reported 
cases of diabetes in Al-Rimal diabetic clinic, of them 31.3% was among age group of 50-64, 
31.0% was among age group of 30-49 years, 18% was among age group 20-29 years, 16.1% 
among age 65 years and over and 3.4% among age group of 5-19 years.  
Distribution of diabetic (type II) cases by management in Al-Rimal health clinic according to 
the MOH annual report, 2005 was as following: 
1. About 28.1% of all diabetics were managed by insulin treatment. 
2. About 18.7% were treated with a combined therapy (insulin and OHA). 
3. Oral anti-diabetic agents was 42.1% 
4. Diet control (exclusively managed by lifestyle modification) was 4.7% 
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While  the visits to diabetes mellitus clinics was as following in 2004, 140,578 visits were 
reported to the governmental PHC-specialized diabetic clinics distributed as 74,011 visits in 
the Gaza Strip compared with 66,567 visits in the West bank (MOH, 2005). 
 
2.4.4.3 Mortality of diabetes mellitus:  in Palestine  
 
DM was not reported as one of  the 10th leading cause of death among Palestinians.  It 
constituted 3.6% of total population deaths.  372 persons died with mortality rate of 10.2 per 
100,000 (176 males, with a rate of 9.5 per 100,000 males and 196 females, with mortality rate 
of 10.9 per 100,000).  The average annual mortality rate of DM was 12.4 per 100,000 
population in the last five years (MOH, 2005). 
 
2.5 Compliance  
Non adherence to treatment protocols is of particular interest and significance in the diabetic 
population.  The diabetic treatment regimen is complex.  It may be modified over the course of 
the disease, is designed for life, does not guarantee recovery, depends largely on the 
responsibility of the patient, and requires active attention to a variety of areas such as: diet, 
exercise, medication, and self-monitoring of blood glucose (Jenny, 1986). 
One of the major problems that arise for persons working with patients with type 2 diabetes is 
the problem of non-compliance (Ferzacca, 2000). 
Compliance can be defined as ‘the extent to which patient’s behavior coincides with medical 
advice (Hunt et al., 1998).  
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2.5.1 WHO historical definition of adherence 
WHO report in 2003 clarified the definition of adherence according to WHO adherence 
meeting in June 2001.  They stated that although most research has focused on adherence to 
medication, adherence also encompasses numerous health-related behaviours that extend 
beyond taking prescribed pharmaceuticals.  The participants at the WHO adherence meeting in 
June 2001 concluded that the definition of adherence as “the extent to which the patient 
follows medical instructions” was a helpful starting point.  However,  the term “medical” was 
felt to be insufficient in describing the range of interventions used to treat chronic diseases. 
Furthermore, the term “instructions” implies that the patient is a passive, acquiescent recipient 
of expert advice as opposed to an active collaborator in the treatment process. 
In particular, it was recognized during the meeting that adherence to any regimen reflects 
behavior of one type or another.  Seeking medical attention, filling prescriptions, taking 
medication appropriately, obtaining immunizations, attending follow-up appointments, and 
executing behavioral modifications that address personal hygiene, self-management of asthma 
or diabetes, smoking, unhealthy diet and insufficient levels of physical activity are all 
examples of therapeutic behaviors.  The participants at the meeting also noted that the 
relationship between the patient and the health care provider (be it physician, nurse or other 
health practitioner) must be a partnership that draws on the abilities of each.  The literature has 
identified the quality of the treatment relationship as being an important determinant of 
adherence.  Effective treatment relationships are characterized by an atmosphere in which 
alternative therapeutic means are explored, the regimen is negotiated, adherence is discussed, 
and follow-up is planned. 
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Finally they adopted the following definition of adherence to long term therapy:    
"The extent to which a person’s behavior – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider" (WHO, 2003). 
 
2.5.2 Medication compliance  
It is defined as the extent to which a person's medication-taking behaviour coincides with 
medical advice (Haynes, 1979).  Despite this definition being dated, a number of authors 
(Kelly, 1995; Cameron, 1996; Balkrishnan, 1998) continue to use this definition in their work. 
Complete medication adherence occurs when the patient follows the instructions completely. 
Partially compliant patients take incorrect doses of their drugs regularly or correct doses more 
or less often than prescribed (Deborah, 2005).  
 
2.5.3 Patient compliance 
As defined by Mark, et al. in 2006 patient compliance is the degree to which a patient follows 
a treatment regimen.  In studies of patient behavior, only about half of patients who leave a 
physician's office with a prescription take the drug as directed.  The most common reason 
given for noncompliance is forgetfulness, which may be more appropriately described as 
denial of illness; having to take a drug is a constant reminder of illness. Older persons may 
take several drugs; the regimen may be complex and hard to remember and to follow, thereby 
increasing the likelihood of an adverse drug interaction (Mark, et al., 2006). 
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2.5.4 Medical non-compliance  
      Following a prescribed course of treatment for a medical or psychological condition can be 
challenging.  Many factors can make adherence difficult, including busy schedules, family 
stress, finances, and remembering instructions.  Not following recommended treatment can be 
dangerous to one’s health; thus, when a person does not follow a doctor-recommended 
treatment regimen, that individual is said to be “medically non-compliant”.  The most 
common forms of medical non-compliance are: not taking prescribed medications, not 
following recommendations for managing a chronic medical condition, and not following 
through with restorative therapy.  Medical non-compliance becomes a significant problem 
when poor adherence to medical treatment or preventative strategies results in delaying or 
worsening a person’s condition and/or increasing disease complications (Deborah, et al., 
2005).  
2.6 Rate of compliance (Adherence) 
      Rates of adherence for individual patients are usually reported as the percentage of the 
prescribed doses of the medication actually taken by the patient over a specified period.  Some 
investigators have further refined the definition of adherence to include data on dose taking 
(taking the prescribed number of pills each day) and the timing of doses (taking pills within a 
prescribed period).  Adherence rates are typically higher among patients with acute conditions, 
as compared with those with chronic conditions; persistence among patients with chronic 
conditions is disappointingly low, dropping most dramatically after the first six months of 
therapy.  The average rates of adherence in clinical trials can be remarkably high, owing to the 
attention study patients receive and to selection of the patients, yet even clinical trials report 
average adherence rates of only 43 to 78 percent among patients receiving treatment for 
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chronic conditions.  The ability of physicians to recognize non-adherence is poor, and 
interventions to improve adherence have had mixed results (Osterberg and Blaschke, 2005). 
 
      2.7 Types of  non-compliance 
      Deborah, et al. in 2005 stated that there is many types of non-compliance such as:  inconsistent 
medication adherence, poor appointment follow through, poor compliance with medical 
homework assignments, poor adherence with dietary recommendation, inconsistent adherence 
to exercise regiment, inconsistent medical data collection, and disease specific measures of 
control. 
      Inconsistent medication adherence (mismedication) can include: failing to initially fill a 
prescription, failing to refill a prescription as directed, omitting a dose(s), over dosing, 
prematurely discontinuing medication, taking a dose at the wrong time, taking a medication 
prescribed for someone else, taking a dose with prohibited foods, liquids, and other 
medications, taking outdated medications, taking damaged medications, storing medications 
improperly and improperly using medication administration devices Rajaei and Pherson in 
1997 suggest that it is generally accepted that non-compliance falls into three categories: 
1- Accidental: the patient forgets to take the dose or takes the medicines incorrectly because 
the instructions were not well understood or could not be followed. 
2- Triggered: the patient starts to feel better and stops taking the medicine, or conversely, the 
patient feels worse, and therefore believes that the medicine is doing no good. 
3-Intentional: the patient makes a conscious decision not to take the medicines as 
recommended (Deborah, et al., 2005). 
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2.8 Risk Factors of diabetes  
2.8.1 Life style modifiable risk factors 
Obesity increases the risk of serious co-morbidities such as type 2 diabetes, cardiovascular 
disease, certain cancers and reduced life expectancy.  The risk of diabetes is particularly 
increased by obesity, and 80-95% of the increase in diabetes can be attributed to obesity and 
overweight with abdominal fat distribution.  A study in Palestine conducted by Sha'at in 2000, 
regarding Diabetes Mellitus Status, where it was found that obesity reported high prevalence 
rates among the study population.  As well another study done by Abu Ramadan in 2004, 
demonstrated that obesity is the major risk factor of type 2 Diabetes Mellitus.  There is robust 
evidence from cross-sectional and longitudinal studies to support that an energy-dense, high 
fat diet and physical inactivity are independent risk factors for weight gain and obesity. 
Furthermore, interaction between dietary fat and physical fitness determine fat balance, so that 
the obesity promoting effect of a high fat diet is enhanced in susceptible subjects, particularly 
in sedentary individuals with a genetic predisposition to obesity.  To prevent obesity and 
diabetes there are grounds for recommending the combination of increasing daily physical 
activity and reducing dietary fat content to 20-25 energy-% in sedentary subjects, and to      
25-35% in more physically active individuals ( Astrup, 2001). 
The public health burden of type 2 diabetes mellitus has been dramatically increased 
worldwide.  Not only its prevalence rate at present but the increase of its incidence in the near 
future can create a global health problem.  The rapid increase of the total number of newly 
diagnosed diabetic patients proved to be associated with the increasing prevalence rate of 
obesity.  The metabolic syndrome and type 2 diabetes can contribute to accelerated 
atherosclerosis and, therefore, the target organ damages can carry a serious problem for the 
individuals and also for the whole society.   It is obvious, that the primary prevention of type 2 
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diabetes mellitus is of great importance.  There is now substantial evidence that type 2 
diabetes can be prevented or delayed by lifestyle interventions, i.e. diet and exercise should be 
the first choice in order to avoid weight gain when preventing diabetes.  The incidence of 
newly diagnosed type 2 diabetes decreased parallel with weight loss (Germendy, 2003).  
Being overweight can be prevented by regular physical activity.  A second, independent 
benefit of regular physical activity is improved blood sugar control in persons who already 
have type 2 diabetes (PHAC, 2001). 
Manson, et al., in 2001 followed 84,941 female nurses from 1980 to 1996; these women were 
free of diagnosed cardiovascular disease, diabetes, and cancer at base line. Information about 
their diet and lifestyle was updated periodically.  A low-risk group was defined according to a 
combination of variables; a bodymass index (the weight in kilograms divided by the square of 
the height in meters) of less than 25; a diet high in cereal fiber and polyunsaturated fat and low 
in trans fat and glycemic load (which reflects the effect of diet on the blood glucose level); 
engagement in moderate-to-vigorous physical activity for at least half an hour per day; no 
current smoking.  During 16 years of follow-up, they documented 3300 new cases of type 2 
diabetes.  Overweight or obesity was the single most important predictor of diabetes.  Lack of 
exercise, a poor diet, and current smoking were all associated with a significantly increased 
risk of diabetes, even after adjustment for the body-mass index.  Their findings support the 
hypothesis that the vast majority of cases of type 2 diabetes could be prevented by the 
adoption of a healthier lifestyle (Manson, et al., 2001).  The Palestinian annual health reports 
(2000, 2003) identified only one risk factor among the Palestinian diabetics, which is the 
obesity (MOH, 2005). 
Obesity is a complex multifactorial chronic disease that develops from an interaction of 
genotype and the environment.  Obesity is clearly associated with increased morbidity and 
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mortality.  There is strong evidence that weight loss in overweight and obese individuals 
reduces risk factors for diabetes and cardiovascular disease (CVD).  Strong evidence exists 
that weight loss reduces blood pressure in both overweight hypertensive and nonhypertensive 
individuals; reduces serum triglycerides and increases high-density lipoprotein (HDL)-
cholesterol; and generally produces some reduction in total serum cholesterol and low-density 
lipoprotein (LDL)-cholesterol.  Weight loss reduces blood glucose levels in overweight and 
obese persons without diabetes; and weight loss also reduces blood glucose levels and HbA1c 
in some patients with type 2 diabetes (Adrienne, 1998). 
According to MOH annual report in 2005, the incidence of diabetic patients with obesity is 
44.5% in males and 55.6% in females in 2000, while in 2002, the incidence of diabetic 
patients with obesity is 60.8% (42.3% in males and 72.4% in females).  
In 2004, Al-Rimal health center  (the only available data in governmental health institution) 
the reported proportion of diabetic patients with obesity (BMI >=30) was 58.7% (43% in 
males and 69.5% in females) while the proportion of overweight diabetic patient was 27.4% 
(36.6% in males and 21.1% in females).  
Regarding the other risk factors such as older age, family history of diabetes, prior history of 
gestational diabetes, impaired glucose tolerance, physical inactivity etc..., there is no 
information or statistics available about them (MOH, 2005). 
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2.8.2 Older age 
Age increases the risk of type 2 diabetes.  In the future there will be more people aged           
65 years and over (older adults).  Although the exact mechanisms underlying normal ageing 
are not fully understood, ageing is generally associated with an increase in chronic diseases, 
such as cardiovascular disease, diabetes, cancer and osteoporosis (McKevith, 2005).  While 
most diabetes occurs in older persons, it should be noted that the appearance of type 2 diabetes 
in children is increasingly being reported in the medical literature (PHAC, 2001). 
 
2.8.3 Family history 
 
The genetic link for type 2 diabetes is stronger than the genetic link for type 1.  Having a 
blood relative with type 2 diabetes increases the risk. If that person is a first-degree relative         
(e.g., a parent, sibling or child), the risk is even higher (PHAC, 2001).  Abu Ramadan, in 
2004, found that positive family history and consanguinity were the most prevalent risk factors 
associated with type 2 Diabetes Mellitus.  A study indicates that a genetic predisposition to 
type 2 diabetes, probably in association with slightly elevated glucose levels, may accelerate 
the development of atherosclerosis and increase the risk for coronary heart disease in glucose-
tolerant individuals (Pannacciulli, 2003). 
 
2.8.4 High blood pressure 
 
Patients with diabetes have a much higher rate of hypertension than would be expected in the 
general population. Regardless of the antihypertensive agent used, a reduction in blood 
pressure helps to prevent diabetic complications. Most diabetic patients with hypertension 
require combination therapy to achieve optimal blood pressure goals. In general, only 25 
percent of patients with hypertension have adequate control of their blood pressure. lifestyle 
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modifications such as exercise and a diet low in salt and high in potassium have clearly been 
shown to decrease blood pressure.  Weight loss and exercise can help to lower blood pressure 
and may also improve glycemic control and insulin sensitivity (Sheeri, et al., 2002).  A cross-
sectional descriptive study was conducted at all UNRWA primary health care facilities in 
Lebanon Field, to assess the quality of care of diabetes mellitus and hypertension.  The study 
reviewed 2202 records of diabetic and hypertensive patients, the major complication in that 
study was cardiovascular disease followed by retinopathy (Yusef, 2000).  
 
2.8.5 Hyperlipidemia 
 
Lipid is the scientific term for fats in the blood.  At proper levels, lipids perform important 
functions in our bodies, but can cause health problems if they are present in excess.  The term 
hyperlipidemia means high lipid levels.  Atherosclerosis increases the risk of heart disease, 
stroke, and other vascular diseases.  Lifestyle changes like exercising and eating a healthy diet 
can also lower lipid levels and are often the first step in treatment.  Most hyperlipidemia is 
caused by lifestyle habits or treatable medical conditions.  Lifestyle contributors include 
obesity, not exercising, and smoking.  Conditions that cause hyperlipidemia include diabetes, 
kidney disease, pregnancy, and an under active thyroid gland (SVS, 2006).  Dyslipidemia 
should be aggressively identified and treated to decrease cardiovascular risk (Dunn, 1992). 
 
2.8.6 Smoking 
 
There is a growing body of evidence to suggest that smoking is an independent risk factor for 
diabetes and that among people with diabetes, smoking aggravates the risk of serious disease 
and premature death.  Macro vascular and micro vascular complications ensue more quickly in 
smokers with diabetes, and risk of  mortality increases.  The increased blood pressure and 
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altered lipid profiles in smokers with diabetes could encourage development of the insulin 
resistance syndrome, setting patients up for further cardiovascular problems (Justin, 2005). 
 
2.9 Diagnosis of DM 
Since the American Diabetes Association (ADA) issued important revisions to its guidelines 
on assessment and treatment of diabetes mellitus (DM) in 1997, the prevalence of diagnosed 
DM in long-term care settings has markedly increased. This rise in DM diagnosis is largely 
due to lowering of the ADA-designated threshold for acceptable fasting plasma glucose (FPG) 
from 139 to 125 mg/dL (ASCP, 2001). 
Criteria for the diagnosis of diabetes in adults 
American Diabetes Association in 2006, stated that  three ways to diagnose diabetes are 
available, and each must be confirmed on a subsequent day unless unequivocal symptoms of 
hyperglycemia are present, these ways are: 
1. Symptoms of diabetes plus casual plasma glucose concentration 200 mg/dl (11.1 mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The classic 
symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. 
Or 
2. FPG 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. 
Or 
3. 2-h postload glucose 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be 
performed as described by World Health Organization in 2003, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water.  
Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more 
specific than fasting plasma glucose (FPG) to diagnose diabetes, it is poorly reproducible and 
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rarely performed in practice. Because of ease of use, acceptability to patients, and lower cost, 
the FPG is the preferred diagnostic test. It should be noted that the vast majority of people who 
meet diagnostic criteria for diabetes by OGTT, but not by FPG, will have an A1C value 
<7.0%. The use of the A1C for the diagnosis of diabetes is not recommended at this time. 
Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is categorized as 
either IFG or impaired glucose tolerance (IGT), depending on whether it is identified through a 
FPG or an OGTT:  
- IFG = FPG 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l).       
-  IGT = 2-h plasma glucose 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l).  
Recently, IFG and IGT have been officially termed "pre-diabetes." Both categories, IFG and 
IGT, are risk factors for future diabetes and cardiovascular disease (CVD).  In the absence of 
unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different 
day.  The OGTT is not recommended for routine clinical use but may be required in the 
evaluation of patients with IFG or when diabetes is still suspected despite a normal FPG, as 
with the postpartum evaluation of women with GDM (ADA, 2006). 
2.10 Monitoring test ( assessment of glycemic control) 
Monitoring of glycemic status, as performed by patients and health care providers, is 
considered a cornerstone of diabetes care.  Results of monitoring are used to assess the 
efficacy of therapy and to guide adjustments in medical nutrition therapy (MNT), exercise and 
medications to achieve the best possible blood glucose control.  
2.10.1 Blood glucose testing by patients  
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Within only a few years, self-monitoring of blood glucose (SMBG) by patients has 
revolutionized management of diabetes.  Using SMBG, patients with diabetes can work to 
achieve and maintain specific glycemic goals.  Given the results of the Diabetes Control and 
Complications Trial (DCCT) and other studies, there is broad consensus on the health benefits 
of normal or near-normal blood glucose levels and on the importance, especially in insulin-
treated patients, of SMBG in treatment efforts designed to achieve such glycemic goals  
(MPG, 2006).  Clinical trials using insulin that have demonstrated the value of tight glycemic 
control have used (SMBG) as an integral part of the management strategy.  For patients using 
less frequent insulin injections or oral agents or medical nutrition therapy (MNT) alone, 
SMBG is useful in achieving glycemic goals (ADA, 2006).  
2.10.2 Blood glucose testing by health care providers  
Blood glucose testing (e.g., laboratory glucose or finger-stick glucose) should be available to 
providers for use as needed.  With the availability of SMBG and glycated protein testing, 
routine laboratory blood glucose testing by health care providers should no longer be used to 
assess glycemic control except to supplement information obtained from other testing methods 
and to test the accuracy of SMBG.  When adjusting oral glucose-lowering medication(s) in     
a patient not taking insulin, laboratory testing also may be appropriate (MPG, 2006).  
2.10.3 Glycated protein testing   
Blood and urine glucose testing and urine ketone testing provide useful information for day-
to-day management of diabetes.  However, these tests cannot provide the patient and health 
care team with a quantitative and reliable measure of glycemia over an extended period of 
time.  Measurements of glycated proteins, primarily hemoglobin and serum proteins, have 
added a new dimension for assessment of glycemia.  With a single measurement, each of these 
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tests can quantify average glycemia over weeks and months, thereby complementing day-to-
day testing (MPG, 2006).  
2.10.4 Hemoglobin A1c  (HbA1c) testing           
GHb, commonly referred to as glycated hemoglobin, glycohemoglobin, glycosylated 
hemoglobin, HbA1c, or HbA1, is a term used to describe a series of stable minor hemoglobin 
components formed slowly and nonenzymatically from hemoglobin and glucose.  The rate of 
formation of GHb is directly proportional to the ambient glucose concentration.  In the normal 
person, about 3–6% of HbA is glycated, in the diabetic, the percentage of HbA1c may double 
or even triple depending upon the degree of hyperglycemia.  With normalization of blood 
sugar in the diabetic, HbA1c values will gradually approach normal levels (Gonen, et al,1997).   
-The values of measuring HbA1c   
HbA1c accumulates within red blood cells and exists in this form throughout the life span of 
the cells.  A single HbA1c value taken every 2 to 3 months serves as an integrated index of 
blood glucose control over those months and thus provides an objective view of the patients  
glycemic control between checkups.  The circulating erythrocyte has an average half-life of 60 
days, so HbA1c levels do not change quickly.  HbA1c values will begin to reflect radical 
changes in diet or changes in other modes of therapy approximately 3 to 4 weeks after 
initiation of the change.  Numerous investigators have shown a correlation between HbA1c 
and glycemic control as assessed by traditional glucose assays.   
The landmark nine-year Diabetes Control and Complications Trial (DCCT), completed in 
1993, showed that the risk for development and progression of the chronic complications of 
diabetes is closely related to the degree of glycemic control, as measured by HbA1c 
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determinations. DCCT results revealed that intensive therapy provides the means of 
preventing or postponing long-term complications such as neuropathy, retinopathy, and 
nephropathy.  People with diabetes who follow an intensive glucose management regimen 
could experience up to a 76% reduction in eye problems, a 35–56% reduction in severe kidney 
problems, and up to 60% reduction in crippling nerve related disorders (Gonen, et al.,1997).  
Similarly, the results of the United Kingdom Prospective Diabetes Study show that lowering 
blood glucose levels, as measured by HbA1c determinations, reduces the incidence of 
microvascular complications in Type 2 diabetes ( Gonen, et al., 1997).   
A cross-sectional study was conducted in US by which published in 2005 in Diabetes Care 
journal studied the relationship between HbA1c level and peripheral arterial disease, they 
found that an association exists between higher levels of HbA1c and peripheral arterial 
disease, even among patients without diabetes. Individuals with HbA1C levels 5.3% should 
be targeted for aggressive risk factor reduction, which may reduce the burden of subclinical 
cardiovascular disease even among those without diabetes (Paul, et al., 2005).  
A retrospective evaluation was performed by Rhee, et al. in 2005 for 1560 patients with type 2 
diabetes who presented for a new visit to the Grady Diabetes Clinic between 1991 and 2001 
and returned for a follow-up visit and HbA1c after 1 year of care, they stated that keeping 
more appointments and taking diabetes medications as directed were associated with 
substantial improvements in HbA1c.  Efforts to enhance glycemic outcomes should include 
emphasis on these simple but critically important aspects of patient adherence (Rhee, et al., 
2005).  Preconception care of women with diabetes entails specialized monitoring.  The 
American Diabetes Association in 2006 recommends lowering glycohemoglobin levels to 
achieve maximum fertility and optimal embryo and fetal development.  Initially, HbA1c levels 
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are assessed on a monthly basis.  When appropriate glycemic control is achieved, HbA1c 
levels are then measured at 6 to 8 week intervals until conception.  Recent studies indicate that 
many patients with diabetes do not receive the recommended number of HbA1c tests.  This is 
surprising given that experts agree that regular HbA1c testing and appropriate therapeutic 
intervention can minimize the complications of the disease (Gonen, et al., 1997).  In general, 
for every 1% reduction in results of HbA1c blood tests (e.g., from 8.0% to 7.0%), the risk of 
developing microvascular diabetic complications (eye, kidney, and nerve disease) is reduced 
by 40% (CDC, 2003).  
-Frequency of testing 
The American Diabetes Association (ADA) in 2006, certified that HbA1c testing should be 
performed routinely in all patients with diabetes, first to document the degree of glycemic 
control at initial assessment and then as part of continuing care.  The ADA recommends 
HbA1c testing at least twice per year in patients who are meeting treatment goals (and have 
stable glycemic control) and 4 times per year in patients whose regimen has been modified or 
are not meeting their glycemic control goals (Gonen, et al., 1997).  For any individual patient, 
the frequency of HbA1c testing should be dependent on the clinical situation, the treatment 
regimen used, and the judgment of the clinician (ADA, 2006). 
 The HbA1c test is subject to certain limitations.  Conditions that affect erythrocyte turnover 
(hemolysis, blood loss) and hemoglobin variants must be considered, particularly when the 
HbA1c result does not correlate with the patient’s clinical situation (ADA, 2006). 
-Glycemic goals regarding HbA1c: 
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American Diabetes Association in 2006 summarized the glycemic goals as:  The HbA1c goal 
for patients in general is an HbA1c goal of <7%, Lowering HbA1c has been associated with a 
reduction of microvascular and neuropathic complications of diabetes.  The HbA1c goal for 
the individual patient is an HbA1c as close to normal (<6%) as possible without significant 
hypoglycemia.  Less stringent treatment goals may be appropriate for patients with a history of 
severe hypoglycemia, patients with limited life expectancies, very young children or older 
adults, and individuals with co-morbid conditions.  Aggressive glycemic management with 
insulin may reduce morbidity in patients with severe acute illness, perioperatively, and 
following myocardial infarction (ADA, 2006). 
2.10.5Microalbumin          
Diabetic nephropathy develops in up to 45% of type I diabetes and up to 35% in type II 
patients.  Microalbuminuria is the increased, but low urinary albumin excretion of >30-300 
mg/L indicating early changes in glomerular permeability.  Current dipstick technology is 
usually sensitive to albumin levels of 200-300 mg/L.  Increasing levels of albumin in urine 
indicates a progressive decline of glomerular function leading to end-stage renal failure. 
Therefore, early detection by monitoring microalbumin in both type I and II diabetic patients 
is advocated. "Detecting Hidden Renal Disease". The earliest clinical evidence of renal 
dysfunction in diabetic patients is the appearance of microscopic amounts of albumin in the 
urine (microalbuminuria).  In the past, this condition often went untreated or undetected. 
Today, however, it is widely accepted that microalbuminuria often advances to overt 
albuminuria (>300 mg/day). This then leads to progressive decline in renal function and 
finally to end-stage renal disease (MPG, 2006).  
2.11 Management of diabetes  
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2.11.1 Management strategies of type 2 diabetes 
Optimal control or ‘tight control’ reduces complication rates if hypoglycemia can be averted 
and the patient/family members are willing to participate in the necessary regimen.  These 
goals are achieved through a medically monitored program of diet, medication, exercise and 
education.  However, education with continuing reinforcement are important in maintaining 
even suboptimal control for some patients (CDC, 2005). 
2.11.2 Non- pharmacological treatment 
Diet and exercise are the cornerstones of treatment for persons with type 2 diabetes mellitus, 
yet patients find these areas of self-management to be the most difficult (Shultz, et al., 2001). 
a-Diet 
Diet is the initial treatment of type 2 diabetes.  No patient should be commenced on oral 
medication before they have been given an adequate trial of diet (6–12 weeks).  If patients are 
unwell and needing urgent treatment insulin should be considered (NHS, 2006). 
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b- Exercise (physical activity) 
This should be encouraged.  The more the better. It will help lower blood glucose but not 
necessarily achieve weight loss.  A minimum target should be 30 minutes moderate intensity 
physical activity most days of the week (NHS, 2006). 
Physical activity promotes weight reduction and improves insulin sensitivity, thus lowering 
blood glucose levels.  Together with dietary treatment, a programme of regular physical 
activity and exercise should be considered for each person. Such a programme must be 
tailored to the individual’s health status and fitness.  
People should, however, be educated about the potential risk of hypoglycaemia and how to 
avoid it (Alwan, 1994). 
 
2.11.3 Pharmacological treatment (medications) 
 
Oral medications are required for type 2 diabetes when the disorder is inadequately controlled 
by diet and exercise programs alone, metformin is drug of choice in patients above ideal body 
weight (BMI>25) with inadequate glycaemic control, gastrointestinal side effects common but 
usually dose and duration related and about 10% of patients will not tolerate.  Sulphonylureas 
indicated for patients who are of normal body weight, where diet alone has failed, may be 
added to patients inadequately controlled on metformin, sulphonylureas are potentially 
dangerous drugs with significant risk of hypoglycaemia.  The other additional medication 
includes thiazolidenediones (glitazones), a new class of oral hypoglycaemic agent reducing 
insulin resistance and increasing glucose uptake into peripheral tissue and acarbose, it is 
occasionally useful in the overweight patient where metformin is contraindicated             
(NHS, 2006). 
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2.11.4 Combined therapy  
Combination of metformin and insulin can be effective especially in overweight patients with 
poorly controlled diabetes.  Can achieve better control with less weight gain than adding 
sulphonylureas.  Combination with sulphonylurea and insulin rarely used.  Achieves similar 
levels of glycaemic control with insulin alone but with lower dose of insulin.  Occasionally 
useful in the elderly where once daily insulin in addition to their oral medication can improve 
control (NHS, 2006). 
 
2.11.5 Insulin therapy 
 
There are a few absolute indications for insulin in type 2 diabetes and a discussion of its use 
with the hospital clinic is recommended.  In the appropriate patient, where the problem is 
predominantly insulin deficiency, (poor control in a lean patient or with weight loss) insulin is 
a good treatment for type 2 diabetes.   
Optimal control or ‘tight control’ reduces complication rates if hypoglycemia can be averted 
and the patient/family members are willing to participate in the necessary regimen           
(NHS, 2006). 
2.12 Optimal control of type-2 diabetes: 
According to the MOH, Palestinian guidelines DM in 2004 obtained control of type 2 divided 
into:  
 1-Maintain fasting glucose levels below 120 mg% (80 to 140 mg% on most tests); less than 
180 mg% 1.5 to 2 hours post-prandial, bedtime glucose 100 to 140 mg%, and maintain the 
average glucose <150 mg%.  In patients with a history of hypoglycemia, these targets should 
be increased on an individualized basis. 
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2-Maintain glycohemoglobin (HbA1c) levels within 1.0 unit of the upper limit of   the normal 
range. 
3-Maintain weight,  adjusted for height, frame and sex. weight control is a key issue for lipid 
and glucose control in the non-insulin dependent diabetic.  
4-The primary goal of therapy for adults should be to decrease blood                        
pressure  to <  130/80 mmHg (MOH, 2004). 
Blood pressure control can reduce cardiovascular disease (heart disease  and stroke) by 
approximately 33% to 50% and can reduce microvascular disease (eye, kidney, and nerve 
disease) by approximately 33%.  In general, for every 10 millimeters of mercury (mm Hg) 
reduction in systolic blood pressure, the risk for any complication related to diabetes is 
reduced by aggressive management of hypertension, particularly using ACE inhibitors, will 
delay the onset of nephropathy and other microvascular-related disorders by 12%            
(CDC, 2005).  
5-Control of blood lipids : In diabetic patients, test for lipid disorders at least annually and 
more often if needed to achieve goals.  Total serum cholesterol should be maintained less than 
200 mg/dl, LDL should be maintained at < 100 mg/dL.  A secondary goal is to increase HDL 
cholesterol to >35 mg/dL in men and > 45 mg/dL in women, triglyceride should be maintained 
less than 150 mg/dl.  lipid assessments may be repeated every 2 years.  Improved control of 
cholesterol or blood lipids can reduce cardio-vascular complications by 20% to 50%. 
6-Smoking cessation is a mandatory recommendation for all smokers; avoid ‘second-hand’ 
smoke. 
7-An exercise program should be a clear and specific recommendation (CDC, 2005). 
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2.13 Complication of diabetes  
Diabetes mellitus, especially if poorly controlled, is a major contributory cause for blindness, 
heart attacks, amputations, strokes, kidney failure and impotence (Anthony, et al., 2004).   
Acccording to diabetes fact sheet, diabetes is the main cause of new blindness, kidney failure 
and amputations.  It is also a major risk factor for heart disease, stroke and birth defects.  
Diabetes is the sixth leading cause of death from disease.   Diabetes doubles the risk for death 
8 and shortens the average life span by up to 15 years (ADA, 2003).  A study was done by 
Abu Mousa about the Magnitude of Diabetes Mellitus in Gaza Strip in 1999, he stated that 
although complication associated diabetes were under reported, 65.5% were found to suffer 
from one or more of the common complications; cardiovascular, retinopathy, nephropathy and 
neuropathy (Abu Mousa, 1999).  
 
2.13.1 Heart disease and stroke  
 
Heart disease is the leading cause of diabetes-related deaths.  CVD is the major cause of 
mortality for individuals with diabetes.  Adults with diabetes have heart disease death rates 
about 2 to 4 times higher than adults without diabetes.  The risk for stroke is 2 to 4 times 
higher among people with diabetes.  About 65% of deaths among people with diabetes are due 
to heart disease and stroke (CDC, 2003).  It is also a major contributor to morbidity and direct 
and indirect costs of diabetes.  Type 2 diabetes is an independent risk factor for macrovascular 
disease, and its common coexisting conditions (e.g., hypertension and dyslipidemia) are also 
risk factors (ADA, 2006). 
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2.13.2 High blood pressure     
 
Hypertension, which also increases the risk of atherosclerosis, is twice as common in patients 
with type 2 diabetes as in persons without diabetes.  Patients with diabetes must have their 
hypertension treated aggressively to lessen their risk of developing serious atherosclerosis 
(Scott and Anne, 2004).  About 73% of adults with diabetes have blood pressure greater than 
or equal to 130/80 mm Hg or use prescription medications for hypertension (CDC, 2003).   
 
2.13.3 Blindness 
 
Diabetic retinopathy depends on the duration of their diabetes as well as the level of glycemic 
control maintained.  Importantly, since the diagnosis of type 2 diabetes often is delayed, 20% 
of these patients have some degree of retinopathy at the time of diagnosis (Scott and Anne, 
2004). 
Diabetes is the leading cause of new cases of blindness among adults aged 20-74 years.  
Diabetic retinopathy causes 12,000 to 24,000 new cases of blindness each year (CDC, 2003).  
 
2.13.4 Kidney disease 
 
All patients with diabetes should be considered to have the potential for renal impairment 
unless proven otherwise (Scott and Anne, 2004). Diabetes is the leading cause of end-stage 
renal disease, accounting for 44 percent of new cases.  In 2001, 42,813 people with diabetes 
began treatment for end-stage renal disease.  And a total of 142,963 people with end-stage 
renal disease due to diabetes were living on chronic dialysis or with a kidney transplant   
(CDC, 2003). 
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2.13.5 Nervous system disease  
 
About 60% to 70% of people with diabetes have mild to severe forms of nervous system 
damage.  The results of such damage include impaired sensation or pain in the feet or hands, 
slowed digestion of food in the stomach, carpal tunnel syndrome, and other nerve problems.  
Severe forms of diabetic nerve disease are a major contributing cause of lower-extremity 
amputations (CDC, 2003). 
 
2.13.6 Amputations  
 
Between 50% and 70% of all nontraumatic lower-extremity amputations occur in diabetic 
patients.  The insensate, poorly perfused foot is at risk for ulcers from pressure necrosis or 
inflammation from repeated skin stress and unnoticed minor trauma.  Either can evolve into 
cellulitis, osteomyelitis, or nonclostridial gangrene and end in amputation                        
(Scott and Anne, 2004). 
2.13.7 Dental disease  
 
Periodontal (gum) disease is more common among people with diabetes.  Among young 
adults, those with diabetes have about twice the risk of those without diabetes.  
Almost one-third of people with diabetes have severe periodontal diseases with loss of 
attachment of the gums to the teeth measuring 5 millimeters or more (CDC, 2003). 
 
2.14 Prevention of diabetes 
2.14.1 Primary prevention: 
The prevention of type 1 and type 2 diabetes requires different strategies, as they have quite 
different causes. Primary prevention efforts are focused on the reduction of obesity and 
physical inactivity, which are the known modifiable risk factors for type 2 diabetes only 
(Show and Chisholm, 2003).  Type 1 diabetes currently cannot be prevented.  It is an 
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autoimmune disorder, and is not caused by poor health behaviors.  Type 2 diabetes can be a 
result of poor health behaviors, such as being overweight or obese. Maintaining a healthy diet, 
weight and exercising regularly may help protect against the development of Type 2 diabetes.  
For people with “pre-diabetes” (elevated blood sugar), losing weight and doing physical 
activity can prevent or delay progression to actual diabetes (ADA, 2002). 
 
2.14.2 Secondary prevention: 
Secondary prevention involves early identification of diabetes through screening to prevent or 
delay the progression of the disease (Show and Chisholm, 2003).   
According to the American Diabetes Association in 2002, at least one-third of people with     
type 2 diabetes go untreated because they do not know they have the condition.  Many of these 
people will be diagnosed with diabetes only after they have developed serious complications, 
such as heart attack, kidney disease, poor circulation, or impaired eyesight. 
People with type 2 diabetes may be able to control their blood sugar through diet and exercise. 
Others may need to take oral diabetes medicines alone or in combination to lower their blood 
glucose levels.  If this does not work, insulin may be necessary to add to the regimen.  
Preventing complications from diabetes is an important focus of diabetes management.  
Maintaining glucose control (as measured by the blood HbA1c level) is the critical aspect of 
diabetes management and prevention of complications. 
Even a minimal reduction in HbA1c has a dramatic impact: for every 1 point reduction in 
HbA1c, the risk of developing eye, kidney and nerve disease is reduced by 40% (ADA, 2002). 
In addition to HbA1c control, people with diabetes need to take care of their eyes, skin and 
heart to prevent diabetes complications.  Detection and treatment of diabetic eye disease 
(through a yearly eye exam) can reduce severe vision loss by 50-60%.  Comprehensive foot 
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care (careful washing and drying of the feet and checking for blisters or cuts that might not 
heal) can reduce the amputation rate by 45-85%.  Detection and treatment of early kidney 
disease can reduce the development of kidney failure by 30-70%.  Blood pressure control can 
reduce risk of heart disease and stroke by 33-50% and eye, kidney and nerve disease by 33%.  
Control of cholesterol can reduce the risk of cardiovascular complications by 20-50%.  
Screening for and treating depression is an important part of diabetes care.  Depression rates 
are much higher in individuals with diabetes. 
The symptoms of depression can affect the course of the illness, as well as the person’s ability 
to follow the treatment recommendations.  Working with their health care providers, people 
with diabetes can learn to manage their diabetes.  Following a treatment plan for medication, 
monitoring (self-monitoring of blood glucose, daily foot exams), and lifestyle changes (diet, 
exercise) are essential.  People with diabetes should see their doctor at least every 3 months, 
and receive all recommended health screenings and services, including: quarterly HbA1c 
blood screening, annual dilated eye exam, annual lipid/cholesterol screening, foot exam at 
every visit, annual screening for kidney disease, dental exams at least twice a year, blood 
pressure screening (at every visit).  Other important aspects of diabetes care include smoking 
cessation (ADA, 2002). 
2.14.3 Tertiary prevention:  
Tertiary prevention is aimed at delaying or preventing the development of complications in 
people who already have diabetes.  Tight control of blood sugar and blood pressure reduces 
the rate of microvascular disease and macrovascular disease (heart disease or stroke) in people 
with type 2 diabetes.  The treatment of hyperlipidemia also prevents the development of 
macrovascular disease in people with diabetes.  For all people with diabetes, regular foot and 
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eye examinations with proper preventive treatment can prevent amputations and progression 
of retinopathy.  Diabetes education of health care professionals and those affected by diabetes 
plays a key role in the tertiary prevention of the disease (Show and Chisholm, 2003).   
Persons with diabetes must understand their disease and be empowered to avoid obesity, 
smoking and unhealthy diets, and encouraged to exercise, and control blood glucose. Good 
health education, health promotion and access to professional care are essential for persons 
with diabetes mellitus (Anthony, 2004).  
 
2.15 Consequences of non-compliance 
There is strong evidence that many patients with chronic illnesses including diabetes, have 
difficulty adhering to their recommended regimens.  This results in less than optimal 
management and control of the illness.  Poor adherence is the primary reason for suboptimal 
clinical benefit.  It causes medical and psychosocial complications of disease, reduces 
patients’ quality of life, and wastes health care resources.  
Rapoff in 1999 summaries the consequences of poor adherence as:  increased office visits,  
decreased responsiveness to medication,  exacerbation of side effects, exacerbation of acute 
illness, increased risk of future health problems, increased risk for future inappropriate 
medical recommendations, and Impaired provider-patient relationship.  The problems that may 
result from non-adherence not only include the personal costs to the patient and provider, but 
also have a negative impact on an already overwhelmed health care system.  Taken together, 
these direct consequences impair the ability of health care systems around the world to achieve 
population health goals.  For these reasons, difficulties with adherence should be assumed and 
each patient should be questioned as though the provider understands how difficult it can be to 
follow medical recommendations (Christophersen and Mortweet, 2005).   
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World Health Organization in 2003, reported that the consequences of poor adherence to long-
term therapies are poor health outcomes and increased health care costs.  Adherence is            
a primary determinant of the effectiveness of treatment because poor adherence attenuates 
optimum clinical benefit.  Good adherence improves the effectiveness of interventions aimed 
at promoting healthy lifestyles, such as diet modification, increased physical activity, non-
smoking, and of the pharmacological-based risk-reduction interventions.  It also affects                       
secondary prevention and disease treatment interventions. 
In studies on the prevention of diabetes type 2, adherence to a reduced-fat diet  and to regular 
physical exercise  has been effective in reducing the onset of the disease.  For those already 
suffering the disease, good adherence to treatment, including suggested dietary modifications, 
physical activity, foot care and ophthalmologic check-ups, has been shown to be effective in 
reducing complications and disability, while improving patients’ quality of life and life 
expectancy.  Level of adherence has been positively correlated with treatment outcomes in 
depressed patients, independently of the anti-depressive drugs used.  
In addition to their positive impact on the health status of patients with chronic illnesses, 
higher rates of adherence confer economic benefits.  Examples of these mechanisms include 
direct savings generated by reduced use of the sophisticated and expensive health services 
needed in cases of disease exacerbation, crisis or relapse. Indirect savings may be attributable 
to enhancement of, or preservation of, quality of life and the social and vocational roles of the 
patients.  The development of resistance to therapies is another serious public health issue 
related to poor adherence, among other factors.  In addition to years of life lost due to 
premature mortality and health care costs attributable to preventable morbidity, the economic 
consequences of poor adherence include stimulating the need for ongoing investment in 
research and development of new compounds to fight new resistant variants of the causative 
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organisms.  The “chronic” investment in research and development could be avoided if 
adherence rates were higher, and the resources could be better used in the development of 
more effective and safer drugs, or by being directed to the treatment of neglected conditions. 
There is growing evidence to suggest that because of the alarmingly low rates of adherence, 
increasing the effectiveness of adherence interventions may have a far greater impact on the 
health of the population than any improvement in specific medical treatments (WHO, 2003). 
 
2.16 Measures of compliance  
Adherence to medication regimens has been monitored since the time of Hippocrates, when 
the effects of various potions were recorded with notations of whether the patient had taken 
them or not.  Even today, patients' self-reports can simply and effectively measure adherence. 
The methods available for measuring adherence can be broken down into direct and indirect 
methods of measurement as mentioned by Osterberg and Blaschke in 2005.  They stated that 
each method has advantages and disadvantages, and no method is considered the gold 
standard.  Directly observed therapy; measurement of concentrations of a drug or its 
metabolite in blood or urine, and detection or measurement in blood of a biologic marker 
added to the drug formulation are examples of direct methods of measures of adherence.  
Direct approaches are expensive, burdensome to the health care provider, and susceptible to 
distortion by the patient.  However, for some drugs, measuring these levels is a good and 
commonly used means of assessing adherence. 
Indirect methods of measurement of adherence include asking the patient about how easy it is 
for him or her to take prescribed medication, assessing clinical response, performing pill 
counts, ascertaining rates of refilling prescriptions, collecting patient questionnaires, using 
electronic medication monitors, measuring physiologic markers, asking the patient to keep a 
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medication diary, and assessing children's adherence by asking the help of a caregiver, school 
nurse, or teacher.  Questioning the patient (or using a questionnaire), patient diaries, and 
assessment of clinical response are all methods that are relatively easy to use, but questioning 
the patient can be susceptible to misrepresentation and tends to result in the health care 
provider's overestimating the patient's adherence (Osterberg and Blaschke, 2005).   
Also they stated that the most common method used to measure adherence, other than patient 
questioning, has been pill counts (i.e., counting the number of pills that remain in the patient's 
medication bottles or vials).  This method is subject to many problems, because patients can 
switch medicines between bottles and may discard pills before visits in order to appear to be 
following the regimen.  For these reasons, pill counts should not be assumed to be a good 
measure of adherence.  A medical system that uses electronic medical records and a closed 
pharmacy can provide the clinician or research scientist with readily available objective 
information on rates of refilling prescriptions that can be used to assess whether a patient is 
adhering to the regimen and to corroborate the patient's responses to direct questions or on 
questionnaires (Osterberg and Blaschke, 2005). 
Electronic monitors capable of recording and stamping the time of opening bottles, these 
devices provide precise and detailed insights into patients' behavior in taking medication, but 
they are still indirect methods of measuring adherence; they do not document whether the 
patient actually ingested the correct drug or correct dose. Patients may open a container and 
not take the medication, take the wrong amount of medication, or invalidate the data by 
placing the medication into another container or taking multiple doses out of the container at 
the same time.   
At present, there is no ‘gold standard’ measure of medication adherence.  Various objective 
methods have been employed to assess adherence (Osterberg and Blaschke, 2005). 
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2.17 Identifying poor adherence   
World Health Organization report in 2003 focused on that poor adherence should always be 
considered when a patient's condition is not responding to therapy.  
The simplest and most practical suggestion for physicians is to ask patients non judgmentally 
how often they miss doses.  Patients generally want to please their physicians and will often 
say what they think their doctor wants to hear.  It can be reassuring to the patient when the 
physician tells them, "I know it must be difficult to take all your medications regularly.  How 
often do you miss taking them?" this approach makes most patients feel comfortable in telling 
the truth and facilitates the identification of poor adherence.  A patient who admits to poor 
adherence is generally being candid. Patients should also be asked whether they are having any 
side effects of their medications, whether they know why they are taking their medications, 
and what the benefits of taking them are, since these questions can often expose poor 
adherence to a regimen (WHO, 2003).   
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2.18 Barriers to adherence  
Research on adherence has typically focused on the barriers patients face in taking their 
medications.  As found in that research common barriers to adherence are under the patient's 
control, so that attention to them is a necessary and important step in improving adherence.  
Physicians contribute to patients' poor adherence by prescribing complex regimens, failing to 
explain the benefits and side effects of a medication adequately, not giving consideration to 
the patient's lifestyle or the cost of the medications, and having poor therapeutic relationships 
with their patients.  More broadly, health care systems create barriers to adherence by limiting 
access to health care, using a restricted formulary and having prohibitively high costs for 
drugs, co-payments, or both.  To improve the patient's ability to follow a medication regimen, 
all potential barriers to adherence need to be considered.  An expanded view that takes into 
account factors under the patient's control as well as interactions between the patient and the 
health care provider and between the patient and the health care system will have the greatest 
effect on improving medication adherence (WHO, 2003). 
 
2.19 Improving compliance: 
The “state-of-the-art” adherence interventions target the patient, the provider, and the health 
care system. 
Several programs have demonstrated good results using multilevel team approaches. 
Researches on interventions to promote adherence has focused largely on modifying patient 
behaviour.  According to several published reviews on adherence, no single intervention 
targeting patient behaviour is effective, and the most promising methods of improving 
adherence behaviour use, a combination of the strategies which include: 
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patient education , behavioural skills ,  self-rewards, social support , and  telephone follow-up. 
Various combinations of these techniques have been shown to increase adherence and improve 
treatment outcomes. 
 
2.19.1  Patient interventions 
The interventions reported by Kem, et al. in 2003 to improve adherence was adherence aids, 
written and oral education/counseling, simplification of the dosage regimen, refill and   
follow-up reminders, contracts with patients, and comprehensive management, including 
special training regarding disease state or medication consumption and contracts with patients.  
The description of these aids was as follow: 
a- Adherence aids 
Adherence aids are devices such as medication calendars, medication organizers, and 
electronic devices that help patients organize and take their medications appropriately. Some 
are low-technology and low-cost (e.g., a pill box or medication calendar). 
Others use more sophisticated technology at a higher cost (e.g., electronic caps, alarms, 
Internet-based devices). 
The ideal adherence device would be described as being “closed loop.” 
Closed-loop devices operate online and in real time, assuring the highest levels of adherence 
and outcomes monitoring capabilities.  These devices help patients in real time with active 
monitoring, they help patients remember to take their medication through the use of alarms 
and verification checks, they help patients remember whether they have taken a particular dose 
by giving information about what has taken place, they reduce the complexity of the 
medication regimen by grouping doses for patients to take at a given time and displaying the 
action required by the patient. 
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b- Refill and follow-up reminders 
Refill and follow-up reminders are printed, electronic, or telephone messages that notify 
patients when it is time to refill their medication or follow up with a health care provider. 
These reminders may be triggered by a pharmacy or patient management computer system.   
c- Simplification of the dosage regimen 
Simplification of the dosage regimen may include conducting a drug utilization review to 
decrease the number of medications a patient is taking, decreasing the number of daily doses 
by switching to extended-release formulations, or using some form of adherence packaging. 
d- Written and oral education 
Written and oral education can take many different forms, such as pharmacist counseling, 
patient specific education sessions focusing on the disease and its treatment, point-of-care 
educational pamphlets, or point-of-care technology that helps pharmacists show patients how 
to use medications appropriately.  Online compendia are available to support pharmacists’ 
decision making regarding patient care. 
Counseling or education sessions that are tailored to individual patients have been shown to 
improve adherence. 
e- Comprehensive management 
This category includes patient education on disease state or medication use in combination 
with one or more of the following: contracts with patients, adherence aids, reminder systems, 
or dosage simplification.  This form of intervention also goes beyond a one-time interaction 
with the patient to include some form of follow-up (Kem, et al., 2003).  
The most effective adherence-enhancing interventions directed at patients aim to enhance self-
regulation or self-management capabilities.  Self-management programmes offered to patients 
with chronic diseases can improve health status and reduce health care utilization and costs. 
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Several strategies appear to be effective, at least in the short term.  These include: self-
monitoring, corrective feedback, behavioural contracting, commitment enhancement, creating 
social support, reinforcement; and relapse prevention.  A meta-analysis of 28 studies revealed 
that the key intervention components were providing reinforcement (WHO, 2003).  
 
2.19.2  Interventions directed to providers 
Because providers have such a significant role in adherence, designing interventions to 
influence their behaviour seems a reasonable strategy.  Training providers in patient-centred 
methods of care may be effective, but the strongest effects of such training appear to be on 
patient satisfaction with treatment (WHO, 2003).  
 
2.19.3 Education of health providers 
Diabetes care at secondary and tertiary levels is ideally provided by a multidisciplinary team 
consisting of a doctor, nurse, dietitian, pharmacist, chiropodist and others, although it is 
recognized that some of these may not be available in many countries of the Region. At the 
primary care level, absence of trained health care professionals makes it difficult to provide 
diabetes care; therefore, one of the main priorities of the diabetes control programme should 
be to respond to this gap by promoting knowledge and skills of primary health care providers 
in diabetes care and strengthening community participation in this respect (Kem, et al., 2003).  
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2.19.4  Interventions in the health system 
Interventions in the health system are higher order interventions affecting health policy; 
organization and financing of care and quality of care programs.  Creation and adoption of 
chronic care models of service delivery, which, at least in patients with diabetes, have been 
shown to result in better patient outcomes (WHO, 2003).   
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The major factors known to affect medication compliance  
Health care providers often believe that patients with diabetes do not follow medication and 
other self-care recommendations due to a lack of self-discipline, limited intelligence, or an 
unreasonably fearless attitude towards the consequences of diabetes.  In fact, data suggest 
that the major factors influencing compliance are not broad personality characteristics, but 
rather are situational and specific in nature.  Such influences are so specific that, for 
example, patients taking multiple medications are likely to be selective about which of their 
medications they take carefully, which they skip from time to time, and which they quit 
altogether. 
The common belief that patients are solely responsible for taking their treatment is 
misleading and most often reflects a misunderstanding of how other factors affect people’s 
behaviour and capacity to adhere to their treatment.  The ability of patients to follow 
treatments in an optimal manner is frequently compromised by more than one barrier 
(WHO, 2003). 
The major factors known to affect medication compliance are as follows:  
 
 
3.1 Demographics and socio-economic factors 
Demographic, such as age, gender, ethnicity, and socio-economic status have been included 
in almost every analysis of adherence, although they do not seem to be consistent correlates 
of whether or not a patient keeps appointments or follows a medication regimen (Platt, 
1994). 
A study by Albaz in Saudi Arabia in 1997 concluded that organizational variables (time 
spent with the doctor, continuity of care by the doctor, communication style of the doctor 
and interpersonal style of the doctor) are far more important than sociodemographic 
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variables (gender, marital status, age, educational level and health status) in affecting 
patients’ adherence (Albaz, 1997). 
Kem, found in 2003 that demographic variables such as age and socioeconomic status have 
an impact on adherence.  Increasing age is generally associated with increasing adherence 
until patients enter their 70s, when adherence declines.  This decrease may be due in part to 
failing memory or the need for complex medication regimens as people age (Kem, 2003). 
Patients who are dependent on significant others, have limited access to transportation, live 
far away from their clinic, or have a fear of being victimized en route to see a physician 
may also be unlikely to adhere to treatment regimens (Anderson and Kerk, 1982).  
Joel, et al. in 2002 studied adherence in an indigent population, they found that  adherence 
to chronic drug regimens is often suboptimal, lower socioeconomic and minority 
populations have greater barriers to adherence, which may thwart efforts at improving care 
and outcomes  ( Joel et al., 2002).  
The out-of-pocket costs of medications have a profound impact on compliance, especially 
for the elderly and the poor.  Patients typically cope with economic hardship by not having 
prescriptions filled, taking a smaller dose, or buying a cheaper over-the-counter product 
that is presumed to have a similar effect. Sadly, recent data suggest that patients only rarely 
discuss this issue with their health care providers, feeling that the cost issue is not their 
doctors' problem (Kem, 2003). 
A retrospective cohort study of newly treated patients (aged 18-64 years) was conducted 
Adherence with antihyperglycemic pharmacotherapy was conductd by Hertz in 2005, and 
found that adherence was  poor among working-aged patients newly treated for type 2 
diabetes (Hertz, 2005). 
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3.2 Patient-based factors  
 Patient-related factors represent knowledge, attitudes, beliefs, perceptions and expectations 
of the patient.  Patients’ knowledge and beliefs about their illness, motivation to manage it, 
confidence (self-efficacy) in their ability to engage in illness-management behaviours, and 
expectations regarding the outcome of treatment and the consequences of poor adherence, 
interact in ways not yet fully understood to influence adherence behaviour (WHO, 2003). 
A study was done by Cramer in 1991, he found in responses to a questionnaire, typical 
reasons cited by patients for not taking their medications included forgetfulness (30 
percent), other priorities (16 percent), decision to omit doses (11 percent), lack of 
information (9 percent), and emotional factors (7 percent), 27 percent of the respondents 
did not provide a reason for poor adherence to a regimen (Cramer, 1991). 
 
3.2.1  Knowledge: 
It has been assumed by many that patients who are knowledgeable about their illness and 
therapeutic regimen usually are more likely to be compliant, studies suggest that increase 
patient knowledge does not necessary affected patient's behavior and compliance 
(Jaser,1999).  
In a study conducted in Egypt by Kamel, et al. in 1999 to determined diabetics' knowledge 
of the disease and their management behavior.  The study aimed to describe the level of 
knowledge of diabetic patients about the disease, showed the relationship between 
demographic variables (age, sex and education) and level of knowledge and revealed the 
relationship between knowledge and management-related behavior of diabetics. The 
researcher studied 300 randomly chosen diabetic patients to assess their behaviors in 
relation to management of their disease, they found that the majority of diabetic patients 
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(90.0%) had poor knowledge about the disease, 83.7% had poor knowledge about the 
complications associated with diabetes and 96.3% had poor awareness of how to control the 
disease.  The poor level of knowledge that diabetics had about their disease suggested that 
health care providers need to be trained in the areas of information, education and 
communication (Kamel, et al., 1999).  Numerous studies have shown a relationship 
between psychosocial factors and treatment adherence in diabetes.  Wilson and colleagues 
reported that mood, knowledge of diabetes care, social support and health beliefs were 
collectively predictive of better compliance (Wilson et al., 1986).   
Adherence is more likely if the patient has experienced the illness previously or has known 
someone impaired by the illness in question. Such experience may make patients aware of 
their vulnerability and of the need to act to minimize the risks of disease                    
(Anderson & Kirk, 1982). 
Health information tailored specifically to the individual appears more effective than 
generic information in promoting risk-reducing behaviour changes in overweight subjects          
(Clark, et al.,  1999).   
Petty and Cacioppo in 1981 proposes that people are more likely to process information 
thoughtfully if they perceive it as personally relevant. 
 
3.2.2 Attitudes and beliefs about non-pharmacological treatment 
A study examined attitudes and beliefs about exercise among 83 persons with non-insulin-
dependent diabetes who had completed outpatient diabetes counseling conducted by         
Swift, et al. in 1995 adapt the health belief model which labeled the exercise behavior 
model, guided perceptual measures which indicated that fifty-two percent of the subjects 
were exercising 3 or more days per week.  Those with a greater length of time since 
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diabetes counseling were more likely to be currently exercising.  Positive and negative 
attitudes toward exercise characterized the group however, only negative attitudes were 
related to exercise. Both exercisers and non-exercisers perceived barriers to exercise. Other 
people, chance happenings, physical discomfort, and perceptions of fitness, weight, and 
appearance played a role in whether the subjects exercised.  The results indicate that 
providing assistance in identifying support for exercise and overcoming perceived barriers 
to exercise may increase compliance to this important aspect of the diabetes regimen 
(Swift, et al., 1995).  
Physical activity is integral to the management of type 2 diabetes. Unfortunately, the 
majority of adults with type 2 diabetes do not regularly engage in physical activity, in a 
study conducted by Hays and Clark in 1999, they found that the majority of the respondents 
(54.6%) reported zero min of weekly physical activity.  This was especially true of older 
female respondents, they also found that  physical activity knowledge varied by age-group, 
and barriers to physical activity were prevalent in all groups, so they concluded that the low 
prevalence of physical activity should raise concerns among clinicians                             
(Hays and Clark, 1999).  
A survey was conducted by Searle and Ready in 1991 to assess the potential for an exercise 
and weight control program for persons with type II diabetes.  Questionnaire forms were 
sent to 1,000 individuals with diabetes, who were randomly selected from the provincial 
health records office.  Physicians and dietitians were the primary sources of information 
about both exercise and diet.  Although few respondents participated in organized (7.7%) or 
informal (36.8%) exercise programs, or expressed an interest in participating (36.8%), the 
majority (84.0%) believed that they should get more exercise. This points to a gap between 
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attitude and behaviour. It was concluded that barriers must be assessed, and behaviour 
modification included, if diet and exercise programs are to be successful (Searle and Ready, 
1991). 
3.2.3 Attitudes and beliefes toward disease 
Non-adherence in many chronic illnesses has been linked to attitude of a patient toward 
him/herself and the illness ( Wichowski and Kubach, 1997). 
In a study was done to investigate attitudes of people with diabetes toward their disease and 
its treatment from their point of view, it was found that the reaction and attitude physicians 
displayed toward patients at the point of diagnosis were crucial in influencing attitudes 
toward perceived seriousness of the disease and consequently compliance. 
Difficulties in adhering to a treatment plan and inadequate perceived seriousness of the 
disease were factors contributing to a lack of compliance.  Participants reported that when 
diabetes complications started their compliance improved (Dietrich, 1996).  
Patients are most likely to comply with medication recommendations if they recognize that:  
diabetes is a serious disease with potentially serious consequences, and the risk of those 
consequences can be reduced through active self-care.  Unfortunately, many people with 
diabetes minimize the dangers of not controlling their disease while many others recognize 
these dangers but feel helpless in preventing them. Studies show that health beliefs and 
diabetes self-efficacy predict adherence to diabetes self-care recommendations            
(Aljasem, et al., 2001).  
Physicians seem to agree that non-compliance by diabetic patients is a problem.  Despite 
this, there have been few qualitative studies on the actual behaviors, beliefs, and attitudes of 
diabetic patients, a study conducted by McCord and Brandenburg in 1995, they concluded 
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that a better understanding of patients' beliefs and attitudes may help physicians increase 
motivation, understanding, and compliance of diabetic patients (McCord and Brandenburg, 
1995). 
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3.2.4 Patient beliefs about their medications 
Patients are most likely to comply with medication recommendations when they can 
recognize that the medication is helping them.  Unfortunately, few patients can feel the 
benefits of important diabetes medications, especially those that lower blood pressure and 
cholesterol levels. Patients may sometimes notice immediate positive benefits when blood 
glucose levels are lowered (eg, reduced fatigue or improved sleep quality), but many 
patients do not feel these changes, and some may become aware of only negative 
consequences                         (eg, hypoglycemia).  The absence of any perceived evidence 
that a medication is working makes it essential that patients understand and appreciate the 
drug's “invisible” benefits.  Compliance is also impaired when significant side effects 
occur.  In addition to hypoglycemia, OHAs may cause gastrointestinal distress, significant 
weight gain, and other troublesome side effects.  In some cases, as in the resistance many 
people with type 2 diabetes feel about beginning insulin therapy, the problem may be 
personal beliefs (often based on invalid assumptions) about the potential side effects of the 
medication (Polonsky, et al., 2003).  
Anderson & Kirk in 1982, suggest that if an illness has easily recognizable and unpleasant 
symptoms that are improved by following treatment recommendations, adherence is more 
likely. In diabetes, many of the symptoms are not evident until later in life. Therefore, 
many individuals will not feel the urgency of undergoing a treatment regimen or making 
lifestyle changes immediately. 
3.2.5 Social and Health Beliefs:  
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Patients hold many beliefs about their health and about the potential efficacy of any 
proposed treatment action. Patients' beliefs can be based on: misconceptions, faulty 
information, and/or cultural conditioning.  For example, some elderly people may 
believe:"You need to give your body some rest from medicine once in awhile or else your 
body becomes dependent on it or immune to it," or 'You only take medicine when you are 
ill and not when you feel better," or "If one dose is good, two must be better.  These beliefs 
and feelings may be shared and supported by significant others in the patient's life 
(Kusserow, et al., 1999). 
Lack of family and social support has been linked to poor compliance with prescribed 
medication use (and other self-care behaviors) across a number of different disease states 
When patients have friends or family members who are providing emotional and/or 
material support (eg, reminders to take medications), it is more likely that higher levels of 
medication compliance will be maintained.  Several studies have shown that persons with 
diabetes who have greater social support are more likely to follow insulin regimen 
recommendations (Ruggiero, et al., 1990). 
 
3.2.6 Belief and use of traditional remedies by diabetic patients 
Al-Saeedi et al, in 2003, interviewed 1039 diabetic patients in Saudi Arabia using a 
structured questionnaire about belief in traditional herbal remedies.  The study showed that 
15.6% of the sample believed that traditional medicines were safe and effective and 25.8% 
that they might be beneficial.  One-third of patients were using traditional remedies.  A 
statistically significant relationship was shown between belief in traditional medicines and 
variables such as female sex, positive family history of diabetes, duration of diabetes and 
compliance with diet. However, there was no relationship with other compliance variables 
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or with glucose and weight control.  They concluded that efforts should be made to enhance 
diabetic education among patients on the basis of evidence-based practice (Al-Saeedi, et al., 
2003). 
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3.3 Regimen factors  
3.3.1 Polypharmacy  
Non-adherence to polypharmacy regimens may be defined as overutilisation, 
underutilisation, discontinuation or abuse of medication, and is most often associated with 
preventable increases in morbidity and mortality. 
Polypharmacy is problematic for older persons because it is the greatest risk factor for 
ADRs (adverse drug reactions), drug interactions, reduced compliance and increased 
emergency room visits, hospitalizations, and nursing home admissions (Michael, 2004).     
Dosing frequency is inversely related to compliance. The highest levels of compliance are 
seen with oral medications taken once daily. Paes et al for example, found that OHA 
compliance dropped from 79% for once-daily medications to 38% for medications taken         
3 times a day.  In addition, when patients are taking multiple OHAs, compliance levels fall.  
Even when OHAs are taken only once daily, problems may arise.  Overconsumption of 
once-daily OHAs has been shown to occur in as many as one-third of patients.  Treatment 
complexity issues are especially important for elderly patients, who may have difficulty 
with memory or concentration (Paes, et al., 1997).  
In another study was conducted by Winkler et al. in 2002 to collect information about the 
dynamics and patterns of compliance of elderly patients with type 2 diabetes mellitus on 
oral treatment.  They found that once daily dosage led to significantly better adherence 
rates than two or three times daily regimens.  However, over-compliance was surprisingly 
high and occurred more frequently on a once daily regimen (Winkler, et al., 2002).   
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Similarly a study done by Jaser, in 1999 in Palestine, he found that the compliance rate was 
significantly higher among patients taking one type of hypoglycemic drugs and among 
patients on single daily dose (Jaser, 1999). 
Grant, et al. in 2003, randomly selected patients with type 2 diabetes from a single 
community health center responded to a pharmacist-administered questionnaire regarding 
medication use to determine medication adherence and predictors of suboptimal adherence 
in a community cohort of patients with diabetes and to test the hypothesis that adherence 
decreases with increased number of medicines prescribed.  They found that patients 
reported very high medication adherence rates regardless of number of medicines 
prescribed.  Among patients on multiple medicines, most patients with suboptimal 
adherence were perfectly adherent to all but one medicine.  Unreported side effects and a 
lack of confidence in immediate or future benefits were significant predictors of suboptimal 
adherence. Physicians should not feel deterred from prescribing multiple agents in order to 
achieve adequate control of hyperglycemia, hypertension, and hyperlipidemia (Grant, et al., 
2003). 
 
3.3.2 Type of medicine 
A literature search (1966–2003) was performed to identify reports with quantitative data on 
adherence with oral hypoglycemic agents (OHAs) and insulin and correlations between 
adherence rates and glycemic control.  Adequate documentation of adherence was found in     
15 retrospective studies of OHA prescription refill rates, 5 prospective electronic 
monitoring OHA studies, and 3 retrospective insulin studies.  Retrospective analyses 
showed that adherence to OHA therapy ranged from 36 to 93% in patients remaining on 
treatment for 6–24 months.  Prospective electronic monitoring studies documented that 
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patients took 67–85% of OHA doses as prescribed.  Electronic monitoring identified poor 
compliers for interventions that improved adherence (61–79%; P < 0.05). Young patients 
filled prescriptions for one-third of prescribed insulin doses. Insulin adherence among 
patients with type 2 diabetes was 62–64%.  This review confirms that many patients for 
whom diabetes medication was prescribed were poor compliers with treatment, including 
both OHAs and insulin. However, electronic monitoring systems were useful in improving 
adherence for individual patients. Similar electronic monitoring systems for insulin 
administration could help healthcare providers determine patients needing additional 
support ( Joyce, 2004). 
  
3.3.3 Complexity of medication instructions 
Medication compliance is likely to be impaired when patients are not certain how 
medications are to be used (ie, “I'm supposed to take my pills at dinner on an empty 
stomach, but what if my stomach isn't that empty right before dinner?”). This may be due to 
problems with “health literacy,” where the patient is unable to understand, and thus follow, 
the provider's specific recommendations. Such confusion may also result when providers 
do not explain their recommendations clearly, if at all. This may be why OHA compliance 
is better in patients who rated their communication with their health care provider as 
"good" (Ciechanowski, et al., 2005).  A meta-analysis of adherence studies suggesting that 
an individual with a history of adherence to a specific treatment regimen would react in a 
similar fashion to subsequent applications of that same regimen (Dunbar, et al., 1990).   
 
3.4 Provider-based factors:  
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Role of the Physician: Although most research focuses on the issue of compliance as a 
patient problem, compliance is the physician's responsibility as well as the patient's.  
Physicians generally underestimate the levels of noncompliance among their own patients? 
They have also been shown to be unreliable predictors of whether or not individual patients 
will comply.  Physicians' beliefs about and attitudes toward diabetic patients can affect their 
interaction and communication with them (Kusserow, et al., 1999). 
Provider characteristics and the medical system also affect patients’ adherence.  Overall 
patient satisfaction with medical care has been found to correlate with increased adherence.  
The perception of providers as being warm and caring has been related to greater 
adherence. Long waiting time and other procedural barriers have been found to decrease 
adherence to both keeping appointments and taking medications.  Because treatment 
adherence is a challenge not only for the patient but also for the provider, the locus of 
responsibility and commitment to treatment adherence shifts from being solely a function 
of the individual to also becoming a function of the provider and the health care team.  The 
relationship between the patient and the provider becomes a therapeutic alliance where both 
parties work toward a common goal: improving the health of the patient.  Defining this goal 
and the patient’s commitment to it largely depends on the therapeutic alliance and the 
ability of the provider to assess the patient’s readiness (Asim, 2004). 
The physician-patient encounter is a situation in which patients must learn a very and set of 
expectations about: the purpose of the medication; which medication should be taken; how 
long each medication should be taken; and the dosage schedule that should be followed. 
(Kusserow, et al., 1999).  
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Anderson and Kirk in 1982 stated that physicians must be aware of the likelihood of 
noncompliance in individual patients and make efforts to persuade patients of the 
importance of adherence to a program designed to reach and maintain therapeutic goals.  
They assert that it is the physician’s responsibility to teach, motivate, and strengthen the 
patient to maximize adherence as part of a “therapeutic partnership” (Anderson and Kirk, 
1982). 
In Svarstaad's study on physician-patient interaction it was evident that physicians 
frequently did not discuss their expectations in an explicit manner. Of the 347 medications 
prescribed during the course of that study:  Seventeen percent were never discussed at all.  
In only ten percent of the cases were patients told how long to take the medication.  Dosage 
schedules were discussed ambiguously 'Take two capsules every four hours" without 
specifying how many should be taken in a twenty- four hour period.  Patients were not 
always given printed or written instructions for proper use of medications (Kusserow, et al., 
1999).  
 
3.5 Health care system 
Relatively little research has been conducted on the effects of health care team and system-
related factors on adherence.  As stated by WHO in 2003, a good patient-provider 
relationship may improve adherence whereas more broadly, health care systems create 
barriers to adherence by limiting access to health care, using a restricted formulary and 
having prohibitively high costs for drugs, co-payments, or both.   
System variables include the availability and accessibility of services, support for education 
of patients, data collection and information management, provision of feedback to patients 
and health care providers, community supports available to patients, and the training 
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provided to health service providers.  Systems direct providers’ schedules, dictate 
appointment lengths, allocate resources, set fee structures and establish organizational 
priorities (WHO, 2003).  
The failure to care adequately for patients with type 2 DM may be assigned to a lack of 
patient adherence, a failure of physicians' knowledge and skill level, or insufficient funding 
and organization of necessary programmes in the current health care system (Brown, et al., 
2002). 
3.6 Condition-related factors 
Condition-related factors represent particular illness-related demands and co-morbidities 
faced by the patient. Some strong determinants of adherence are those related to the 
severity of symptoms, level of disability (physical, psychological, social and vocational), 
rate of progression and severity of the disease, and the availability of effective treatments. 
Their impact depends on how they influence patients’ risk perception, the importance of 
following treatment, and the priority placed on adherence (WHO, 2003). 
Presence of other disease/chronic diseases decreases the compliance, (Jaser, 1999).   
It would seem important to take such a psychological profile into consideration when 
attempting to understand and even alter the health beliefs ( Harris, et al., 1984). 
For many people, effective, regular diabetes self-care is very difficult.  People often make 
poor personal decisions about health (not just people with diabetes) and do not adequately 
confront the underlying emotional and psychological issues associated with a diagnosis of 
diabetes. People with diabetes may feel angry, guilty, resentful or afraid when confronted 
by the fact of diabetes, and these reactions may interfere with their ability or desire to 
manage their illness effectively (Wilson, et al., 1986).  
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Depression is at least twice as common in patients with diabetes as compared with the non-
diabetic population. Recent evidence suggests that as many as one-quarter of patients with 
diabetes may be suffering with a moderate to major depressive disorder, and depression 
may often go undiagnosed and/or untreated. Needless to say, depression may contribute to 
problematic medication use, due to increases in forgetfulness and/or a loss of interest in 
protecting one's health (Mojtabai and Olfson, 2003). 
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Chapter 4 
Methodology 
 
 4.1 Study design 
It is a cross-sectional study.  Cross-sectional study is generally carried out in a population at 
a part of time or over a short period of time. This type of study is quick and gives some 
insight into the association between cause and effect, "compliance and other variables", and 
it provides important pointers to the possible causes. 
 
4.2 Study population 
The population of the study consists of a sample of patients from both genders with proved 
type-2 diabetes patients who registered at Diabetic Clinic in Al-Rimal Central Clinic, 
According to diabetic care medical records in 2006  the target population is 6400 patients.   
 
4.3 Sample size 
A presentative sample of 197 sample size were determined using EPI-6 – program.   
19 patients (10%) were added. The total sample size  was consisted of 216 patients. 
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4.4 Sampling method 
Cases are chosen by convenient sampling method.  
The diabetic clinic works three days per week.  Diabetic patients come to Al- Rimal 
diabetic clinic from different districs of Gaza Strip according to their appointment.  
Approximately  30 patients are seen per day, 5-10 patients were selected per each visit. 
 
4.5 Eligibility criteria 
4.5.1 Inclusion criteria 
Type2 diabetic patients who are registered, treated and followed  in central diabetic clinic at 
Al-Rimal clinic, both genders male and female.   
 
4.5.2 Exclusion criteria 
Type1 diabetic patients both genders male and female. 
 
4.6 Setting of the study 
The study is carried out at Al- Rimal governmental central diabetic clinic- Gaza City . 
 It is one of the specialized clinics of  primary health care central clinics of Ministry of 
Health in Gaza Strip.  
 
4.7 Data collection 
Data collection was carried out using retrospective review of medical records, structured 
face to face questionnaire and biophysiological measures.   
The questionnaire was designed and prepared to compile information relating to the 
objectives of the study.  
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The questionnaire consisting of two parts: information from the patients (personal, 
sociodemographic, family history of diabetes, lifestyle, medical history of other chronic 
diseases, medication, knowledge, attitude and practice of patients), and information from 
the patient's medical file includes (Date of diagnosis, management plan, and 
biophysiological measures that considered as an indicators for the glycemic control  
includes the  last two reading one year before the date of interview for FBS and HbA1c, the 
other biophysiological measures include: Total cholesterol, Triglyceride, last four reading 
of blood pressure, weight and hight for calculation of BMI).  The instrument used was in 
Arabic language because it is the mother language for the participants, annex (7).  The 
average time for filling                      a questionnaire was 15-20 minutes.  Total period of 
data collection was three months. 
Accordind to ADA, 2006 the normal values of the biophysiological measures was as 
follow: HbA1c=7%, FBS=126mg/dl, total cholesterol=200mg/dl, triglyceride =150mg/dl, 
Blood pressure=130/80mmHg, Body Mass Index( the weight in kilograms divided by the 
square of the height in meters),normal weight= BMI range between18.5-24.9, 
overweight=BMI range between 25-29.9, Obese= BMI range between 30-39.9, morbid 
obese= BMI range between 40 and over 40.  The researcher used these normal values to 
measure the objectives of the study. 
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4.8 Compliance definition: 
The extent to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health care 
provider" (WHO, 2003). 
In this study compliance was discussed and measured according to the medication regimens 
plan using indirect method,  so that compliance was measured by questioning the patient 
(or using a questionnaire), then every participant was asked about the medication regimen 
and comparing the mentioned plan with the exact regimen which had been written by the 
doctors in his file, if the mentioned plan was compatible with the written one, that 
participant was considered as compliant and if not, considered as non-compliant.   
The non-compliance then was studied in relation to different variables of the study and to 
biophysiological measures including (HbA1c which is considered as a good indicator of 
therapeutic outcomes and the glycemic control for the last three months, FBS which reflect 
the daily glycemic control,blood pressure, total cholesterol and triglyceride).  Non-
compliance was also dicussed according to the life style (diet and physical activity).   
 
4.9 Content validity 
The instrument used for data collection in this study is professtionally prepared with high 
face validity. The instrument designed after reviewing related literature to enhance content 
related validity.  The researcher depends also on content validity, where the questionnaire 
was distributed to 10 experts on Public Health and specialists in the field where discussed 
the questionnaire content validity.  Their comments concerning some items were added 
and/or modified. 
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4.10 Data entry and analysis 
Data was entered and analyzed using statistical package of social science version 10 
(SPSS).  Data cleaning was performed to check entry errors.  Data analysis was as follow: 
Defining and coding of data, Descriptive analysis was performed to examine the 
distribution of different factors among the study population Using frequency tables for the 
study variables.  
The dependent variable in the study was the non compliant participants toward their 
medication regimen, the independent variables were socio-demographic and economic 
factors, Patient Factors (knowledge, attitude, feelings, beliefs and practice), conditions 
related problems, regimen factors, provider-based factors and health care system factors. 
The relationship between the dependent variables and the independent variables were tested 
by using Chi Square, the level of significance by using P-value and odds ratio for different 
variables.  
     
4.11 Ethical matter 
1-Helsinki committee (Ethical committee in the Gaza Strip) approval to conduct the study 
(annex 4). 
2-Ministry Of Health approval to collect data from Al- Rimal central diabetic clinic (annex 
5). 
3-Explanation of purpose of the study, instrument,  period of interview, voluntary and 
optional participation and confidentiality pledge (annex 6). 
4-All the ethical concepts were taken into consideration: respect of people, dignity and 
privacy. 
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5-Confidentiality was given and maintained all the time. 
 
 
4.12 Pilot study 
 A pilot study was carried out on  15 subjects selected by convenient sampling methods to 
examine predictability, reliability, and validity of study, and to identify any defects in the 
study design and also areas of difficulties and ambiguity so that changes and adjustments 
on the design will be made.  After piloting process some changes and modifications in the 
questions were done.  These subjects were omitted from the study. 
   
4.13 Limitation of the study 
The study included only the registered patients at Al- Rimal central diabetic clinic as it is 
the only central clinic that have updating  files (hard and electronic) which provide rapid 
and available full data about the patient where information of the study was taken 
especially HbA1c and this test again is performed only in Al-Rimal clinic. 
Convenient sampling is one of the weakest way of sampling.  
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Chapter 5 
 
Results 
 
 
 
 Introduction 
This chapter represents the core results of the study including socio-demographic 
characteristic of the study population, health status, risk factors of diabetes, prevalence of 
non-compliance and associated factors that affecting compliance in the study population.    
 
5.1 Socio-demographic and economic characteristic of the study population 
The study population was 216 diabetic patients, type-2 who are attending Al-Rimal clinic, 
the study showed obvious variations in socio-demographic characteristic.  
The distribution of study population according to socio-demographic characteristic 
including gender, age, marital status, locality, educational level, consanguineous marriage, 
occupation, family size and income presented in table (5.1) 
 
 
 
 
 
 
 83
Table 5.1: Distribution of the study sample by sociodemographic and economic 
characteristics 
 
Characteristics 
Frequency 
(N 216) 
Percent % 
Sex 
Male 77 35.6 
Female 139 64.4 
Age Group 
30-49 years 70 32.4 
50-64  years 112 51.9 
65 years  & more   34 15.7 
Marital status 
Single 14 6.5 
Married 202 93.5 
Locality 
North Gaza 45 20.8 
Gaza 140 64.8 
Mid-zone 31 14.4 
Educational level 
Low        (0-6years) 110 50.9 
Medium  (7-12years) 89 41.2 
High        (>12years) 17 7.9 
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Consanguineous 
marriage 
First degree 73 33.8 
Second degree 33 15.3 
No consanguinity 110 50.9 
Occupation 
Working 22 10.2 
Not working 194 89.8 
 Family size 
1-5 69 31.9 
6-10 103 47.7 
>10 44 20.4 
Income 
<1000 NIS 52 24.1 
1000-2000 NIS 48 22.2 
>2000 NIS 40 18.5 
Refuse to answer 76 35.2 
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5.1.1 Gender 
Considering the gender, diabetic females were twice more than males (64.4% and 35.6% 
respectively) as shown in Figure (5.1). 
Figure 5.1: Distribution of study population by gender 
 
 
64.4
35.6
Female Male
 
5.1.2Age 
The mean age of patients participated in the study was 54.4 years with standard deviation 
(SD) 10.3, median 55 years and range from 31 to 85 years old.  The highest age category 
was among middle age group (50-64years), it was represented by 51.9%, then followed by 
the young age group (30-49), represented by 32.4% then the least percentage 15.7% was 
among age 65 years and over as shown in Figure(5.2).  
Figure 5.2: Distribution of the study population by age group 
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5.1.3 Marital status 
The samples showed that the majority were married (93.5%) and 6.5% were single. 
5.1.4 Locality 
Concerning the locality, most of sample was from Gaza 64.8%, followed by North Gaza 
20.8%, and the lowest were from Mid-zone 14.4% as demonstrated in figure (5.3).  
 
          Figure 5.3: Distribution of the study population by place of residence  
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5.1.5 Educational level 
Regarding the educational level, the researcher categorized and re-coded the years of 
education into three categories. The first was low level of 6 years of education and less 
which represented the majority of the study population (50.9%), the second group was the 
median level from 7 to 12 years, it was represented by 41.2%, and the third group, high 
level with more than 12 years of education was represented by 7.9%. 
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5.1.6 Consanguineous marriage: 
There were 73 (33.8%) had first degree consanguinity (cousin), 33 (15.3) were second 
degree consanguinity (from the family) and the majority were not consanguineous marriage 
(50.9%). 
5.1.7 Occupation 
Concerning the occupation, the majority of the sample didn't work (89.9%), only 10.2% 
were working as shown in figure (5.4).  
 
 
Figure 5.4: Distribution of study population by occupation 
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5.1.8 Family size 
As showed in table (5.1), the highest percentage 47.7% had a family size ranged between     
(6-10 persons),  followed by family size ranged between (1-5 persons) represented by 
31.9%, while the family size  of more than 10 persons represented by 20.4%. 
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5.1.9 Income 
Income was divided into three categories; first group was below 1000 NIS, the second 
category range between 1000-2000 NIS, and the third category above 2000 NIS as shown 
in table (5.1).  Only 18.5% their income was above 2000 NIS, 22.2% of the sample, their 
income was between 1000-2000 NIS and 24.1% income was below or equal to 2000 NIS, 
while 35.2% of the study population refused to answer to that question and could be 
explained  as they  considered as a confidential matter or didn't know the monthly income 
of the family.    
   
5.2 Health profile 
Health profile for each diabetic patient includes duration of diabetes, family history, 
associated chronic disease, initial treatment and current treatment as shown in table (5.2) 
and (5.3) respectively. 
Duration of disease was divided into two groups, first group was ten years and over, 
represented the majority of study population by 64.8%, and the second group included 
those with duration of diabetes less than ten years represented by 35.2% of study 
population as shown in table (5.2).  A recent study revealed that high post-meal blood 
sugars cause nerves damage.  Ten years of very high post-meal values will eventually 
destroy the beta cells.        By the time; ten years of exposure to high blood sugars have had 
time to ruin the nerves, blood vessels, retina, kidneys and other useful bits of equipment 
that we need to stay alive (Tracy,            2006).  
Regarding the family history, the majority of the sample had positive family history, it was 
represented by 78.2%, family history of diabetes related to mother representing with 29.7%, 
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who related to brother or sister was representing also by (29.7%), 18% related to the father, 
and others related to uncle, grandfather and son or daughter.  
Considering the association of chronic diseases 59.7% of the study population had 
associated chronic diseases while 40.3% did not.  The highest percent (44.9%) of sample 
population had hypertension, while about 8.8% with ischemic heart disease (IHD) and 
5.1% with renal diseases.  
 
Table 5.2: Distribution of study population by duration of diabetes, family history and 
associated chronic diseases 
 
 
 
As shown in table (5.3), all patients were asked about their treatment (Initial and current). 
Concerning initiation of treatment, there were 33.3 % of the study population who started 
their treatment with diet as non-pharmacological treatment.  The highest percent were 
started with hypoglycemic agent only (60.2%), and 6.5%were started with insulin only.  As 
Variables Frequency Percent % 
Duration of diabetes 
 
10 years &over 140 64.8 
<10 years 76 35.2 
Family History 
Positive 169 78.2 
Negative 47 21.8 
1-Father 
 
54 18 
2-Mother 89 29.7 
3-Brother\sister 89 29.7 
4-son\daughter 10 3.3 
5- uncle 37 12.3 
 
6-Grandfather 21 7 
Associated chronic diseases 
 
Yes  129 59.7 
No 87 40.3 
1-hypertension 
 
97 44.9 
2-IHD 19 8.8 
3-Renal 11 5.1 
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a comparison, all patients who were on diet only had been changed to hypoglycemic agents, 
insulin or mixed treatment (hypoglycemic agents and insulin), they were represented with 
64.4%, 17.6% and 18.1% respectively. 
 
Table 5.3: Comparison between initial treatment and current treatment regimen 
 
Treatment regimen Initial treatment Current treatment No % No % 
Diet  72 33.3 00 0.0 
Hypoglycemic agent 130 60.2 139 64.4 
Insulin 14 6.5 38 17.6 
Mixed 00 0.0 39 18.1 
 
 
This could be explained by that diabetic disease needs a good control. Once the non-
pharmacological treatment is insufficient to control diabetes, other forms of 
pharmacological treatment should be added.   
 
5.3 Prevalence of non-compliance among study population 
 
The researcher asked the patients about their treatment and frequency of doses, and 
compared what  patients mentioned with the exact regimen that had been written in their 
files, any missing to their current treatment or doses frequency was considered as non- 
compliance.  The results revealed that the prevalence of non- compliance among the study 
population was 109 (50.5%), as shown in table (5.4). According to World Health 
Organization a number of rigorous reviews have found that, in developed countries, 
adherence among patients suffering chronic diseases average only 50% (WHO, 2003).  In 
this study adherence among diabetic patients was 49.5%. 
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Table 5.4:  Distribution of study population according to compliance to management 
plan and possible reasons for non-compliance: 
 
 
 
  
Figure 5.5: Distribution of the study population by reasons of non compliance 
 
 
 
 
 
Variable Frequency Percent % 
Compliance to management plan 
Compliant 107 49.5 
Non –compliant 109 50.5 
Total 216 100.0 
Reasons of non-compliance
Forgetfulness 71 66.4 
Frustration 26 24.3 
Feeling better without treatment 21 19.6 
Polypharmacy 15 14.0 
Fear of drug side-effect 13 12.1 
Unavailability of drugs 9 8.4 
8.4 12.1
14
19.6
24.3
66.4
20
30
40
50
60
70
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Figure (5.5) clarified the percentage of possible causes of non-compliance as mentioned by 
the patients. Typical reasons cited by patients for not taking their medications included 
forgetfullness, it is about 66.4%, frustration 24.3%, feeling better without treatment 19.6%, 
polypharmacy 14%, and other causes such as fear from drug side-effect and  unavailability 
of drugs which representing by 12.1%, 8.4% respectively. The results of the present study 
was congruent with other study; research on adherence has typically focused on the barriers 
patients face in taking their medications conducted by Osterber and Blaschke in 2005, , 
they claimed that common barriers to adherence were forgetfulness 30%, which was found 
in this study as the highest percentage 66.4%, other barriers as found by Osterber and 
Blaschke were related to the other priorities represented by 16%, decision to omit doses 
11%, lack of information 9%, and emotional factors 7%, and 27% of the respondents did 
not provide a reason for poor adherence to a regimen . 
 
5.4 Control of diabetes 
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Control of diabetes was measured according to the biophysiological markers including 
glycated haemoglobin (HbA1c) and fasting blood sugar (FBS). 
 
Table 5.5: Distribution of study population according to the biophysiological marker 
 
Biophysiological  Measures Frequency (N 216) Percent % 
HbA1c
less than 7% 53 24.5 
more than 7%  163 75.5 
FBS 
less than 126  mg/dl  23 10.5 
more than 126   mg/dl 193 89.4 
 
As shown in table (5.5), according to HbA1c (less than 7 %), the prevalence of control was 
24.5%.  According to FBS (less than 126mg/dl), the prevalence of control was 10.5%.   
The hemoglobin A1c goal for people with diabetes is less than 7 percent. The Diabetes 
Control and Complications Trial, DCCT findings showed that people with diabetes who 
keep their hemoglobin A1c levels close to 7 percent have a much better chance of delaying 
or preventing diabetes problems that affect the eyes, kidneys, and nerves than people with 
hemoglobin A1c levels 8 percent or higher. A change in treatment is almost always needed 
if a person’s hemoglobin A1c is over 8 percent. 
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Figure 5.6: Distribution of controlled and uncontrolled of study population  
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5.5 Knowledge about the disease 
 
Knowledge of patients was assessed by asking the patients about diabetes and drugs.  They 
were asked if diabetes is a curable disease or not, and they were asked about drug side-
effects. Table (5.6) clarify that about one third of the sample population 30.1% answered 
that diabetes is a curable disease, 11.1% of them said that they didn't know weather 
diabetes is a curable disease or not, and 58.8% of the study sample stated that diabetes is 
not a curable disease.   
61.1% of patients mentioned that they had knowledge about drugs side-effects, and the 
remaining 38.9% were not having this knowledge.  The patients who claimed that they had 
knowledge were asked about the source of information, the main source of information was 
from doctors and nurses, represented by 70.9%, 20.9% respectively and 8.4% from other 
sources of information which was related to relatives and neighbors, drug leaflets or from 
media.  
 
Table 5.6: Distribution of study population by knowledge of the disease, drug side 
effects and source of information 
 
Variable Frequency Percent % 
1-Knowledge of disease 
Could be cured 65 30.1 
Couldn't be cured 127 58.8 
Don't know 24 11.1 
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2-Knowledge about drug side effects 
Yes 132 61.1 
No 84 38.9 
3-Source of information 
Doctor 105 70.9 
Nurse 31 20.9 
Others 12 8.4 
 
Generally, a moderate proportion of diabetic patients had knowledge about diabetes and 
drug side-effects 58.8%, and 61.1% respectively, and the main source of information was 
from the medical staff (doctors and nurses). This could be explained as health providers 
have a role in patient's knowledge about their disease. 
A study conducted in Egypt by Kamel et al, 1999 to determined diabetics' knowledge of the 
disease, they found that the majority of diabetic patients (90.0%) had poor knowledge about 
the disease. 
  
5.6 Attitudes and practices 
 
The researcher clarified the attitude of respondents and their practices as shown in table 
(5.7), all participants were asked whether they had ever used drugs prescribed to others or 
about usage of traditional remedies.  It was found 89.8% of study population had never 
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used drugs prescribed to others, 7.9% of patients used drugs had been prescribed to others, 
and 2.3% used sometimes. 
Concerning usage of traditional remedies, 19.9% used in the past, and 10.2% used in the 
past and still using, among them 1.9% were used to stop their treatment when taking the 
traditional remedies.  70% of respondents claimed that they had never used the traditional 
remedies.  It was clear that there is an attitude of some patients towards either using 
traditional remedies or using drugs prescribed to others. 
The respondents were also asked about their medications; regularity of taking their 
medications, reliance of doses, and their reaction and practice in case of missing a dose in 
its proper time, or relieve from diabetic symptoms. 
The vast majority (88%) of the study population claimed that they took their drugs 
regularly as prescribed by doctors, 10.6% claimed they sometimes be regular in taking their 
drugs and the remaining 1.4% a certain that they didn't take their drugs regularly.  
 
Table 5.7: Distribution of study population by their attitudes and practices regarding 
antidiabetic drugs 
 
Variable No (n 216) Percent % 
1- Use drugs prescribed to others 
Yes 17 7.9 
Sometimes 5 2.3 
No 194 89.8 
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2-Using traditional remedies 
Yes, still use 22 10.2 
Yes, in the past 43 19.9 
Never used 151 69.9 
3-Take his drug regularly 
Yes 190 88.0 
Sometimes 23 10.6 
No 3 1.4 
4-Reliance 
Self reliance 200 92.6 
Relied on other 16 7.4 
5-Missing to take the drug 
Take it soon 170 78.7 
Don’t take it at all 46 21.3 
6-Relieve diabetic symptoms 
Continue taking the drug 182 84.3 
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Decrease the dose 12 5.6 
Stop the drug 10 4.5 
Consult the doctor 12 5.6 
 
Moreover, as shown in table (5.7), 92.6% of the study population depends on themselves 
reliance for their dose time and this is could be susceptible for forgetfulness. However, 
7.4% relied on others.   
The patients were asked in case of missing their drugs on time, about three quarter (78.7%) 
claimed that they took their drugs soon once they remember the dose, the remaining 21.3% 
certain that they didn't take them in case of missing. 
The majority of the study population (84.3%) mentioned that they continue to take their 
medications even if they relieved from diabetic symptoms. Meanwhile, 5.6% claimed that 
they consult their doctors, 5.6% decrease the dose and 4.5% stop the drug.  
When patients have friends or family members who are providing emotional and/or support 
(eg, reminders to take medications), it is more likely that higher levels of medication 
compliance will be maintained. Several studies have shown that persons with diabetes who 
have greater social support are more likely to follow regimen recommendations                 
(Paes, et al., 1997). 
In this study the majority of study population (92.6%) depending on themselves in 
remembering there doses which is susceptible for forgetfulness. It was shown in table (5.7), 
the majority of study population who were non-compliant 66.4% of them related their 
causes to forgetfulness.   
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Concerning the traditional remedies, a study was done in Saudi Arabia showed one-third of 
patients were using traditional remedies (Al-Saeedi, et al, 2003), and this result congruent 
with the  present study were about 30% of the study population found to use traditional 
remedies either at present or in the past. 
  
5.7 Attitudes, feeling and beliefs 
An attitude of participants toward their disease and treatment regimen is shown in table 
(5.8). About 17.6% feeling not to take the drugs, 14.4% feeling sometimes not to take the 
drugs, the reasons for their desire not to take their drugs; fear from drug side effects at 
present (26.1%), fear from drug side effect in the future (20.3%), fear from drug 
dependence (17.4%), on the other hand 5.8% feel there is no confidence with drugs and 
30.4% related to other causes that mentioned by patients who were on insulin treatment, 
they specify their reasons as fear from hypoglycemia. 
Table 5.8: Distribution of study population by their feeling and beliefs towards the 
antidiabetic drugs. 
 
Variable No (n 216) Percent % 
1-Feeling not to take the drug 
Yes 38 17.6 
Sometimes 31 14.4 
No 147 68.1 
Reasons 
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Fear of side effects  18 26.1 
Fear of side effects in future 14 20.3 
Fear of dependence 12 17.4 
No confidence with drugs 4 5.8 
Others 21 30.4 
Feeling to have a rest from drugs 
Yes 34 15.7 
No 182 84.3 
Believing that the drug is not needed 
Yes 35 16.2 
Sometimes 48 22.2 
No 133 61.6 
 
 
 
As the participants were asked if they feel at any time a need to have a rest period from 
drug taking, 15.7%  prefer to have a rest and the remaining 84.3% did not. 
Regarding participants believe in their need to medication to control the disease, there was 
16.2% believing in their need to medication, while 22.2% stated that they sometimes 
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believing in their need to medication, and 61.6% were certain that they believe in 
medication and to take a rest is not logic. 
As stated by Kusserow et al, in 1999, patients are most likely to comply with medication 
recommendations when they can recognize that the medication is helping them. 
Patients' beliefs can be based on: misconceptions, faulty information, and/or cultural 
conditioning.  For example, some people may believe:" You need to give your body some 
rest from medicine once in awhile or else your body becomes dependent on it or immune to 
it," Or 'You only take medicine when you are ill and not when you feel better, some may 
become aware of only negative consequences eg: hypoglycemia, and these beliefs 
congruent with the finding in this study that were related to diabetic feeling and beliefs 
(Kusserow, et al., 1999).                                                   
 
5.8 Attitude, practice and knowledge regarding life-style  
                            
Regarding life-style, all the respondents were asked about diet and physical activity as 
shown in table (5.9).  More than one third of the study population (38.9%) did not follow 
any diet regimen as they had mentioned, on the other hand 61.1% claimed that they follow 
a diet regimen but the sources of getting or following a good diet regimen varies as follow; 
nearly half of them had the diet regimen advice from their doctors (51.1% ) and 23.7% 
from nurses while the other sources of diet regimen were from protocols, relatives and 
neighbors presenting by 16.8% and 8.4% respectively.                             
 
Table 5.9: Distribution of study population by their attitudes and practices regarding 
life-style  
 
Variables No (n 216) Percent % 
Following Diet regimen 
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Yes 132 61.1 
No 84 38.9 
Source of getting the diet 
regimen 
  
Doctor 67 51.1 
Nurses 31 23.7 
Protocols 22 16.8 
Relatives and others 11 8.4 
Benefit of exercise 
Yes, beneficial 213 98.6 
No 3 1.4 
Practice exercise 
Yes 83 38.4 
No 133 61.6 
Frequency of practice   
Three days or more per week  39 18.1 
Less than three days week 44 20.3 
For those who treated by Insulin (n 77, 35.6%) 
Who give you the injection 
Myself 57 74.0 
Family member 18 23.4 
Others 2 2.6 
Received training on injection 
Yes 53 93.0 
No 4 7.0 
Who trained you 
Health providers 38 71.7 
Family members 11 20.8 
Others 4 7.5 
Necessity of eating after insulin injection 
Yes 72 93.5 
No 5 6.5 
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It was found that 98.6% of study population believed in the benefit of exercise for their 
health, in spite that only 38.4% of the subjects was actually practicing exercise (brisk 
walking), and among them 18.1% of them were exercising 3 or more days per week, 20.3% 
were exercising less than 3 days per week.                                                 
These results was congruent with the results of a survey conducted by Searle and Ready 
1991, they found that physicians and dietitians were the primary sources of information 
about both exercise and diet, and they found that although few respondents participated in 
organized (7.7%) or informal (36.8%) exercise programs, or expressed an interest in 
participating (36.8%), the majority (84.0%) believed that they should get more exercise                       
(Searle and Ready, 1991). This points to a gap between attitude and behaviour.  
 In a study conducted by Hays and Clark in 1999, they found that the majority of the 
respondents (54.6%) reported zero min of weekly physical activity.  This result agreed with 
the results in the presented study, as 61.6% of respondents were not exercising at all.   
Being overweight can be prevented by regular physical activity.  A second, independent 
benefit of regular physical activity is improved blood sugar control in persons who already 
have type 2 diabetes (PHAC, 2001). 
In conclusion as found in the result; the majority of study population didn't follow the non-
pharmacological treatment (Diet and exercise) in spite of their believing in them.  
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For those who treated with insulin (n=77, 35.6%), they were asked about the injection, 
training and knowledge. The majority (74%) of patients who were treated with insulin took 
the injection by themselves, and 23.4% by other members of the family and 2.6% by others 
like neighbors, relatives or medical providers.  
Concerning the training, 93% of respondents received training, among them 71.7% were 
trained by health providers, 20.8% were trained by family members and 7.5% were trained 
by others.  As a neglection of eating after half an hour of injection could expose diabetic 
patients to hypoglycemia, the respondents were asked about their knowledge, 93.5% of 
patients mentioned that eating after insulin is necessary, among them only 51.4% who 
knew that eating should be after half an hour, while 44.4% of them thought that eating 
could be directly after injection, and 4.2% thought that eating could be after more than one 
hour. Although most of participants who were on insulin injection had a training 93%, or 
had an information about treatment. But it is necessary to enhance the awareness and the 
education about the proper way of taking  insulin and precocious from drug side effects.                                 
 
5.9 Medications, sources, availability and polypharmacy: 
 
The study results showed that the majority of patients 88.9% got their drugs from 
governmental health center, 6.9% got their drugs from UNRWA, while 4.2% of participants 
got their drugs from others such as neighbors, relatives, private pharmacy, The majority 
62% of the study population were certain that drugs is always available, 35.2% claimed that 
drugs are sometimes available and who mentioned that drugs are not available at all was 
represented by 2.8% as shown in table (5.10). 
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Table 5.10:  Distribution of study population by sources of drug prescription, 
availability of drugs and number of daily medication 
  
Variable No (n 216) Percent % 
Sources of drug prescription 
Governmental health center 192 88.9 
UNRWA 15 6.9 
Other  sites 9 4.2 
Availability of drugs 
Always available 134 62 
Sometimes available 76 35.2 
Not available 6 2.8 
Other sources to get drugs  
UNRWA clinic 23 10.6 
another  governmental clinic   2 0.9 
private pharmacy 133 61.6 
Use drugs from relatives          13 6 
Remain without treatment       45 20.9 
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All the participants were asked about other sources of drug prescription in case of 
unavailability of drugs in the governmental health center.  The results showed that the 
majority mentioned that they bought  their drugs from a private pharmacy represented by 
61.6%, others 20.9% remained without treatments, other options of getting the drugs varies 
between UNRWA, relatives and another  governmental clinic 10.6%, 6%, and 0.9 
respectively. 
Among the study population 59.7% were taking drugs other than diabetic drugs. Regarding 
the number of daily drugs taken by diabetic patients including the diabetic drugs, more than 
half of study sample were taking two or three drugs per day which was represented by 
50.5%, and 34.3% of patients were taking more than three drugs per day, and the remaining 
15.3% of the participants were taking only one drug as clarified in table (5.10).  
  
Taking drugs other than antidiabetic drugs 
Yes 129 59.7 
No 87 40.3 
No of daily drugs taken by patients 
One drug 33 15.3 
Two-Three drugs 109 50.5 
> three drugs 74 34.3 
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5.10 Diabetic risk factors 
 
Concerning the risk factors as shown in table (5.11), the majority of study population had 
uncontrolled blood pressure, more than 130/80mmHg and represented by 68.5%, Patients 
with diabetes have a much higher rate of hypertension than would be expected in the 
general population (Sheeri, et al., 2002), According to International Diabetes Federation, 
(2005). Blood pressure control can reduce cardiovascular disease (heart disease and stroke) 
by approximately 33% to 50% and can reduce microvascular disease (eye, kidney, and 
nerve disease) by approximately 33%. In general, for every 10 millimeters of mercury (mm 
Hg) reduction in systolic blood pressure, the risk for any complication related to diabetes is 
reduced by 12%. (CDC, 2005).   
Additionally, about two thirds (64.8%) of the study population had hypercholesterolemia, 
68.5% had hyper triglyceridemia, and more than half of the respondents were obese 
(52.8%), 10.2% were reported as morbid obese, 30.6% were overweight and only 6.5% 
who were within normal body mass index. Regarding smoking only 4.6% were smokers, 
1.9% were ex-smokers (stopped smoking for more than six months), and the majority were 
non-smokers 93.5%, this could be related to that most of the study population were 
females.   
Astrup in 2001 found that 80-95% of the increase in diabetes can be attributed to obesity 
and overweight with abdominal fat distribution (Astrup, 2001). 
 
Table 5.11:  Distribution of study population by the risk factors 
Variable(Risk factors) No (n 216) Percent % 
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1-Blood Pressure 
Controlled 68 31.5 
Uncontrolled 148 68.5 
2-BMI 
 18.5-24.9(Normal) 14 6.5 
25-29.9(overweight) 66 30.6 
30-39.9(obese) 114 52.8 
40->40(morbid obese) 22 10.2 
3-Hypercholesterolemia 
0-200 mg/dl 76 35.2 
>200 mg/dl 140 64.8 
4-Hypertriglyceremia 
0-150 mg/dl 68 31.5 
>150 mg/dl 148 68.5 
5-Smoking 
Yes 10 4.6 
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According to the MOH, annual report in 2005 the incidence of diabetic patients in 2002 
with obesity is 60.8% (42.3% in males and 72.4% in females), (MOH, 2005), in this study 
it was about 52.8% as obese and 10.2% as morbid obese which is congruent with the MOH 
annual report in 2005.  
 
 
 
5.11 Complications of diabetes 
Table (5.12) clarifies the complication of diabetes that affect the study population.  It was 
found that 57.9% of them had complication, 37% didn't have and 5.1% mentioned that they 
did not know whether they have complication or not.   
The highest complications were ophthalmic, neuropathy and diabetic foot represented as 
56.8%, 44.8% and 34.4% respectively, followed by ischemic heart disease (IHD),  renal 
and cerebrovascular complications 15.2%, 8.8%, and 0.8% respectively.   
    
Table 5.12: Distribution of study population by complication of diabetes 
 
No 202 93.5 
Ex-smoker (more than 6months) 4 1.9 
Variable No (n 216) Percent % 
Having complications 
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Yes  125 57.9 
No 80 37 
Didn't Know 11 5.1 
Type of complication (n 125) 
Ophthalmic 71 56.8 
Renal 11 8.8 
Diabetic foot 43 34.4 
Neuropathy 56 44.8 
IHD 19 15.2 
CVA 1 0.8 
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5.12 Diabetic clinic visit 
 
It was found that 88% of study population respect their appointments to the diabetic clinic, 
while 12% were not.  The proportion who did not respect their appointments related the 
causes to the increasing waiting time, it was represented by 77.8 of causes, the other causes 
related to either doctors did not give the patients' their care or attention (14.8%) or 
unavailability of drugs (7.2%). 
 
Table 5.13: Distribution of study population according to the clinic visit 
 
 
 
 
 
5.13 Monitoring of glycemic control 
 
Clinic Visit Appointment Frequency Percent % 
Respect appointments to the diabetic clinic 
Yes 190 88 
No 26 12 
Reasons for not keeping the appointment
Waiting time 21 77.8 
Doctors did not give 
attention 
2 14.8 
Unavailability of drugs 4 7.2 
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It was shown that only 11.1% of study population checking the glucose level by 
themselves, Self-monitoring of blood glucose (SMBG), the frequency of using SMBG was 
distributed as follow; daily use (8.3%), weekly use (16.7%), monthly use (20.8%) and more 
than monthly use (54.2%). It was clear that self-monitoring of blood glucose represented a 
small percentage 11.1%. According to American Diabetes Association in 2006, self-
monitoring of blood glucose considered as an integral part of the management strategy and 
for patients using less frequent insulin injections or oral agents or medical nutrition therapy 
(MNT) alone, SMBG is useful in achieving glycemic goals.                                                                                
   
 Table 5.14: Distribution of study population according to the self-management 
 
 
 
Variable Frequency Percent % 
Self-monitoring of blood glucose (SMBG) 
Yes 24 11.1 
No 192 88.9 
Frequency of measurement
Daily 2 8.3 
Weekly 4 16.7 
monthly 5 20.8 
More than monthly 13 54.2 
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5.13 Compliance and socio-demographic factors 
 
Table (5.15) clarifies the relationship between selected socio-demographic factors and non 
compliance, which are gender, age, marital status, locality, educational level, occupation 
and income.    
Comparing between males and females regarding the non compliance rate, it was the 
highest among female as 52.9% of female were not complied, while 46.1% of males were 
not complied. Although the non- compliance rate was higher among females the difference 
didn't reach a statistical significant (P=0.393).                                               
Non-compliance rate varies from one age group to another.  Non-compliance with 
percentage 60% was higher among age group (30-49) than those who were complaints 
(40%) and similarly the non compliance rate was higher among age 65 years and over.  On 
the other hand among age group (50-64), the compliance rate increased, 56.2% were 
compliers and higher than the non compliant.  
Table 5.15: The relationship between compliance and sociodemographic and 
economic variables 
 
Sociodemographic 
characteristics 
Compliant Non -compliant X2 P -value 
No % No % 
Sex 
Male 41 53.9 35 46.1 0.912 0.393 Female 66 47.1 74 52.9 
Age Group 
30-49 28 40 42 60 
4.650 0.098 50-64 63 56.2 49 43.8 
65&over 16 47.1 18 52.9 
Marital status 
Single 9 64.3 5 35.7 1.303 
 
0.282 
 Married 98 48.5 104 51.5 
Locality 
North Gaza 25 55.6 20 44.4 
1.372 0.504 Gaza 69 49.3 71 50.7 
Mid-Zone 13 41.9 18 58.1 
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Educational level 
Low 61 55.5 49 45.5 
3.180 0.204 Medium 39 43.8 50 56.2 
High 7 41.2 10 58.8 
Consanguinity 
First degree 30 41.1 43 58.9 
4.788 0.091 Second degree 21 63.6 12 36.4 
No consanguinity 56 50.9 54 49.1 
Occupation 
Working 12 54.5 10 45.5 0.246 0.659 Not working 95 49 99 51 
Family number 
1-5 33 47.8 36 52.2 
0.718 0.698 6-10 54 52.4 49 47.6 
>10 20 45.5 24 54.5 
Income 
<1000 NIS 28 53.8 24 46.2 
2.005 0.571 1000-2000 NIS 24 50 24 50 >2000 NIS 22 55 18 45 
Refuse the answer 33 43.4 43 56.6 
 
 
In conclusion, the compliance rate is the highest among the middle age group (50-64) but 
the result did not reach the statistical significance (P= 0.098).  This result agree with Platt, 
(1994), Platt stated that demographic factors, such as age, gender, ethnicity, and socio-
economic status have been included in almost every analysis of adherence although they do 
not seem to be consistent correlates of whether or not a patient keeps appointments or 
follows a medication regimen (Platt,1994).  And the results agreed with Albaz in Saudi 
Arabia in 1997, who concluded that organizational variables (time spent with the doctor, 
continuity of care by the doctor, communication style of the doctor and interpersonal style 
of the doctor) are far more important than sociodemographic variables (gender, marital 
status, age, educational level and health status) in affecting patients. 
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As shown in the results, increasing age is generally associated with increasing adherence 
until patients enter their 65s, when adherence declines, this result agree with Kem in 2003 
as he found that compliance is generally associated with increasing age until patients enter 
70s and this decrease might be due in part to failing memory or the need for complex 
medication regimens as people age (Kem, 2003). 
Regarding the marital status, it was found that the majority were married represented 
93.5%, and the compliants were 51.5% among them.  It did not reach the statistical 
significance(P=0.282).                                                                                                    
Concerning the locality of the study population, the proportion who were not compliants 
were more than who were compliant in Gaza and Mid-Zone represented by 50.7%, and 
58.1% respectively. In North-Gaza the compliants 55.6% were higher.  The result did not 
reach the statistical significance (P=0.504). 
As mentioned before, the researcher categorized the education level into three categories.  
The first was low level of 6 years of education and less, the second group was the median 
level from 7 to 12 years, and the third group, high level with more than 12 years of 
education.  It was found that as the degree of education increased, the non compliance 
increased too; among the median level of education, 56.2% were not compliant and 58.8% 
were not compliant among the high level, but did not reach the statistical significance 
(P=0.204).                                                                                                                                  
Concerning the consanguinity, the non compliance rate was the highest among those who 
had first degree consanguinity, the result did not reach the statistical significance(P=0.091). 
Regarding the occupation, it was found that 89.9% of the study population was not 
working; about half of non-workers (51%)  were not complaints while the majority of 
 118
workers 54.5% were compliant.  Hertz, et al in 2005 found that adherence was poor among 
working-aged patients but in this study adherence was good among workers but the result 
did not reach the statistical significance (P=0.659).                                               
Number of Participants family size were divided into three categories as shown in table 
(5.15), the non compliance rate was higher among the group who had family size above 10 
persons but the result didn't reach the statistical significance (P=0.698).         
Concerning the income, it was found that the compliance rate little bit increased among 
both groups who their income below 1000 NIS and above 2000 NIS and there were no 
difference in compliance rate with those their monthly income is between 1000-2000 NIS. 
The result did not reach the statistical significance (P=0.571).                
 This is congruent with Platt, in 1994 who stated that socio-economic status not seemed to 
be consistent correlates with compliance.  On the other hand Joel, et al. in 2002 found that 
adherence for chronic drug regimen is often suboptimal, lower socioeconomic and minority 
population have greater barriers to adherence (Joel, et al., 2002).    
              
5.14 Compliance and health profile 
 
The researcher studied the relationship between compliance and health profile, including 
duration of diabetes, family history and associated chronic disease. It was found that the 
non compliance rate was higher among participants who had diabetes for more than ten 
years and were represented by 52.6%, while it decreased among participants who had 
diabetes for less than ten years (49.3%).  This indicates that the compliance rate decreased 
as the duration of diabetes increased, but it didn't reach the statistical significance 
(P=0.671).  
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Among patients who had positive family history, 50.9% found to be not-compliant, which 
is higher than the complaints.  On the other hand the compliance rate was higher among 
patients who didn't have positive family history (51%).  It was shown that compliance rate 
decreased when patients had positive family history of diabetes. Regarding patients who 
had positive family history especially their mothers, 58.4% were not compliant and higher 
than those compliant (41.6%) and this result was statistically significant (P=0.046, 
OR=0.526 and C.I= (0.285-0.970). this result could indicate that there is a negative 
relationship between compliance and family history, especially when the mother is diabetic.                             
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Table 5.16: The relationship between compliance and health profile 
 
Health profile Compliant Non compliant X2 P- value 
No % No % 
Duration of diabetes
<10 years 71 50.7 69 49.3 0.221 0.671 >10 years 36 47.4 40 52.6 
Family history 
Yes 83 49.1 86 50.9 0.056 0.870 No 24 51.1 23 48.9 
Mother 
 Yes 37 41.6 52 58.4 4.276 0.046 No 46 57.5 34 42.5 
               O.R=0.526                                      C.I=(0.285-0.970) 
Associated chronic diseases 
Yes 59 45.7 70 54.3 1.851 0.212 No 48 55.2 39 44.8 
Hypertension 
Yes 46 47.4 51 52.6 0.315 0.587 No 61 51.3 58 48.7 
Ischemic heart disease 
Yes 5 26.3 14 73.7 4.494 0.052 No 102 51.8 95 48.2 
Kidney disease 
Yes 6 54.5 5 45.5 0.116 0.767 No 101 49.3 104 50.7 
 
The non-compliance rate generally increased as there were associated chronic diseases. 
While 54.3% of patients were not compliant, 45.7% were complied, but it didn't reach 
the statistical significance.  Considering hypertension and ischemic heart disease, the non 
compliant patients were higher than the complaints as shown in table (5.16), the result 
reach the statistical significant with those associated ischemic heart disease ( P=0.052). 
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5.15 Compliance and current treatment 
Concerning the current treatment, the participants who were on oral hypoglycemic agents 
(OHAs) alone, the compliance rate was higher than the non compliance rate represented by 
51.8%, among participants who were on insulin alone, the non compliance rate was more 
higher, represented by 57.9%, similarly among those who on mixed treatment (OHAs and 
insulin) again the non compliance was more than the compliance rate represented by 51.3% 
as shown in table (5.17).  The results didn't reach the statistical significance.  
 
Table 5.17: The relationship between compliance and current treatment 
Current treatment Compliant Non compliant X2 P –valueNo % No % 
Oral hypoglycemic agent(OHA)
Yes 72 51.8 67 48.2 0.798 0.396 No 35 45.5 42 54.5 
Insulin 
Yes 16 42.1 22 57.9 1.019 0.373 No 91 51.1 87 48.9 
Mixed 
Yes 19 48.7 20 51.3 0.013 1.000 No 88 49.7 89 50.3 
 
 
As mentioned by Polonsky, et al. in 2003, many people with type 2 diabetes feel about 
beginning insulin therapy, and this result is congruent with the results of the presenting 
study.  Similarly, a review of literature search (1966–2003) was performed and confirmed 
that many patients for whom diabetes medication was prescribed were poor compliers with 
treatment, including both OHAs and insulin (Joyce, 2004). 
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5.16 Compliance and control measures of diabetes 
As mentioned before the control of diabetes was measured according to the 
biophysiological markers including glycated haemoglobin (HbA1c) and fasting blood sugar 
(FBS) as an indicators of therapeutic outcomes.  The compliers were much higher among 
controlled group whose HbA1c was less than 7%. The relationship between compliance 
and the control of disease was highly significant (P=0.000), as the compliance increased 
control of disease increased by five times, (OR=5.021, C.I(2.456-10.268). Regarding FBS, 
the compliers were higher among controlled group whose FBS below 126mg/dl and the 
result was statistical significant (P=0.004, OR=4.207, C.I= (1.501-11.789). 
Table 5.18: The relationship between compliance and the biophysiological markers 
Biophysiological Markers Compliant Non compliant X2 P –valueNo % No % 
HbA1c
less than 7percent  41 77.4 12 22.6 21.747 0.000 more than 7percent  66 40.5 97 59.5 
                        OR= 5.021                                C.I(2.456-10.268) 
FBS 
less than 126   18 78.3 5 21.7 8.496 0.004 more than 126  89 46.1 104 53.9 
                       OR=4.207                                  C.I(1.501-11.789) 
 
 
A single HbA1c value taken every 2 to 3 months serves as an integrated index of blood 
glucose control over those months and thus provides an objective view of the patients' 
glycemic control between checkups, as showed in the landmark nine-year Diabetes Control 
and Complications Trial (DCCT), which completed in 1993, the risk for development and 
progression of the chronic complications of diabetes is closely related to the degree of 
glycemic control, as measured by HbA1c determinations (Gonen, et al.,1997). Similarly the 
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results of the United Kingdom Prospective Diabetes Study show that lowering blood 
glucose levels, as measured by HbA1c determinations, reduces the incidence of 
microvascular complications in Type 2 diabetes.( Gonen, et al.,1997). 
 
5.17 Compliance and knowledge  
 
In this field, different variables concerning the relationship between the patients and 
compliance rate were included.  These were related to the information of the patient about 
the cure from diabetes, knowledge of drugs and their side-effect and the source of 
information.  Patients who believed in that diabetes is a curable disease  have higher 
compliance rates 52.3%, whereas the non compliance rate was higher among patients who 
didn't have a knowledge about the disease weather it is a curable disease or not.  The results 
did not reach a statistical significant level (P=0.443). so that patients beliefs or knowledge 
reflect a positive action but not significant on their compliance. The presenting results 
disagree with the results of Jaser in 1999, where he found that patients' beliefs didn't reflect 
positive action on their compliance (Jaser,1999). 
The participants where asked about drug side-effects knowledge, the majority of those who 
didn't know about drug side-effects were not complaints and presented by 75%, on the 
other hand the complaints were higher among those who had a knowledge of drugs, 
represented by  65.2%, the difference was strongly statistical significant with P=0.000, so 
there is a positive association between knowledge and compliance and the risk of poor 
knowledge to increase the non compliant rate was about six times higher (OR=5.609, 
C.I=(3.048-10.322)). 
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Table 5.19: The relationship between compliance and  knowledge about the disease, 
drugs side effects and source of information 
 
Variables Compliant Non compliant X2 P -value No % No % 
Knowledge of diabetes
Curable 34 52.3 31 47.7 
1.628 0.443 Not curable 64 50.4 63 49.6 
Did not know 9 37.5 15 62.5 
Knowledge of drug side- effects 
Yes 86 65.2 46 34.8 33.106 0.000 No 21 25.0 63 75.0 
                   OR=5.609                                              C.I=(3.048-10.322) 
Source of information 
1-From the doctor 
Yes 71 67.6 34 32.4 1.909 0.187 No 15 53.6 13 46.4 
2-From the nurse 
Yes 19 61.3 12 38.7 0.170 0.675 No 66 63.3 35 34.7 
 
 
Generally, knowledge and awareness are an important factors to enhance compliance, this 
result is congruent with Wilson and colleagues in 1986, they reported that mood, 
knowledge of diabetes care, social support and health beliefs were collectively predictive of 
better compliance. Similarly Petty and Cacioppo (1981) proposed that people are more 
likely to process information thoughtfully if they perceive it as personally relevant (Petty 
and Cacioppo, 1981).  
The results also showed that the mean source of information about disease, drugs and side-
effects of medicine was the doctors and the nurses and the compliance rates among them 
was higher than the non compliance but the difference didn't reach the statistical 
significance. 
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5.18 Compliance and attitude regarding medicine 
 
Considering feeling and believes of diabetic patients and their compliance toward regimen 
plan, table (5.20) clarifies that patients who believed in that medicine is not needed, 62.9% 
of them were not compliant and higher than who were compliant represented by 37.1%.  
Among those who believed in that medicine is sometimes not needed, 56.2% were not 
compliant and higher than who were compliant (43.8%).  While those who believe in that 
medicine is needed, the compliant participants about 54.9% were higher than who were not 
complaints.  
As shown in the results, as believing in the need of medicine increased, compliance 
increased too but the result didn't reach the statistical significance (P=0.116). 
 
Table 5.20: The relationship between compliance and attitude regarding medicine 
 
Feeling & beliefs Compliant Non compliant X2 P-Value No % No % 
Believing in that medicine is not needed
Yes 13 37.1 22 62.9 
4.317 0.116 Sometimes 21 43.8 27 56.2 
No 73 54.9 60 45.1 
Feeling didn't like to take medicine 
Yes 10 26.3 28 73.3 
12.315 0.002 Sometimes 13 41.9 18 58.1 
No 84 57.1 63 42.9 
Feeling in need for rest period 
Yes 9 26.5 25 73.5 8.589 0.005 
No 98 53.8 84 46.2 
                                        OR=0.309                        C.I=(0.136-0.698) 
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It was found that feeling toward taking the medicine, the non-compliance rate increased 
among participants who feel or sometimes feel that they didn't like to take the medicine 
73.3%, and 58.1% respectively, while the complaints 57.1% were higher than the non 
compliant among those feeling was positive toward taking the medicine.  This indicate that 
patients' feeling affect significantly the compliance (P=0.002). 
It was found that the compliance rate 26.5% decreased compared with the non- compliant 
rate 73.5% regarding participants feeling in need to have a rest period from medicine and 
the results reach the statistical significant, P=0.005, OR=0.309 and C.I=(0.136-0.698).  
In conclusion, the compliance rate significantly decreased and associated with patients' 
feeling; (didn't like to take medicine or feeling in need for rest period). The present study 
was congruent with results of Jaser, 1999 regarding patients feeling and beliefs.  
Non-adherence in many chronic illnesses has been linked to attitude of a patient toward 
him/herself and the illness (Wichowski and Kubach, 1997). 
A study conducted by McCord and Brandenburg, in 1995, they concluded that a better 
understanding of patients' beliefs and attitudes may help physicians increase motivation, 
understanding, and compliance of diabetic patients. 
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5.19 Compliance and attitude and practice regarding medicine 
 
Concerning the attitudes, the non compliance rate was higher among participants who could 
sometimes use others drugs and among those who didn't use others drugs, they represented 
60% and 51.5% respectively, on the other hand the compliers among those who used to 
take drugs prescribed to others were higher 64.7%, although the result didn't reach the 
statistical significance (P=0.399), but this result indicate that the compliants tried to get 
their drug even from other.  
As mentioned before, small percent of participants who used traditional remedies around 
20% used in the past, and 10% still use, among them the non-compliance rates 46.5% and 
40.9% respectively were lesser than the compliance rates as presented in the table (5.21), 
this means that using of traditional remedies or not didn't affect the compliance but the 
result didn't reach the statistical significance. Similarly Al-Saeedi, et al. in 2003, found a 
statistically significant relationship between belief in traditional medicines and variables 
such as female sex, positive family history of diabetes, duration of diabetes and compliance 
with diet, but they didn't found relationship with other compliance variables or with glucose 
and weight control and they concluded that efforts should be made to enhance diabetic 
education among patients on the basis of evidence-based practice.  
Regarding the regularity of drug taking as mentioned by the participants, those who 
claimed that they sometimes be regular, all of them were not complaints (100%), and 
participants who claimed that they were not be regular  in taking their drugs, the non 
compliance rate was 66.7% higher than the compliance rate 33.3%.  The compliance rate 
55.8% among participants who mentioned that they were regularly taking their drugs was 
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higher than the non compliance rate.  The result had shown a highly statistical significance 
with (P=0.000).    
Table 5.21: The relationship between compliance and their attitude and practice 
regarding medicine 
 
Feeling & beliefs 
Compliant Non compliant 
X2 P –value 
No % No % 
Using of drugs had been prescribed to others
Yes 11 64.7 6 35.3 
1.838 0.399 Sometimes 2 40.0 3 60.0 
No 94 48.5 100 51.5 
Using of traditional remedies 
Yes 13 59.1 9 40.9 
1.455 0.483 Yes, in the past 23 53.5 20 46.5 
Never used 71 47.0 80 53.0 
Taking of drug regularly 
Yes 106 55.8 84 44.2 
25.864 0.000 Sometimes 0.0 0.0 23 100 
No 1 33.3 2 66.7 
Reliance 
Self reliance 100 50.0 100 50.0 0.232 0.796 Relied on others 7 43.8 9 56.3 
Missing to take drug  
Take it soon 98 57.6 72 42.4 21.003 0.000 Not take it 9 19.6 37 80.4 
                                        OR=5.596                        C.I=(2.541-12.323) 
Relieve from diabetic symptoms(feeling improvement) 
Continue taking drugs 91 50 91 50 
4.915 0.178 Decrease the dose 6 50.0 6 50.0 Stop the drugs 2 20.0 8 80.0 
Consult the doctor 8 66.7 4 33.3 
 
 
It was found that among participants who depends on themselves in reliance, half of them 
were non complaints, and it was found 56.3% among patients who relied on others were 
non complaints and higher than compliant, but the results didn't reach the statistical 
significance.    
 130
 In case of missing a dose most of participants who claimed that didn't take the dose later 
were also non compliant to their regimen (80.4%), and they were about six times higher 
than the complaints (OR=5.596, C.I=(2.541-12.323)) and the result was strongly associated 
with compliance and reach the statistical significance where ( P=0.000). This was 
congruent with as mentioned before about the causes of non compliance where it was found 
that forgetfulness is the common cause of non compliance (66.4%).     
The participants were asked about their practice once the diabetic symptoms relieved and 
by comparison most of patients who claimed that they stop treatment were not compliant 
(80%), while among those who decide to decrease the dose 50% were not compliant.  The 
others who mentioned either continue the treatment or consult their doctors(The good 
options), the non compliance rate was lesser among them (50%, and 33.3% respectively), 
although the result didn't reach the statistical significance, but the result  indicate that 
compliance is negatively affected by feeling of symptoms that means when the symptoms 
disappear compliance decrease too, so it is important to give attention to this point by 
health providers and to educate the patients not to discontinue the treatment and to clarify 
that their goal of treatment is to decrease the symptoms and to improve their health and the 
quality of life.   
The result disagrees with Anderson and Kirk in 1982, who suggest that if an illness has 
easily recognizable and unpleasant symptoms that are improved by following treatment 
recommendations, adherence is more likely.  
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5.20 Compliance and life style  
 
It was important to study the relationship between compliance and the non-pharmacological 
factors (diet and exercise).  Diet and exercise are the cornerstones of treatment for persons 
with type 2 diabetes mellitus (Shultz, et al., 2001). 
It was found that 73.8% were non compliant to regimen treatment and not following any 
diet regimen while only 26.2% were compliants and not following a special diet, as shown 
the result revealed that the compliance rate had a strong statistical significance with the diet 
regimen, (P=0.000).  The non compliants were five times higher among those who didn't 
follow diet regimen (OR=5.097 and C.I=(2.789-9.314)). 
 
Table 5.22: The relationship between compliance and physical activity, benefits and 
diet 
 
Variables 
Compliant Non compliant 
X2 P -value No % No % 
Following diet regimen
Yes 85 64.4 47 35.6 29.971 0.000 No 22 26.2 62 73.8 
                                    OR=5.097                        C.I=(2.789-9.314) 
Benefits of physical activity 
Yes beneficial 105 49.3 108 50.7 
0.357 0.620 
No 2 66.7 1 33.3 
Practice of physical activity 
Yes 48 57.8 35 42.2 3.710 0.069 
No 59 44.4 74 55.6 
                                      OR=1.720                        C.I=(0.989-2.993) 
 
 
About half of patients who believed in that exercise is beneficial were not compliants 
50.7% but the result didn't reach the statistical significance.  Among patients who did not 
practice physical activity 55.6% were not compliants where 44.4% were compliants and 
 132
didn't reach statistical significance.  As it was shown non-compliance rate was higher 
among patients who didn't follow a special diet regimen and who didn't practice any 
physical activity.   
There is now substantial evidence that type 2 diabetes can be prevented or delayed by 
lifestyle interventions, i.e. diet and exercise should be the first choice in order to avoid 
weight gain when preventing diabetes. The incidence of newly diagnosed type 2 diabetes 
decreased parallel with weight loss (Germendy, 2003). Generally regular physical activity 
is improved blood sugar control in persons who already have type 2 diabetes (PHAC, 
2001). So it is important to focus on lifestyle intervention and to increase the education in 
this field. 
 
5.21 Compliance and insulin 
The proportion of participants who treated with insulin (35.6%), the non compliance rate 
was the highest among them, represented by 54.5%, it didn't reach the statistical 
significance (P=0.396).  
the result was congruent with a review of literature search (1966–2003), which confirmed 
that many patients for whom diabetes medication was prescribed were poor compliants 
with treatment, including both OHAs and insulin (Joyce, 2004). 
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Table 5.23: The relationship between compliance and insulin  
Variable 
Compliant Non compliant 
X2 P –value No % No % 
On Insulin  
Yes 35 45.5 42 54.5 0.798 0.396 No   72 51.8 67 48.2 
Who give the injection 
Myself 30 52.6 27 47.4 
5.119 0.077 Person from the family 4 22.2 14 77.8 
Others 1 50 1 50 
Training 
Yes 29 54.7 24 45.3 1.317 0.336 No  1 25 3 75 
                                 OR=3.625                                    C.I=(0.354-37.142) 
Eat after injection 
Yes 32 45.1 39 54.9 0.049 1.000 No 2 40 3 60 
Time of eating after the injection 
Directly after the injection 13 40.6 19 59.4 
0.992 0.609 After half an hour 18 48.6 19 51.4 
After an hour 2 66.7 1 33.3 
 
As mentioned before, the majority of participants were taking the injection by themselves 
(74%), and most of them were compliants 52.6%, and among those who received training 
on injection were compliants represented by 54.7%.  The result didn't reach the statistical 
significance (P= 0.336) but the risk of non compliance to increase was three times higher if 
they were not trained, so that training on injection improve the compliance. 
As shown in the same table eating after the injection had no statistical significant with 
compliance. 
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5.22 Compliance and risk factors 
 
The researcher studied the relationship between selected risk factors and compliance; they 
include smoking, blood pressure, hypercholesterolemia, hypertriglyceridemia, and obesity. 
As mentioned before only 4.6% were smokers and had no effect on the compliance rate in 
this study. Regarding other risk factors the non compliant patients in general were higher 
than the complaints.  It was found that 54.1% of patients who had high blood pressure were 
not compliant while 45.9% were complaints but it didn't reach the statistical significant.  
Among patients who had hypercholesterolemia, 51.4% were not complaints and also didn't 
reach the statistical significant.  Concerning hypertriglyceridemia 55.4% were not 
compliant  and higher than compliant, the relation was statistically significant as P-
value=0.040, the risk of non compliant patients to have hypertriglyceridemia was twice 
more than that who were complaints where OR=1.88 and C.I=(1.052-3.383).   
It was clear in the same table that the non- compliant among obese patients (54.4%) and 
among the morbid obese patients (72.7%) were higher than the compliant patients (45.6%, 
and 27.3% respectively), and this result reach the statistical significance, P=0.016.  
Most hyperlipidemia is caused by lifestyle habits or treatable medical conditions (SVS, 
2006).  
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Table 5.24: The relationship between selected risk factors and compliance: 
 
Risk factors Compliant Non compliant X2 P –value No % No % 
1-Smoking
Yes 5 50.0 5 50.0 1.061 0.588 No 99 49.0 103 51.0 
2-Blood pressure 
Yes 68 45.9 80 54.1 
2.425 0.143 
No 39 57.4 29 42.6 
3-Hypercholesterolemia 
Yes 68 48.6 72 51.4 0.148 0.776 No 39 51.3 37 48.7 
4-Hypertriglyceridemia 
Yes 66 44.6 82 55.4 4.594 0.040 No 41 60.3 27 39.7 
                        OR=1.887                                    C.I=(1.052-3.383) 
5-Obesity (BMI) 
• 18.5-24.9 7 50.0 7 50.0 
10.314 0.016 • 25-29.9 42 63.6 24 36.4 • 30-39.9 52 45.6 62 54.4 
• >40 6 27.3 16 72.7 
 
There is strong evidence that weight loss in overweight and obese individuals reduces risk 
factors for diabetes and cardiovascular disease and a strong evidence exists that weight loss 
reduces blood pressure in both overweight hypertensive and nonhypertensive individuals; 
reduces serum triglycerides (Adrienne, 1998). 
  
5.23 Compliance and diabetic complications 
In general, as shown in table(5.25), non compliance rate was higher among patients who 
had any of diabetic complication, representing by 57.6%, and was lesser among who didn't 
have diabetic complication represented by 41.3%, the result indicated that compliance rate 
significantly associated with diabetic complication and it reached the statistical significance 
as ( P=0.046). 
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Table 5.25: The relationship between compliance and diabetic complications: 
 
Diabetic Complication 
Compliant Non compliant 
X2 P –value 
No % No % 
Having diabetic complication 
Yes 53 42.4 72 57.6 
6.138 0.046 No 47 58.8 33 41.3 
Didn't know 7 63.6 4 36.4 
1-Ophthalmic (retinopathy) 
Yes 24 33.8 47 66.2 4.974 0.030 No 29 53.7 25 46.3 
                                     OR=0.44                        C.I=(0.213-0.910) 
2-Renal 
Yes 6 54.5 5 45.5 
0.832 0.524 No 46 40.4 68 59.6 
3-Diabetic foot 
Yes 12 27.9 31 72.1 5.059 0.035 No 40 48.8 42 51.2 
                                     OR=0.406                       C.I=(0.184-0.900) 
4-Neurological 
Yes 24 42.9 32 57.1 0.066 0.856 No 28 40.6 41 59.4 
5-Ischemic heart disease  
Yes 5 26.3 14 73.7 2.154 0.206 No 47 44.3 59 55.7 
6-Cerebrovascular accident 
Yes 1 100.0 0 0.0 1.415 0.416 No 51 41.1 73 58.9 
 
 
As stated before retinopathy was the most frequent complication among the study 
population (57%), the non compliance rate was higher among patients who had retinopathy 
represented by 66.2% and was lesser in those without retinopathy with percent of 46.3%, 
the result reach the statistical significance (P=0.030).  The results revealed that there was a 
negative association between retinopathy and compliance (OR=0.44, C.I=(0.213-0.910)). 
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Similarly there was a negative association between compliance and the presence of diabetic 
foot, where 72.1% were non compliants among patients who had diabetic foot the 
difference was statistically significant with (P=0.035, OR=0.406, C.I=(0.184-0.900)).  
The non compliant rates were higher among those with neurological and ischemic heart 
disease and presented by 57.1% and 73.7% respectively but the result didn't reach the 
statistical significance.  
On the other hand, non compliance rate was higher among patients without renal 
complication and lesser among those with renal complication, but the difference didn't 
reach statistical significant level (P=0.524).  Regarding cerebrovascular accident it was 
found only one patient who exposed to CVA and was compliant.   
In a study was done by Dietrich, 1996, he studied the attitudes of people with diabetes 
toward their disease and its treatment from their point of view, participants reported that 
when diabetes complications started their compliance improved and this result disagree 
with the result of the present study where the presence of diabetic complication increase the 
non compliance rate especially retinopathy complication and diabetic foot and the results 
was statistically significant.    
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5.24 Compliance and source of drug prescription and availability of drugs  
 
Compliance rate varies in relation to source of drug prescription, among participants who 
got their drugs from governmental health centers, the non- compliance rate was higher than 
the compliance rate, it was 52.1%. While it was lesser among those who got their drugs 
from UNRWA, it was 40%.  It didn't reach the statistical significance; (P=0.384). 
Concerning the availability of drugs, patients who said drug is always available were more 
compliant, represented by 62.7%.  While patients who answered that drug is sometimes 
available or said drug is not available were less complaint, presented by 72.4%, and 66.7% 
respectively.  The result was strongly statistically significant as (P=0.000).   
Referring to other options to get the drugs in case of unavailability, the non compliants 
were higher among those who mentioned that they can't get the drugs from private 
pharmacy and among those who remains without treatment, represented by 65.1%, and 
88.6% respectively, the results reach strongly the statistical significance where P=0.001 and 
P=0.000 respectively. The result revealed that there was a positive relationship between 
compliance and capability to get the medicine from private pharmacy (OR=2.641, 
C.I=(1.496-4.661)), as well there was a negative relationship between compliance and 
remaining without treatment (OR=0.088, C.I=(0.033-0.2234)). This could be related to the 
low socioeconomic status or to the cost of the drugs that might be as a barrier to 
compliance. 
The other options to get the drugs were from UNRWA, from another governmental health 
center, and from relatives, the compliants were higher represented by about 60.9%, 100%, 
and 53.8% respectively, although the result didn't reach the statistical significance but it 
also indicated to the same barriers and the factors that might lead to non-compliance such 
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as the socioeconomic status, as whenever there was another options to get medicine, the 
compliance increased too.   
Table 5.26: The relationship between compliance and sources of drug prescription, 
availability of drugs and number of daily medication 
 
Variable Compliant Non compliant X2 P –valueNo % No % 
Sources of drug prescription 
Governmental health center 92 47.9 100 52.1 
1.915 0.384 UNRWA 9 60.0 6 40.0 
Other  sites 6 66.7 3 33.3 
Availability of drugs 
Always available 84 62.7 50 37.3 
24.488 0.000 Sometimes available 21 27.6 55 72.4 
Not available 2 33.3 4 66.7 
Other sources to get drugs  
1- UNRWA clinic 
Yes 14 60.9 9 39.1 1.332 0.277 No 93 48.2 100 51.8 
2-Another  governmental clinic 
Yes 2 100.0 0 0.0 2.056 0.244 No 105 49.1 109 50.9 
3- Private pharmacy 
Yes 78 58.6 55 41.4 11.490 0.001 No 29 34.9 54 65.1 
                                  OR=2.641                                    C.I=(1.496-4.661) 
4-Use drugs from relatives 
Yes 7 53.8 6 46.2 0.103 0.782 No 100 49.3 103 50.7 
5-Remain without treatment              
Yes 5 11.4 39 88.6 32.210 0.000 No 102 59.3 70 40.7 
                                  OR=0.088                                    C.I=0.033-0.234) 
Respect  Diabetic Clinic appointments 
Yes 94 49.5 96 50.5 0.003 1.000 No 13 50 13 50 
Taking drugs other than antidiabetic drugs 
Yes 59 45.7 70 54.3 1.851 0.212 No 48 55.2 39 44.8 
No of daily drugs taken by patients 
One drug 30 90.9 3 9.1 
42.333 0.000 Two-Three drugs 59 54.1 50 45.9 
> three drugs 18 24.3 56 75.7 
 140
The result of the present study was congruent with Kem, 2003, as he said that patients 
typically cope with economic hardship by not having prescriptions filled, taking a smaller 
dose, or buying a cheaper over-the-counter product that is presumed to have a similar 
effect, and found that the out-of-pocket costs of medications have a profound impact on 
compliance (Kem, 2003). 
Concerning the diabetic clinic visit commitment, the compliance rate was 49.5% among 
who respect their appointments, and it was 50% among who were not respect their 
appointments, and the result did not reach the statistical significance (P=1.000).   
Regarding poly pharmacy, about 54.3% of patient who taking drugs other than diabetic 
were not compliants and higher than the compliants (45.7%) but the result didn't reach the 
statistical significance (P=0.212).   
Considering number of daily drugs taking by the patients, the compliers were higher among 
patients who either take one drug or who take two-three drugs per day and represented by 
90.9%, and 54.1% respectively. The compliance rate was decreased among patients who 
take more than three drugs daily (24.3%).  There was a strong statistical significance 
between non compliance and polypharmacy, as the number of daily drugs increased, the 
compliance decreased too (P=0.000).  This result agreed with Paes et al in1997, he found 
that compliance dropped from 79% for once-daily medications to 38% for medications 
taken 3 times a day.  The result was congruent also with Winkler, et al. in 2002 as they 
found that once daily dosage led to significantly better adherence rates than two or three 
times daily regimens. 
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Similarly the results agreed with Jaser in 1999 in Palestine, as he found that the compliance 
rate was significantly higher among patients taking one type of hypoglycemic drugs and 
among patients on single daily dose (Jaser, 1999). 
In contrast, Grant, et al. in 2003, found that patients reported very high medication 
adherence rates regardless of number of medicines prescribed.   
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Chapter 6 
 
Conclusion and Recomendations 
 
Conclusion  
One ongoing challenge to diabetes care is maintaining compliance to the recommended 
treatment and lifestyle program that will reduce the risk of long-term complications. 
Diabetes is a chronic illness requiring extensive adjustments to daily living.  
 Patients often do not take their medication as prescribed, and the reasons for non-
adherence to prescribed medication are very heterogeneous. 
This study assess the non compliance in type2 diabetes patients, prevalence and associated 
factors.  The results revealed that the prevalence of non- compliance among the study 
population was (50.5%), typical reasons cited by patients for not taking their medications 
included forgetfulness (66.4%), frustration (24.3%), feeling better without 
treatment(19.6%), polypharmacy (14%), and other causes such as fear from drug side-effect 
and  unavailability of drugs which representing by 12.1%, 8.4% respectively.   
According to HbA1c, the prevalence of controlled patients was only 24.5%, while the 
prevalence of uncontrolled was 75.5%.  Glycemic control was strongly significantly  
affected by compliance, around five times as the non-compliance increased,  poor glycemic 
control increased; (HbA1c more than 7%) .   
As it was shown there was a difference between prevalence of non compliance (50.5%) and 
uncontrolled patients (75.5%).  That difference could be related to that diabetic patient 
didn't comply to the non-pharmacological treatment in addition to their non compliance to 
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the regimen treatment,  HbA1c values reflect the radical changes in diet or changes in other 
modes of therapy approximately 3 to 4 weeks after initiation of the change. 
Finding of this study showed that 38.9% did not follow any diet regimen, and 61.6% of 
respondents were not exercising at all,  More over the non-compliance rate was 
significantly decreased among patients who did not follow any diet regimen.  In conclusion 
the compliance towards diet and exercise is poor  and it is important to focus on lifestyle 
intervention and to increase the education in this field congruent with medication to 
improve compliance.  
 
Most of the study population was from Gaza 64.8%, followed by North Gaza 20.8%, and 
the lowest were from Mid-zone 14.4%.  The mean age of patients participated in the study 
was 54.4 years, diabetic females were twice more than males.  The majority of the study 
population  (50.9%) were of low level of education, not working (89.8%), and with low 
income; about half of the sample population 46.3 their income was 2000 NS or less. 
Non compliance rate was higher among females and increased among patients with high 
educational level as well with long duration of diabetes but the difference did not 
significantly affect the compliance.  There was no significance difference in compliance 
rates regarding demographic factors, such as age, gender, locality, consanguinity, 
educational level and socio-economic status.  Similarly associated chronic diseases showed 
no significance difference on compliance except the associated ischemic heart disease 
which showed a significant effect on non-compliance. 
A positive family history; regarding the mother showed a negative significant effect on 
compliance, this could be explained as diabetic patients needs a social support which could 
be lost when the mother is also diabetic.  
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 It was found that 64.4% Of the study population were on oral hypoglycemic agents 
(OHAs), 17.6% on insulin and 18.1% on mixed therapy (OHAs&Insulin).  The non 
compliance rate was the highest, among those who were on insulin and on mixed treatment 
(OHAs and insulin), but the type of medicine did not show a significant association with 
compliance.   
 
The results showed that 15.3% of the participants were taking only one drug therapy, more 
than half of study sample (50.5%) were taking two or three drugs per day, 34.3% of 
patients were taking more than three drugs per day.  It was found a significant relationship 
between polypharmacy and non-compliance rate.  The compliance rate was the highest 
among those who were on one drug treatment, and decreased gradually as the number of 
taking drugs increased.  
The majority of patients who were on insulin treatment (35.6% of study population) had 
their injections by themselves represented by 74%, among them 93% had a training either 
by health providers (71.7%), or by family members (20.8%).   
  
More than half of the study population had a knowledge and information about the disease; 
cure of diabetes and drug side-effects (58.8%, and 61.1% respectively).  The main source of 
information was from the health providers (doctors and nurses).  This result indicates that  
health providers have a good role in patient's knowledge about their disease.  The results 
showed that increased knowledge of drug side-effect had a significant positive association 
with the compliance rate.  And it was found that poor knowledge increase the risk of non 
compliace by about six times. 
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As shown in the results there was a positive attitude of some patients towards either using 
traditional remedies or using drugs prescribed to others but that attitude did not 
significantly affect the non compliance.  
The results showed that patients had a negative attitude regarding taking of a missed dose 
and that attitude was highly significantly  increasing the non compliance.  
 
Patients' feeling regarding their medicine especially their feeling not to take their medicine 
and feeling in need for a rest period were significantly associated and increasing the non 
compliance rate, and feeling in need for rest period showed a negative association with 
compliance.  Patients related the causes of their feeling regarding medicines to as follow; 
fear of drug side- effect at present or in future, fear from drug dependence or no confidence 
of drugs.  There were a belief by some patients (38.4%)  in that medicine is not needed, but 
it didn't significantly affect the compliance.  
 
In conclusion, feeling and attitude had shown to have an effect on compliance, so that a 
better understanding of patients' feeling and attitudes may help physicians increase 
motivation, understanding, and compliance of diabetic patients. 
 
Concerning patient practice; patients who were regular on taking their drugs as they had 
claimed had a highly significant higher compliance rate than those who were irregular.  
Moreover the compliance rate was highly significantly affected by the attitude of patients 
regarding taking of a missed dose. 
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The results revealed that 98.6% of study population believed in the benefit of exercise for 
their health, in spite that only 38.4% of the subjects was actually practicing exercise, and 
among them 18.1% of them were exercising 3 or more days per week, 15.3% were 
exercising one or two days per week and 5% were practicing little exercise.  This indicated 
that there is a gap between attitude and behaviors, so that barriers must be assessed, and 
behaviour modification should be included, if diet and exercise programs are to be 
successful.  
  
It was found that the majority of study population (92.6%) depending on themselves in 
remembering their doses time which is susceptible for forgetfulness. 
 
Only 11.1% of study population checking the glucose level by themselves, self-monitoring 
of blood glucose (SMBG), It is important to focus on SMBG in order to achieve good 
glycemic control. 
The majority of study population had associated risk factors; uncontrolled blood pressure 
(68.5%), hypercholesterolemia (64.8%), hyper triglyceridemia (68.5%), and obesity (63%). 
The non compliance rate in general was higher than the compliance rate regarding risk 
factors but hypertriglyceridemia and obesity were significantly increased among non 
compliance. This result indicated that non compliance is highly linked and significantly 
associated with obesity and hypertriglyceridemia. 
 
It was found that 57.9% of the study population had complication, more over  presence of 
complication was significantly increased in relation to non compliance rate in general, and 
in particular for ophthalmic and diabetic foot complication.  Presence of complication; "co 
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morbidities" may increase or lead to depression and resulted in a negative effect on 
compliance.    
Concerning the availability of medicine in the governmental health center, 62% of the study 
population certain that medicine is always available, and the results showed a strong 
statistical significance regarding the availability of drugs and increasing of compliance rate.   
It was shown in case of unavailability of medicine, The compliance rate had a significant 
positive association with the option of getting the medicine from private pharmacy and a 
strong significant negative association with the option of remaining without treatment.  
This result indicated that medicine availability and cost of medicine had a significance 
effect on adherence, as the patients who forced to get their drugs from private sources when 
their drugs are unavailable, the non compliance increases and remaining without treatment 
increased, this result reflect that socio-economic status had a negative impact on 
compliance as low socioeconomic status may put patients in the position of having to 
choose between competing priorities. 
It was found in the results that 88% of study population keeping their appointment to the 
diabetic clinic, the proportion who did not omit their appointment related the causes to the 
increasing waiting time (77.8), doctors did not give the patients' his care or attention 
(14.8%) or unavailability of drugs (7.2%).  It was found that commitment of the diabetic 
clinic appointment, source of getting the drug, and taking drugs other than ant diabetic 
drugs had no significant association with non compliance. 
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In conclusion, compliance to medications as well as to diet  and exercise was poor. 
Many factors affecting and lead to poor compliance;  patient related factors (forgetfulness, 
poor knowledge, attitude, feeling, beliefs or socio-economic), regimen factors 
(polypharmacy), health system related factors (unavailability of drugs or increase waiting 
time), provider-based factors (the perception of providers as being warm and caring), and 
condition-related factors (social support, frustration, presence of complications of diabetes, 
associated chronic diseases).  On the other hand socio-demographic factors (age, gender, 
locality, consanguinity,  marital status, family size educational level and income)  did not 
report a role  on compliance.     
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Recommendations 
 
Efforts to enhance compliance should target patient, provider and health care system related 
factors according to the following recommendations:   
 
1- Helping the patients to increase their self awareness of their values, needs, and goals for 
diabetes care by directing  efforts  towards developing educational programs on 
consanguineous marriage and on diabetes knowledge, dietary practices, physical exercise, 
medication compliance, self-monitoring of blood glucose, and glycosylated hemoglobin.  
 
2-Enhancing patients factors that could overcome forgetfulness by using adherence aids 
such as medication calendars, medication organizers, and electronic devices or alarms. 
 
3-More efforts must be made to enhance the role of health provider by  increasing 
motivation, understanding, and compliance of diabetic patients by focusing on  
understanding of patients' beliefs and attitudes that may help physicians to improve 
compliance and to overcome the gap between attitude and behaviors. 
 
4-Encouraging and enhancing  specific training in adherence management for practitioners 
and the health care systems include educating staff nurses and setting up standards of 
patient care, protocols for the prevention and care of diabetes-related complications of the 
eyes, lower extremities, and cardiovascular system as well as educating patients. 
 
5-Simplification of the dosage regimen; simplification of the dosage regimen may include 
conducting a drug utilization review to decrease the number of medications a patient is 
taking, decreasing the number of daily doses by switching to extended-release 
formulations. 
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6-Increasing efforts by policy makers for creation and adoption of chronic care models of 
service delivery, for improving access to medicines and health care, decreasing waiting 
time and to offer medications for all patients. 
 
 
Further researches: 
1-More researches needed at the national level including other health providers. 
 
 151
 References 
Abu Mosa, H., (1999), " Magnitude of Diabetes Mellitus in Gaza Strip", UNRWA-Gaza.  
Abu Ramadan,M., (2004), "Risk Factors of Diabetes Mellitus Type 2 In Gaza Strip ", 
School of Public Health, Al -Quds University, Gaza, Palestine. 
 
Adrienne Blount, B.S., Maureen Harris, M.S., R.D., Anna Hodgson, M.A., and Pat 
M.,(1998), Clinical Guidelines On The Identification, Evaluation, And Treatment Of 
Overweight And Obesity In Adults. The Evidence Report.  Obesity Education Initiation, 
National Institute of Health, NIH publication, 98-4083. 
 
Albaz RS. (1997), Factors affecting patient compliance in Saudi Arabia. Journal of Social 
Sciences, Vol. 25:5-8. 
 
Aljasem., LI., Peyrot, M., Wissow, L., and Rubin, RR., (2001), The impact of barriers and 
self-efficacy on self-care behaviors in type 2 diabetes. Diabetes Educator. Vol. 27:393-404.  
 
Alwan A.S., (1994), Management Of Diabetes Mellitus Standers of Care and Clinical 
Practice Guidelines, Diabetes prevention and control, World Health Organization Regional 
Office for the Eastern Mediterranean, Alexandria, Egypt. 
 
Al-Saeedi, M., Elzubier, AG., Bahnassi, AA., and Al-Dawood, KM., (2003), Patterns of 
belief and use of traditional remedies by diabetic patients in Mecca, Saudi Arabia. East 
Mediterranean Health Journal. Jan-Mar,9(1-2):99-107.  
 
American Diabetes Association (ADA), 2002, National Diabetes Fact Sheet, Available at 
http://www.diabetes.org/diabetesstatistics/ national-diabetes-fact-sheet.jsp (accessed in1st 
of august,2006). 
 
American Diabetes Association (2003), Economic Costs of Diabetes in the U.S. in 2002. 
Diabetes Care  Vol.26(3):917-932. 
 
American Diabetes Association,(2005), Diagnosis and classification of Diabetes Mellitus, 
Diabetes Care 28:S37-S42, 2005. 
 
American Diabetes Association, (2006), Standards of Medical Care in Diabetes, Diabetes 
Care 29:S4-S42, 2006. 
 
American society of consultant pharmacist Journal (ASCP), supplement 4, 2001: Clinical 
consult, Oral Therapy for Management of Diabetes Mellitus in the Elderly, Vol.16. 
 
Anderson, R. & Kirk, L. (1982), Methods of Improving Patient Compliance in Chronic 
Disease States.  Archives of Internal Medicine, 142, 1673-1675. 
 
 152
Anthony. S., Odgers, T., and Kelly, W., (2004), Health promotion and health education 
about diabetes mellitus, Diabetes Care Centre, J R Soc Health. Mar;124(2):70-3, England. 
 
Asim, A.J., (2004), Adherence to HIV Treatment Regimens: Recommendations for Best 
Practices APHA – www.apha.org/ppp/hiv - June (accessesd on 3rd Sep.2006) 
  
Astrup, A., (2001), Healthy lifestyles in Europe: prevention of obesity and type II diabetes 
by diet and physical activity, Public Health Nutr. Apr;4(2B):499-515. 
 
Balkrishnan, R., (1998): Predictors of Medication Adherence in the Elderly. Clinical 
Therapeutics, 20; 4: 764-771. 
 
Brown, JB., Harris, SB., Webster-Bogaert S., Wetmore, S., Faulds, C. and Stewart, M., 
(2002),  The role of patient, physician and systemic factors in the management of type 2 
diabetes mellitus. Family Practice,Vol. 19: 344–349. 
 
Cameron, C., (1996): Patient compliance: recognition of factors involved and suggestions 
for promoting compliance with therapeutic regimens. Journal of Advanced Nursing, 24: 
244-250. 
 
Ciechanowski, PS., Katon, WJ., Russo, JE., and Walker, EA., (2005), The patient-provider 
relationship, attachment theory and adherence to treatment in diabetes. Am J Psychiatry. 
158:29-35. 
  
Christophersen ER, Mortweet SL., 2005, Treatments that Improving Adherence in the 
Primary Care or Specialist Care Setting, How to improve adherence to medical regimens 
using behavior principles , Washington, D.C.: APA Books, 2001. 
 
Clark, E., Oswald, D., Kreuter, M. & Bull, F. (1999). Understanding How People Process 
Health Information: A Comparison of Tailored and Nontailored Weight-Loss Materials. 
Health Psychology, 18, 487-494. 
 
Centers for Disease Control and Prevention, CDC, (2003): National Center for Chronic 
Disease Prevention and Health Promotion, National diabetes fact sheet: general 
information and national estimates on diabetes Department of Health and Human Services, 
United States . 
 
Centers for Disease Control and Prevention, CDC, (2005): National Center for Chronic 
Disease Prevention and Health Promotion, National diabetes fact sheet: general information 
and national estimates on diabetes Department of Health and Human Services, United 
States . 
 
Cramer, J., (1991), Identifying and improving compliance patterns. Patient compliance in 
medical practice and clinical trials. New York: Raven Press, Vol. 387-92.  
 
 153
Deborah, J.C., Cert, D.N.,and coleman,R., August (2005), Medication compliance in the 
elderly, JCN journal, Vol. 19, Issue 08. 
 
Dietrich, UC., (1996), Factors influencing the attitudes held by women with type II 
diabetes: a qualitative study, Patient Educ Counc, Oct;29(1):13-23. 
 
Dunbar, J., Shumaker, S., and Eleanor, B., (1990), Predictors of patient adherence, Patient 
Characteristics. The Handbook of health behavior change. New York, NY, USA: Springer 
Publishing Co, Inc. 
 
Dunn, FL., (1992):  Management of hyperlipidemia in diabetes mellitus.  Endocrinol Metab 
Clin North Am. Jun;21(2):395-414. 
Ferzacca, S.(2000), “Actually, I don’t feel that bad”, Managing diabetes and the clinical 
encounter.  Medical Anthropology Quarterly 14(1):28-50. 
Germendy, G., (2003), Is type-2 diabetes mellitus preventable? Orv Hetil, Sep 
28;144(39):1909-17 
Gonen, BA., Rubinstein, AH., and Rochman, H., (1997), Hemoglobin A1: An Indicator of 
the Metabolic Control of Diabetic Patients. The Lancet Oct 8,2(8041):7347. 
http://diabetes.bio-rad.com/html/story.html#hba1c,(accessed on 6th Sep). 
Grant, RW., Devita, NG., Singer, DE., and Meigs, JB.(2003), Polypharmacy and 
medication adherence in patients with type 2 diabetes, Diabetes care. May;26(5):1408-12.  
USA. rgrant@partners.org 
Harris R., Linn MW., and Pollack L., (1984), Relationship between health beliefs and 
psychological variables in diabetic patients. Diabetes Care Sep.57 ( Pt 3): 9-253 
Haynes, R.B., Taylor, D.W., Sackett, D.L. (1979): Compliance in Healthcare. The John 
Hopkins Press, London. 
 
Hays, LM., and Clark, DO.,(1999): Correlates of physical activity in a sample of older 
adults with type 2 diabetes, Diabetes Care, May;22(5):706-12. 
Hertz, RP., Unger, AN. And Lustik, MB., (2005), Adherence with pharmacotherapy for 
type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health 
insurance. Clinical Therapy, Pfizer Inc., New York, Vol.27(7):1064-73. 
 
Hunt, Linda M., Jacqueline P., and Miguel V., (1998), How patients adapt diabetes self-
care recommendations in everyday life.  The Journal of Family Practice 46(3):207-215. 
 
Jaser, NA., (1999)," Compliance of Diabetic Patients with the treatment regimen at 
UNRWA health centers in Gaza strip", School of Public Health, Al Quds University, Gaza, 
Palestine. 
 154
 
Jenny, J. (1986), Differences in Adaptation to Diabetes Between Insulin-Dependent and 
Non-Insulin Dependent Patients: Implications for Patient Education. Patient Education and 
Counseling, 8, 39-50. 
Joel, S., Mohan, N., and John, V.,(2002),  The Association Between Diabetes Metabolic 
Control and Drug Adherence in an Indigent Population, Diabetes Care 25:1015-1021. 
Joyce A.C., (2004),  Systematic Review of Adherence With Medications for Diabetes. 
Diabetes Care. 27:1218-1224.   
Justin J. S., (2005), The Impact of Smoking and Quitting Smoking on Patients With 
Diabetes.  Diabetes Spectrum, Vol. 18:202-208. 
International Diabetes Federation (2004), Creating a European Framework for Diabetes 
Prevention, Diagnosis and Control. Information Paper – June 2004. 
Kamel, NM., Badawy, YA., El-Zeiny, NA., and Merdan, IA., (1999), Socio-demographic 
determinants of management behavior of diabetic patients Part II. Diabetics' knowledge of 
the disease and their management behavior, EMHJ, Vol. 5:5, 974-983. 
Kell,y J., (1995): Making sense of drug compliance by patients. Nursing Times, 91; 40: 40-
41. 
 
Kem, P., Krueger, Bill, G., Felkey, and Bruce, A. Berger,(2003),  Improving Adherence 
and Persistence: A Review and Assessment of Interventions and Description of Steps 
Toward a National Adherence Initiative, Journal of the American Pharmacists Association 
Vol.43:668–79. 
  
Kumar, P.  and Clark, M., (2002), Clinical Medicine, Forth edition, W.  B.  
Saunders,London. 
 
Kusserow, R., Dufresne, J., and Greene,V., June (1990), Medication regimens,"Causes of 
non-compliance". Office of Inspection General (OIG), Office of Evaluation and 
Inspection(OEI)-04-89-89121. 
Manson, JE., Stampfer, MJ., Colditz, G., Liu, S., Solomon, CG., Willett, WC.,(2001), Diet, 
lifestyle, and the risk of type 2 diabetes mellitus in women. New England J. Med. Sep 
13;345(11):790-7. 
  
Mark H., Robert S. P., Thomas V. J., Justin L. K., Michael B., (2006),The Merk Manual of 
Diagnosis and therapy, Section 2. Endocrine and Metabolic Disorders, Diabetes Mellitus, 
Published by Merck Research Laboratories, Merck & Co., Inc. Whitehouse Station, N.J.  
 
 155
McCord, EC. and Brandenburg, C., (1995),  Beliefs and attitudes of persons with diabetes.  
Family and Community Medicine, USA, Apr;27(4):267-71.  
 
McGill, M. (2001 Sep-Dec), Diabetes education: a keystone in the management of diabetes. 
Papua New Guinea Medical Journal, 44(3-4), 131-4. 
McKevith, B.,(2005), Diet and healthy ageing,  J Br Menopause Soc. Dec;11(4):121-5.  
Medical practice guidelines (MPG), 2006, Monitoring test options. http://www.diabetes-
tests.com/Monitoring_Test_Options.html#Top(accessed on 10th Oct.2006).  
Michael H., (2004), Improving Adherence in the Polypharmacy Management of Disease, 
Business Briefing: Pharmatech, Technology and Survices. 
www.touchbriefings.com/pdf/890/scolr.pdf (accessed on 20th Oct.).  
Ministry of Health, (2002), Health status in Palestine, Annual Report (2001), State of 
Palestine, Ministry of Health; Health Management Information Center (HMIS). 
 
Ministry of Health, (2004), Health status in Palestine, Annual Report (2003), State of 
Palestine, Ministry of Health; Health Management Information Center (HMIS). 
 
Ministry of Health, (2004), Health System Development Project Quality Improvement 
Program, Palestinian Guideline For Diagnosis and Management Of Diabetes Mellitus, 
Palestinian National Authority. 
 
Ministry of Health, (2005), Health status in Palestine, Annual Report (2004), State of 
Palestine, Ministry of Health; Health Management Information Center (HMIS). 
Mojtabai, R., and Olfson, M., (2003):  Medication costs, adherence, and health outcomes 
among Medicare beneficiaries. Health Aff. Vol. 22:220-229.  
National Health System (NHS), 2006: Guide To The Management Of Diabetes For 
Primary Care Practitioners, Primary Care, West Hertfordshire. 
 
Osterberg L., and Blaschke., T., (2005), Adherence to Medication, The New England 
Journal Of Medicine.,  August 4,Vol. 353:487-497. 
Paes, AH., Bakker, A., and Soe-Agnie, CJ.,(1997),  Impact of dosage frequency on patient 
compliance. Diabetes Care.;20:1512-1517.  
Paul M., Rachel P. W., Kristi R., Karen B. D., Jing C., and Vivian F.,(2005), Relationship 
Between HbA1c Level and Peripheral Arterial Disease, Diabetes Care 28:1981-1987 
Palestinian Central Bureau of Statistics, (2004): demographic status of the Palestinian in 
the Palestinian Territory, Palestinian National Authority: Author. 
 
 156
Palestinian Central Bureau of Statistics, (2006): demographic status of the Palestinian in 
the Palestinian Territory, Palestinian National Authority: Author. 
Pannacciulli, N., Pergola, D., Ciccone, M., Paolo Rizzon, R., Giorgino, F., and Giorgino, 
R., 2003:  Effect of Family History of Type 2 Diabetes on the Intima-Media Thickness of 
the Common Carotid Artery in Normal-Weight, Overweight, and Obese Glucose-Tolerant 
Young Adults Diabetes Care 26:1230-1234 
 
Petty, R.E. and Cacioppo, J. T. (1981), Attitudes and persuasion: Classic and contemporary 
approaches. Dubuque, IA: William C.Brown. 
 
Platt, F.W., Tippy, P.K. & Turk, D.C. (1994, October 30). Helping patients adhere to  
the regimen. Patient Care, 43-52.  
Polonsky WH., Fisher L., Dowe, S., and Edelman S., (2003), Why do patients resist insulin 
therapy? Diabetes. 52(suppl 1),A417.  
Primary Health Agency of Canada (PHAC),(2003), Risk factors associated with diabetes. 
"Eat well.  Be active.  Have a fun"., You can prevent type-2 diabetes, www.phac-
aspc.gc.ca/ccdpc-cpcmc/diabetes-diabete/english/risk/index.html - 21k-(accessed on 
16.oct.2006). 
Rajaei DZ., MacPherson, G., (1997): Drug-related problems in older people. Nursing 
Times, 93; 28: 54-56. 
Rapoff, M.A., (1999), Adherence to pediatric medical regimens. New York: Kluwer 
Academic/Plenum. 
Rhee, MK., Slocum, W., Ziemer, DC., Culler, SD., Cook, CB., El-Kebbi, IM., Gallina, 
DL., Barnes, C., and Phillips, LS.,(2005),  Patient adherence improves glycemic control. 
Diabetes Educucation, Mar-Apr.31(2):240-50. 
Ruggiero, L., Spirito, A.,, Bond A., Coustan, D., and McGarvey, S., (1990), Impact of 
social support and stress on compliance in women with gestational diabetes. Diabetes 
Care. Vol. 3:441-443.  
Scott,R.V., and Anne, L.P., (2004),  Diabetes Mellitus, Type 2 - A Review, Emedicine. 
Searle, MS., and Ready, AE.,(1991),  Survey of exercise and dietry knowledge and 
behaviour in persons with type2 diabetes, Can J Public Health, Sep-Oct;82(5):344-8. 
Sha'at,O., (2000), "Diabetes Mellitus Status Among Registered Pregnant Women in 
Primary Health Care Centers in the Southern of Gaza Province, Palestine", School of 
Public Health, Al Quds University, Gaza, Palestine. 
 157
Sheeri, L. K., Victoria, S. D., David, W. B., (2002), Controlling Hypertension in Patients 
with diabetes.   American Academy of Family Physicians (AAFP). October 1,Vol.66, No.7. 
Show, J.,and Chisholm, D., (2003), Epidemiology and prevention of type 2 diabetes and the 
metabolic syndrome, National prevention programs are needed, but GPs can contribute 
through screening and lifestyle advice, MJA  179: 379–383. 
 
Shultz, JA., Sprague, MA., Branen, LJ., and Lambeth, S. (2001), A comparison of views of 
individuals with type 2 diabetes mellitus and diabetes educators about barriers to diet and 
exercise, J Health Commun.  Apr-Jun,6(2):99-115. 
Society for vascular surgery(SVS),(2006):Patient and Family Health Information, 
hyperlipidemia. 
www.vascularweb.org/_CONTRIBUTION_PAGES/Patient_Information/NorthPoint/Hyper
lipidemia.html - 17k-(accessed on 16th Aug.2006). 
Swift, CS., Armstrong, JE., Beerman, KA., Campbell, RK., and Pond-Smith D., 1995, 
Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes, 
Diabetes Education, Nov-Dec., 21(6):533-40. 
 
Tracy, JK., 2006, Diabetes Update, High Post Meal Blood Sugars Destroy Nerves Before 
Diagnosis,  Kings College, London. diabetesupdate.blogspot.com/2006/08/, (Accessed on 
10th Nov) 
 
World Health Organization WHO,(1993), Khalil, S., Ruznamaji, N, Sherif, I, Khatib, O, 
Mukhtar, ED, MacKinnon, M., Alwan, A. and King, H,(1993),  Diabetes prevention and 
control, Health Education For People with Diabetes. Alexandria, 10—14 November 1993. 
 
World Health Organization, (1998), World Health Report (1998), Life in the 21st Century: 
A Vision for All. WHO: Geneva. 
 
World Health Organization, (2003), Adherence to long-term therapies: evidence for action., 
WHO Library Cataloguing-in-Publication Data,WHO, 20 Avenue Appia, 1211 Geneva 27, 
Switzerland. 
 
World Health Organization, (2005), WHO Global Strategy on Diet, Physical Activity and 
Health.  
 
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004), Global Prevalence of 
Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-
1053. 
Wichowski, H. and Kubach, S. (1997), The Relationship of Self-Perception of Illness and 
Compliance with Health Care Regimens. Journal of Advanced Nursing, Vol. 25, 548-553. 
 
Wilson, Hanson and  Glasgow(1986), Psychosocial predictors of self-care behaviors 
(compliance) and glycemic control in non-insulin-dependent diabetes mellitus. Diabetes 
Care 9:614-622.(Building compliance in diabetes) 
 158
 
Winkler, A., Teusche, A.,  Mueller, B., and Diem, P.(2002), Monitoring adherence to 
prescribed medication in type 2 diabetic patients treated with sulfonylureas, Swiss Medical 
Weekly (SMW), Vol. 132:379–385 
Yusef J.I., (2000), Management of diabetes mellitus and hypertension at UNRWA primary 
health care facilities in Lebanon, Eastern Mediterranean Health Journal. Vol.6: 378-
390378-390 
Zimmet, P. (2003 Sep), The burden of type 2 diabetes: are we doing enough? Diabetes 
Metababolism, 29(4 Pt 2), 6S9-18. 
 159
Annex 1 
 
 
Body Mass Index 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body Mass Index Weight Status 
Below 18.5 Underweight 
18.5-24.9 Normal 
25.0-29.9 Overweight 
30-39.9 Obese 
=>40 Morbid obese 
 160
 
Annex 2 
Map of Palestine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 161
Annex 3 
Map of Gaza Strip 
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  :ﻤﻭﺍﻓﻘﺔ ﻋﻠﻰ ﺇﺠﺭﺍﺀ ﺍﺴﺘﺒﻴﺎﻥ ﺤﻭل ﺩﺭﺍﺴﺔ
 
ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘﻲ ﺘﺅﺩﻱ ﺇﻟﻰ ﻋﺩﻡ ﺍﻟﺘﺯﺍﻡ ﻤﺭﻀﻰ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﺒﺎﻟﻌﻼﺝ ﻭﺩﺭﺍﺴﺔ ﻤﻌﺩل " 
  "ﺍﻨﺘﺸﺎﺭ ﻫﺫﻩ ﺍﻟﻅﺎﻫﺭﺓ
–ﻁﺎﻟﺒﺔ ﻓﻲ ﺒﺭﻨﺎﻤﺞ ﻤﺎﺠﺴﺘﻴﺭ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻤﺔ ﻓﻲ ﺠﺎﻤﻌﺔ ﺍﻟﻘـﺩﺱ " ﺃﻤل ﻋﺒﺩ ﺍﻟﻌﺯﻴﺯ ﺯﻗﻭﺕ" ﺃﻨﺎ ﺍﻟﺒﺎﺤﺜﺔ 
  .ﻓﻠﺴﻁﻴﻥ -ﺃﺒﻭ ﺩﻴﺱ
ﺩﺭﺍﺴﺔ ﺍﻟﻌﻭﺍﻤل ﺍﻟﺘـﻲ " ﻨﻲ ﺃﻗﻭﻡ ﺒﻌﻤل ﺒﺤﺙ ﻋﻠﻤﻲ ﻫﻭ ﺠﺯﺀ ﻤﻥ ﺩﺭﺍﺴﺘﻲ ﻓﻲ ﺍﻟﺠﺎﻤﻌﺔ ﻴﻬﺩﻑ ﺇﻟﻰ ﺇﻨ   
  "ﺘﺅﺩﻱ ﺇﻟﻰ ﻋﺩﻡ ﺍﻟﺘﺯﺍﻡ ﻤﺭﻀﻰ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﺒﺎﻟﻌﻼﺝ ﻭﺩﺭﺍﺴﺔ ﻤﻌﺩل ﺍﻨﺘﺸﺎﺭ ﻫﺫﻩ ﺍﻟﻅﺎﻫﺭﺓ
ﺍﻟﺘـﻲ ﻟﺘﺯﺍﻡ ﺒﺎﻟﺨﻁﺔ ﺍﻟﻌﻼﺠﻴﺔ ﻭﻤﻌﺎﻟﺠﺔ ﺍﻟﻌﻭﺍﻤـل ﻻﺍ ﺤﻴﺙ ﺃﻥ ﻨﺘﺎﺌﺞ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻗﺩ ﺘﺅﺩﻱ ﺇﻟﻰ ﺘﺤﺴﻴﻥ 
  .ﻟﺘﺯﺍﻡ ﺒﺫﻟﻙﻻﺘﺤﻭل ﺩﻭﻥ ﺍ
ﻫﻨﺎﻟﻙ ﺨﻴﺎﺭﺍﺕ ﻟﻺﺠﺎﺒﺔ ﻋﻥ ﻜل ﺴﺅﺍل، ﺍﻟﺭﺠﺎﺀ ﺍﺨﺘﻴﺎﺭ ﺍﻹﺠﺎﺒﺔ ﺍﻷﻗﺭﺏ ﻟﻙ ﻭﻟﻤﻤﺎﺭﺴﺘﻙ ﺍﻟﻭﺍﻗﻌﻴﺔ، ﻤـﻊ 
ﺍﻟﻤﻼﺤﻅﺔ ﺃﻨﻪ ﻻ ﻴﻭﺠﺩ ﺇﺠﺎﺒﺎﺕ ﺨﺎﻁﺌﺔ ﻭﺇﺠﺎﺒﺎﺕ ﺼﺤﻴﺤﺔ ﺍﻟﻤﺸﺎﺭﻜﺔ ﻓﻲ ﻫﺫﺍ ﺍﻟﺒﺤﺙ ﺘﻁﻭﻋﻴﺔ ﻭﻟﻙ ﺍﻟﺤﻕ 
  .ﻨﺴﺤﺎﺏ ﻓﻲ ﺃﻱ ﻭﻗﺕ ﺘﺸﺎﺀﻻﻓﻲ ﺍ
ﺩﻗﻴﻘﺔ، ﻤﻊ ﺍﻟﺘﺄﻜﻴﺩ ﻋﻠﻰ ﺃﻥ ﺍﻟﺤﻔﺎﻅ ﻋﻠﻰ ﺍﻟﺴﺭﻴﺔ ﺘﺅﺨﺫ ﺒﻌﻴﻥ  51ﺇﻟﻰ  01 ﺘﻌﺒﺌﺔ ﺍﻻﺴﺘﺒﻴﺎﻥ ﺘﺴﺘﻐﺭﻕ ﻤﻥ
  .ﻋﺘﺒﺎﺭ ﻭﻻ ﺤﺎﺠﺔ ﻟﻜﺘﺎﺒﺔ ﺍﺴﻤﻙ ﻋﻠﻰ ﺍﻻﺴﺘﺒﻴﺎﻥﻻﺍ
  ﻗﺩﺭ ﻋﺎﻟﻴﺎﹰ ﻤﺸﺎﺭﻜﺘﻙ ﺒﺎﻟﺒﺤﺙﺃ
 
 ﻭﺘﻔﻀﻠﻭﺍ ﺒﻘﺒﻭل ﺠﺯﻴل ﺍﻟﺸﻜﺭ
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 ﺑﺴﻢ ﺍ ﺍﻟﺮﲪﻦ ﺍﻟﺮﺣﻴﻢ
  :...................   ﺍﻟﺭﻗﻡ ﺍﻟﻤﺘﺴﻠﺴل   
 ﻤﻌﻠﻭﻤﺎﺕ ﻤﻥ ﻤﻘﺎﺒﻠﺔ ﺍﻟﻤﺭﻴﺽ : 
  ﺃﻨﺜﻰ      ﺫﻜﺭ     :  ﺍﻟﺠﻨﺱ  -1
 
  ﻋﺯﺒﺎﺀ / ﺃﻋﺯﺏ      :ﺍﻟﺤﺎﻟﺔ ﺍﻻﺠﺘﻤﺎﻋﻴﺔ -2
  ﻤﺘﺯﻭﺠﺔ / ﻤﺘﺯﻭﺝ      
  ﻤﻁﻠﻘﺔ / ﻤﻁﻠﻕ      
  ﺃﺭﻤﻠﺔ / ﺃﺭﻤل      
 
  :...................................ﺍﻟﻌﻤﺭ -3
 
  ........................... :ﺍﻟﻌﻨﻭﺍﻥ -4
 
     ﻻ ﻴﻌﻤل     ﻴﻌﻤل      : ﺍﻟﻤﻬﻨﺔ -5
  ..(ﺃﻁﺒﺎﺀ ، ﻤﺤﺎﻤﻭﻥ ، ﻤﺤﺎﺴﺒﻭﻥ ، ﻜﻴﻤﻴﺎﺌﻴﻭﻥ )ﻤﺅﻫﻠﻭﻥ     :ﺇﺫﺍ ﻜﺎﻥ ﻴﻌﻤل 
  .....(ﻤﺩﺭﺴﻭﻥ ،  –ﻤﺩﻴﺭﻭﻥ )ﻤﻬﻨﺔ ﻤﺘﻭﺴﻁﺔ     
  ﺘﺎﺠﺭ ، ﻤﻼﻙ     
  ....(.ﺭﺌﻴﺱ ﺍﻟﻌﻤﺎل ، ﻁﺒﺎﺥ ، ﺒﻘﺎل ، )ﺃﺼﺤﺎﺏ ﻤﻬﺎﺭﺍﺕ     
  ..(ﻋﺎﻤل ﺍﻟﺘﻠﻔﻭﻥ ، ﻤﺤﺼل ﺍﻟﺘﺫﺍﻜﺭ ،)ﺃﻨﺼﺎﻑ ﺍﻟﻤﻬﺭﺓ     
  ....(ﺍﻟﻌﺘﺎل ، ﻋﺎﻤل ﺍﻟﻨﻅﺎﻓﺔ،)ﻏﻴﺭ ﺍﻟﻤﻬﺭﺓ     
  ..........................................ﺃﺨﺭﻯ                          
 
  ................................................. -:ﻋﺩﺩ ﺴﻨﻭﺍﺕ ﺍﻟﺘﻌﻠﻴﻡ -6
 
  .............................................. :ﻋﺩﺩ ﺍﻷﻓﺭﺍﺩ ﻓﻲ ﺍﻟﻤﻨﺯل  -7
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  : ﺩﺨل ﺍﻟﻌﺎﺌﻠﺔ ﺍﻟﺸﻬﺭﻱ ﻤﻥ ﻜل ﻤﺼﺎﺩﺭ ﺍﻟﺩﺨل  -8
  ﺭﻓﺽ ﺍﻹﺠﺎﺒﺔ  >     ﺸﻴﻜل   0002    ﺸﻴﻜل  0002-0001  <ﺸﻴﻜل   0001 
 
  :ﺼﻠﺔ ﺍﻟﻘﺭﺍﺒﺔ ﺒﻴﻥ ﺍﻟﻭﺍﻟﺩﻴﻥ -9
  (. ﺍﻟﺨﺎﻟﺔ/ﺃﺒﻨﺎﺀ ﺍﻟﺨﺎل –ﺍﻟﻌﻤﺔ / ﺃﺒﻨﺎﺀ ﺍﻟﻌﻡ) ﺩﺭﺠﺔ ﺃﻭﻟﻰ  
  "(.ﻤﻥ ﺍﻟﻌﺎﺌﻠﺔ"ﻗﺭﺍﺒﺔ ﻤﻥ ﺒﻌﻴﺩ ) ﺩﺭﺠﺔ ﺜﺎﻨﻴﺔ  
  .ﻻ ﻴﻭﺠﺩ ﻗﺭﺍﺒﺔ 
 
  ؟ ﻫل ﻴﻌﺎﻨﻲ ﺃﺤﺩ ﺃﻓﺭﺍﺩ ﺃﺴﺭﺘﻙ ﻤﻥ ﺩﺍﺀ ﺍﻟﺴﻜﺭﻯ - 01
  :ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻹﺠﺎﺒﺔ ﻨﻌﻡ ﻓﺤﺩﺩ   ﻻ       ﻨﻌﻡ  
 
  ﺍﻟﻌﻤﺔ /ﺍﻟﻌﻡ   ﺍﻻﺒﻨﺔ /ﺍﻻﺒﻥ     ﺍﻷﺨﺕ/ﺍﻷﺥ    ﺍﻷﻡ     ﺍﻷﺏ  
  ﺔﺍﻟﺨﺎﻟ/ﺍﻟﺨﺎل    ﺍﻟﺠﺩﺓ / ﺍﻟﺠﺩ 
 
  ؟ ﻫل ﺃﻨﺕ ﻤﺩﺨﻥ -11
  ﻻ            ﻨﻌﻡ  
  (ﺃﺸﻬﺭ 6ﺃﻜﺜﺭ ﻤﻥ )ﺘﻭﻗﻑ ﻋﻥ ﺍﻟﺘﺩﺨﻴﻥ  
 
  :ﺍﻟﺸﻴﺸﺔ                                     ﺍﻟﺴﺠﺎﺌﺭ  :    ﻟﻠﻤﺩﺨﻨﻴﻥ
  ......................ﻋﺩﺩ ﻤﺭﺍﺕ ﺍﻟﺘﺩﺨﻴﻥ : .....................            ﻋﺩﺩ ﺍﻟﺴﺠﺎﺌﺭ ﻓﻲ ﺍﻟﻴﻭﻡ
  : ............................ﻤﺩﺓ ﺍﻟﺘﺩﺨﻴﻥ: ..............................             ﻤﺩﺓ ﺍﻟﺘﺩﺨﻴﻥ
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  ؟ ﺨﺭﻯﻫل ﺘﻌﺎﻨﻲ ﻤﻥ ﺃﻤﺭﺍﺽ ﻤﺯﻤﻨﺔ ﺃ -21
  ﻻ          ﻨﻌﻡ  
 
  :ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﺠﺎﺒﺘﻙ ﻨﻌﻡ ﺤﺩﺩ
  ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﺸﺭﻴﺎﻨﻲ             
  (ﺘﺼﻠﺏ ﺍﻟﺸﺭﺍﻴﻴﻥ ﺍﻟﺘﺎﺠﻴﺔ) ﻨﻭﺒﺔ ﻗﻠﺒﻴﺔ     
  ﺃﻤﺭﺍﺽ ﻓﻲ ﺍﻟﺠﻬﺎﺯ ﺍﻟﺘﻨﻔﺴﻲ     
  ﺍﻟﺘﻨﺎﺴﻠﻲ / ﺃﻤﺭﺍﺽ ﻓﻲ ﺍﻟﺠﻬﺎﺯ ﺍﻟﺒﻭﻟﻲ     
  ﺃﻤﺭﺍﺽ ﻓﻲ ﺍﻟﻐﺩﺩ ﺍﻟﺼﻤﺎﺀ    
  (ﺍﻟﻔﺎﻟﺞ ﺍﻟﺸﻘﻲ) ﺍﻟﻨﻭﺒﺔ ﺍﻟﺩﻤﺎﻏﻴﺔ     
  ..........................ﺃﺨﺭﻯ                              
 
  ؟ ﻜﻴﻑ ﺒﺩﺃﺕ ﺍﻟﻌﻼﺝ ﺒﻬﺫﺍ ﺍﻟﻤﺭﺽ -31
   ﺤﻘﻥ ﺒﺎﻷﻨﺴﻭﻟﻴﻥ              "ﺃﻗﺭﺍﺹ"ﻋﻼﺝ ﺩﻭﺍﺌﻲ ﺒﺎﻟﻔﻡ        ﺤﻤﻴﺔ  
  (ﻋﻼﺝ ﺩﻭﺍﺌﻲ+ ﺃﻨﺴﻭﻟﻴﻥ )ﻤﺨﺘﻠﻁ  
 
  :  ﻤﺎ ﻨﻭﻉ ﺍﻟﻌﻼﺝ ﺍﻟﺤﺎﻟﻲ ﺍﻟﺫﻱ ﺘﺄﺨﺫﻩ -41  
   ﺤﻘﻥ ﺒﺎﻷﻨﺴﻭﻟﻴﻥ    "ﺃﻗﺭﺍﺹ"ﻋﻼﺝ ﺩﻭﺍﺌﻲ ﺒﺎﻟﻔﻡ     ﺤﻤﻴﺔ  
  (.ﻋﻼﺝ ﺩﻭﺍﺌﻲ+ ﺃﻨﺴﻭﻟﻴﻥ )ﻤﺨﺘﻠﻁ  
 
ﻴﻁﻠﺏ ﻤﻥ ﺍﻟﻤﺭﻴﺽ ﺃﻥ ﻴﺤﺩﺩ ﺍﻟﺠﺭﻋﺔ ﺍﻟﺩﻭﺍﺌﻴﺔ ﺍﻟﺘﻲ ﻴﺘﻨﺎﻭﻟﻬﺎ ﻓﺈﺫﺍ ﻜﺎﻨﺕ ﻨﻔﺱ ﺍﻟﺨﻁﺔ ﺍﻟﻌﻼﺠﻴـﺔ  -51
  .ﺍﻟﻤﻭﺠﻭﺩﺓ ﻓﻲ ﻤﻠﻔﻪ ﻓﺈﻥ ﺍﻟﻤﺭﻴﺽ ﻤﻠﺘﺯﻡ ﻭﻨﺸﻴﺭ ﺇﻟﻰ ﻤﻠﺘﺯﻡ ﻭﺍﺫﺍ ﻜﺎﻥ ﻏﻴﺭﺫﻟﻙ ﻓﻨﺸﻴﺭﺍﻟﻰ ﻏﻴﺭ ﻤﻠﺘﺯﻡ
  ﻏﻴﺭ ﻤﻠﺘﺯﻡ      ﻤﻠﺘﺯﻡ 
  "71"ﺍﺫﺍ ﻜﺎﻥ ﺍﻟﻤﺭﻴﺽ ﻤﻠﺘﺯﻡ ﺍﻨﺘﻘل ﺇﻟﻰ ﺴﺅﺍل ﺭﻗﻡ 
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  ﻟﻤﺎﺫﺍ ﻟﻡ ﺘﻠﺘﺯﻡ ﺒﺎﻟﻌﻼﺝ ﺤﺴﺏ ﺍﻟﺨﻁﺔ ﺍﻟﻌﻼﺠﻴﺔ ؟ -61
  ﻻ           ﻨﻌﻡ                        .                           ﺒﺴﺒﺏ ﺍﻟﻨﺴﻴﺎﻥ  
  ﻻ           ﻨﻌﻡ                        .                  ﺍﻟﻌﻼﺝ ﻏﻴﺭ ﻤﺘﻭﻓﺭ ﺩﺍﺌﻤﺎﹰ 
  ﻻ           ﻨﻌﻡ                         .        ﺃﺸﻌﺭ ﺒﺎﻟﺘﺤﺴﻥ ﻤﻥ ﺩﻭﻥ ﺍﻟﻌﻼﺝ  
  ﻻ           ﻨﻌﻡ                       .                ﻜﺜﺭﺓ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺃﺘﻨﺎﻭﻟﻬﺎ  
  ﻻ             ﻨﻌﻡ                    .      ﻟﻡ ﺃﻓﻬﻡ ﺍﻟﺨﻁﺔ ﺍﻟﻌﻼﺠﻴﺔ ﺒﺸﻜل ﻭﺍﻀﺢ ﻤﻥ ﺍﻟﻁﺒﻴﺏ 
  ﻻ             ﻨﻌﻡ                      .               ﺃﺨﺸﻰ ﺍﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻠﻌﻼﺝ 
  .............................................................................ﺃﺴﺒﺎﺏ ﺃﺨﺭﻯ 
..................................................................................................
 .........................................................................................
 
 
  ﻫل ﻟﺩﻴﻙ ﻤﻌﻠﻭﻤﺎﺕ ﻋﻥ ﺍﻷﺩﻭﻴﺔ ﺍﻟﺘﻲ ﺘﺄﺨﺫﻫﺎ ﻭﺍﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻬﺎ ؟ -71
  ﻻ         ﻨﻌﻡ  
  :ﺇﺫﺍ ﻨﻌﻡ ﻤﻥ ﺃﻴﻥ ﺤﺼﻠﺕ ﻋﻠﻰ ﻫﺫﻩ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ 
   ﺍﻟﻜﻤﺒﻴﻭﺘﺭ     ﺍﻷﻫل ﺃﻭ ﺍﻟﺠﻴﺭﺍﻥ     ﺍﻟﺘﻤﺭﻴﺽ    ﺍﻟﻁﺒﻴﺏ  
  ﻭﺴﺎﺌل ﺍﻹﻋﻼﻡ                     ﺍﻟﻨﺸﺭﺍﺕ ﺍﻟﺩﻭﺍﺌﻴﺔ 
  ...............................................ﺃﺨﺭﻯ  
 
  ﻤﺎ ﻫﻭ ﻤﻜﺎﻥ ﺼﺭﻑ ﺍﻟﻌﻼﺝ ؟  -81
  .ﻤﺭﻜﺯ ﺼﺤﻲ ﺤﻜﻭﻤﻲ 
  ﻭﻜﺎﻟﺔ  
  .....................................ﺃﺨﺭﻯ 
 
  ﻫل ﻴﺘﻭﻓﺭ ﻋﻼﺝ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺍﻟﻤﻭﺼﻭﻑ ﻟﻙ ﻓﻲ ﺍﻟﻤﺭﻜﺯ ﺍﻟﺼﺤﻲ ؟  -91
  ﻻ ﻴﺘﻭﻓﺭ                  ﻨﻌﻡ ﺃﺤﻴﺎﻨﺎﹰ             ﻨﻌﻡ ﺩﺍﺌﻤﺎﹰ                  
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  ﺇﺫﺍ ﻟﻡ ﻴﺘﻭﻓﺭ ﻋﻼﺝ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻓﻤﻥ ﺃﻴﻥ ﺘﺤﺼل ﻋﻠﻴﻪ ؟ -02
  (.ﺃﺨﺭﻯ               ﻭﻜﺎﻟﺔ           ﺤﻜﻭﻤﺔ               :    )  ﻤﻥ ﻤﺭﻜﺯ ﺼﺤﻲ ﺁﺨﺭ 
  ﻤﻥ ﺼﻴﺩﻟﻴﺔ ﺨﺎﺼﺔ  
  ﺃﺴﺘﻌﻤل ﻋﻼﺝ ﺃﺤﺩ ﺍﻷﻗﺎﺭﺏ 
  ﺃﺒﻘﻰ ﺒﺩﻭﻥ ﻋﻼﺝ  
  ..........................................ﺃﺨﺭﻯ 
 
ﺩﻭﻥ  ﺀﺃﻭ ﺍﻷﺼـﺩﻗﺎ  لﻫل ﺘﺴﺘﻌﻤل ﺃﺩﻭﻴﺔ ﻟﻌﻼﺝ ﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻗﺩ ﺘﻡ ﻭﺼﻔﻬﺎ ﻟﻠﺠﻴـﺭﺍﻥ ﺃﻭ ﺍﻷﻫ  ـ -12
 ﺍﻟﺭﺠﻭﻉ ﻟﻠﻁﺒﻴﺏ ؟
  ﻻ        ﺃﺤﻴﺎﻨﺎﹰ                        ﻨﻌﻡ  
 
  ﺍﻵﻥ ﺃﺩﻭﻴﺔ ﻷﻤﺭﺍﺽ ﻤﺯﻤﻨﺔ ﻏﻴﺭ ﺃﺩﻭﻴﺔ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ؟ ﻫل ﺘﺘﻨﺎﻭل  -22
  ﻻ                               ﻨﻌﻡ  
  ............................................ﺇﺫﺍ ﻨﻌﻡ ﺤﺩﺩ ﻋﺩﺩﻫﺎ 
 
  ﻭﻓﺔ ﻟﻙ ﻭﻓﻲ ﺍﻟﻤﻭﺍﻋﻴﺩ ﺍﻟﻤﺤﺩﺩﺓ ﻟﻬﺎ ؟ﻫل ﺘﺘﻨﺎﻭل ﺃﺩﻭﻴﺔ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﺒﺎﻟﺠﺭﻋﺎﺕ ﺍﻟﻤﻭﺼ -32
  ﻻ     ﺃﺤﻴﺎﻨﺎﹰ        ﻨﻌﻡ  
 
  ﺇﺫﺍ ﻟﻡ ﺘﺘﻨﺎﻭل ﺃﺤﺩ ﺍﻟﺠﺭﻋﺎﺕ ﻓﻲ ﻤﻭﻋﺩﻫﺎ ﻓﻬل ﺘﺄﺨﺫﻫﺎ ﻓﻴﻤﺎ ﺒﻌﺩ ؟ -42
  ﻨﻌﻡ ﻗﺒل ﺍﻟﻨﻭﻡ      ﻨﻌﻡ ﻤﻊ ﺍﻟﺠﺭﻋﺔ ﺍﻟﺘﺎﻟﻴﺔ      ﻨﻌﻡ ﻓﻭﺭﺍﹰ  
  ﻻ ﺃﺘﻨﺎﻭﻟﻬﺎ 
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  ﻜﻴﻑ ﺘﺘﺫﻜﺭ ﻤﻭﻋﺩ ﺃﺨﺫ ﺍﻟﺠﺭﻋﺎﺕ ؟ -52
  ﺒﺎﻻﻋﺘﻤﺎﺩ ﻋﻠﻰ ﺍﻟﻨﻔﺱ  
  ﻋﻠﻰ ﺍﻵﺨﺭﻴﻥ ﺒﺎﻻﻋﺘﻤﺎﺩ  
  ﺒﺎﺴﺘﻌﻤﺎل ﺍﻟﻤﻨﺒﺔ 
  ﻋﻠﻰ ﺍﻟﺘﺴﺎﻫﻴل  
  .........................................ﻏﻴﺭ ﺫﻟﻙ   
 
ﺭﻱ ﻓﻲ ﺤﺎﻟﺔ ﺍﻨﺘﻅﺎﻡ ﻤﺴﺘﻭﻯ ﺍﻟﺴﻜﺭ ﻓﻲ ﺍﻟﺩﻡ ﻋﻨﺩﻙ ﻭﺘﺤﺴﻥ ﺼﺤﺘﻙ ﻤﻥ ﺃﻋﺭﺍﺽ ﺍﻟـﺩﺍﺀ ﺍﻟﺴـﻜ  -62
  -:ﺍﻟﺘﻲ ﻜﻨﺕ ﺘﻌﺎﻨﻲ ﻤﻨﻬﺎ، ﻫل ؟ 
  ﺘﺴﺘﻤﺭ ﻓﻲ ﺃﺨﺫ ﺍﻟﻌﻼﺝ ﺒﺎﻨﺘﻅﺎﻡ  
  ﺘﺨﻔﺽ ﺍﻟﺠﺭﻋﺔ  
  ﺘﺘﻭﻗﻑ ﻋﻥ ﺍﺴﺘﻌﻤﺎل ﺍﻟﻌﻼﺝ  
  ﺘﺴﺘﺸﻴﺭ ﺍﻟﻁﺒﻴﺏ 
  .........................................................................ﺃﺨﺭﻯ ﺤﺩﺩ   
 ..........................................................................................
  
  ﻫل ﺘﺸﻌﺭ ﺃﻨﻙ ﻗﺩ ﻻ ﺘﻜﻭﻥ ﺒﺤﺎﺠﺔ ﻟﺘﻨﺎﻭل ﺍﻟﻌﻼﺝ ؟ -72
  ﻻ      ﺃﺤﻴﺎﻨﺎﹰ               ﻨﻌﻡ  
 
  ﻫل ﺘﺸﻌﺭ ﺃﻨﻙ ﻻ ﺘﺭﻏﺏ ﻓﻲ ﺘﻨﺎﻭل ﺍﻟﻌﻼﺝ ؟ -82
  ﻻ     ﺃﺤﻴﺎﻨﺎﹰ               ﻨﻌﻡ  
  ﻌﻡ ﻓﻤﺎ ﻫﻭ ﺍﻟﺴﺒﺏ ؟ﺇﺫﺍ ﻨ 
  ﻟﻭﺠﻭﺩ ﺃﻋﺭﺍﺽ ﺠﺎﻨﺒﻴﺔ ﻋﻨﺩ ﺘﻌﺎﻁﻲ ﺍﻟﺩﻭﺍﺀ  
  ﺍﻟﺨﻭﻑ ﻤﻥ ﺍﻷﻋﺭﺍﺽ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻟﻠﺩﻭﺍﺀ ﻓﻲ ﺍﻟﻤﺴﺘﻘﺒل 
  ﺍﻟﺨﻭﻑ ﻤﻥ ﺍﻹﺩﻤﺎﻥ ﻋﻠﻰ ﺘﻌﺎﻁﻲ ﺍﻟﺩﻭﺍﺀ  
  ﻟﺜﻘﺔ ﻓﻲ ﺍﻷﺩﻭﻴﺔ ﺍﻟﻤﻭﺠﻭﺩﺓ ﻓﻲ ﺍﻟﻤﺭﻜﺯ ﺍﻟﺼﺤﻲ ﻋﺩﻡ ﺍ 
  ...........................................................................ﺁﺨﺭﻯ   
......................................................................................
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  .ﺘﺤﺘﺎﺝ ﺇﻟﻰ ﻓﺘﺭﺓ ﺭﺍﺤﺔ ﻻ ﺘﺴﺘﻌﻤل ﻓﻴﻬﺎ ﺍﻟﻌﻼﺝ ؟ ﻋﻠﻤﺎﹰ ﺒﺄﻨﻙ ﻁﺒﻴﺎﹰ ﻓﻲ ﺤﺎﺠﺔ ﺇﻟﻴﻪ ﻫل ﺘﺸﻌﺭ ﺒﺄﻨﻙ -92
  ﻻ         ﻨﻌﻡ  
 
  ﻫل ﺘﻌﺎﻟﺞ ﺒﺎﻷﻨﺴﻭﻟﻴﻥ؟ -03
  ﻻ         ﻨﻌﻡ  
  (63)ﺍﻨﺘﻘل ﺇﻟﻰ ﺴﺅﺍل ﺭﻗﻡ  ﻹﺠﺎﺒﺔ ﻻﺇﺫﺍ ﻜﺎﻨﺕ ﺍ
  -:ﺇﺫﺍ ﻜﻨﺕ ﺘﻌﺎﻟﺞ ﺒﺎﻷﻨﺴﻭﻟﻴﻥ
 
  ﻤﻥ ﻴﻘﻭﻡ ﺒﺈﻋﻁﺎﺌﻙ ﺍﻟﺤﻘﻥ؟ -13
  ﺃﺤﺩ ﺃﻓﺭﺍﺩ ﺍﻷﺴﺭﺓ       ﺒﻨﻔﺴﻙ                                         
  ﺃﺫﻫﺏ ﺇﻟﻰ ﺍﻟﻌﻴﺎﺩﺓ      ﻟﻴﺔ ﺨﺎﺼﺔ                    ﺃﺫﻫﺏ ﺇﻟﻰ ﺼﻴﺩ  
  ......................................................ﻏﻴﺭ ﺫﻟﻙ   
 
  ﺇﺫﺍ ﻜﺎﻨﺕ ﺇﺠﺎﺒﺘﻙ ﺒﻨﻔﺴﻙ، ﻫل ﺘﻡ ﺘﺩﺭﻴﺒﻙ ﻋﻠﻰ ﺫﻟﻙ؟ -23
  ﻻ         ﻨﻌﻡ  
 ﺇﺫﺍ ﻜﺎﻥ ﻨﻌﻡ، ﻤﻥ ﻗﺎﻡ ﺒﺘﺩﺭﻴﺒﻙ؟
  ﺘﻡ ﺘﺩﺭﻴﺒﻲ ﻓﻲ ﺍﻟﻤﺭﻜﺯ ﺍﻟﺼﺤﻲ                     
  ﺍﻷﻫل ﺃﻭﺍﻷﻗﺎﺭﺏ                       
  ....................................................ﻏﻴﺭ ﺫﻟﻙ   
 
  ﺇﺫﺍ ﻜﺎﻥ ﻤﻥ ﻴﻌﻁﻴﻙ ﺍﻷﻨﺴﻭﻟﻴﻥ ﺃﺤﺩ ﺃﻓﺭﺍﺩ ﺍﻷﺴﺭﺓ ﻓﻬل ﺘﻡ ﺘﺩﺭﻴﺒﻙ ﻋﻠﻰ ﺫﻟﻙ؟ -33
  ﻻ         ﻨﻌﻡ  
 
 ﺇﺫﺍ ﻨﻌﻡ ﻤﻥ ﻗﺎﻡ ﺒﺘﺩﺭﻴﺒﻪ؟
  ﺍﻟﻤﺭﻜﺯ ﺍﻟﺼﺤﻲ              ﺘﻡ ﺘﺩﺭﻴﺒﻪ ﻓﻲ    
                               ﺏﺍﻷﻫل ﺃﻭ ﺍﻷﻗﺎﺭ 
  ................................................ﻏﻴﺭ ﺫﻟﻙ  
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  ﻫل ﺘﻌﺘﻘﺩ ﺃﻨﻪ ﻤﻥ ﺍﻟﻀﺭﻭﺭﻱ ﺘﻨﺎﻭل ﺍﻟﻁﻌﺎﻡ ﺒﻌﺩ ﺍﻟﺤﻘﻥ ﺒﺎﻷﻨﺴﻭﻟﻴﻥ؟ -43
  ﻻ         ﻨﻌﻡ  
 
  -:ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻟﺠﺎﺒﺔ ﻨﻌﻡ ﻓﻬل -53
  .ﺘﺘﻨﺎﻭل ﺍﻟﻁﻌﺎﻡ ﻤﺒﺎﺸﺭﺓ ﺒﻌﺩ ﺍﻟﺤﻘﻥ  
  .ﺘﺘﻨﺎﻭل ﺍﻟﻁﻌﺎﻡ ﻤﺒﺎﺸﺭﺓ ﺒﻌﺩ ﻨﺼﻑ ﺴﺎﻋﺔ  
  .ﺘﺘﻨﺎﻭل ﺍﻟﻁﻌﺎﻡ ﻤﺒﺎﺸﺭﺓ ﺒﻌﺩ ﺴﺎﻋﺔ  
  ...............................................ﺃﻜﺜﺭ ﻤﻥ ﺫﻟﻙ ﺤﺩﺩ   
 
 
  :ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻷﻤﺭﺍﺽ ﺍﻟﺘﻲ  -63
  ﻴﻤﻜﻥ ﺍﻟﺸﻔﺎﺀ ﻤﻨﻬﺎ ﺘﻤﺎﻤﺎﹰ 
  ﻟﺸﻔﺎﺀ ﻤﻨﻬﺎ ﺘﻤﺎﻤﺎﹰ ﻻ ﻴﻤﻜﻥ ﺍ 
  ﻻ ﺃﻋﺭﻑ  
  
  ﻫل ﺘﻌﺘﻤﺩ ﻋﻠﻰ ﺍﻟﻭﺼﻔﺎﺕ ﺍﻟﺸﻌﺒﻴﺔ ﻓﻲ ﻋﻼﺝ ﺍﻟﺴﻜﺭﻱ ؟ -73
  ﻨﻌﻡ  
  ﺴﺎﺒﻘﺎﹰ  
  ﻟﻡ ﺃﺘﻨﺎﻭﻟﻬﺎ ﻤﻁﻠﻘﺎ 
 
ﻌﺒﻴﺔ ﻫل ﻜﻨﺕ ﺘﺘﻭﻗﻑ ﻋﻥ ﺃﺨﺫ ﺍﻟﻌﻼﺝ ﺍﻟﻤﻭﺼﻭﻑ ﻟﻙ ﻓﻲ ﺍﻟﻤﺭﻜـﺯ ﻓﻲ ﺤﺎل ﺘﻨﺎﻭل ﺍﻟﻭﺼﻔﺎﺕ ﺍﻟﺸ -83
 ﺍﻟﺼﺤﻲ ؟
  ﻻ        ﻨﻌﻡ  
 
  ﻫل ﺘﻌﺘﻘﺩ ﺃﻥ ﻤﻤﺎﺭﺴﺔ ﺍﻟﺭﻴﺎﻀﺔ ﻗﺩ ﺘﻔﻴﺩﻙ ﻓﻲ ﻋﻼﺝ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻋﻨﺩﻙ ؟ -93
  ﻻ        ﻨﻌﻡ  
 
  ﻫل ﺘﻤﺎﺭﺱ ﺍﻟﺭﻴﺎﻀﺔ؟ -04
  ﻻ                ﻨﻌﻡ  
 ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻹﺠﺎﺒﺔ ﻨﻌﻡ
  ................................................................: ﻤﺎ ﻨﻭﻉ ﺍﻟﺭﻴﺎﻀﺔ ﺍﻟﺘﻲ ﺘﻤﺎﺭﺴﻬﺎ
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  :ﺴﺔﻤﺎ ﻫﻲ ﻜﻴﻔﻴﺔ ﺍﻟﻤﻤﺎﺭ -14
  ( ﺃﺴﺒﻭﻋﻴﺎﹰ ﺃﻭ ﺃﻜﺜﺭ/ ﺃﻴﺎﻡ 3ﻴﻘﻭﻡ ﺒﺎﻟﺭﻴﺎﻀﻴﺔ )  
  (.ﺃﺴﺒﻭﻋﻴﺎﹰ / ﺃﻴﺎﻡ 3ﻴﻘﻭﻡ ﺒﺎﻟﺭﻴﺎﻀﻴﺔ ﺃﻗل ﻤﻥ )  
 
  ﻫل ﺘﺘﺒﻊ ﻨﻅﺎﻡ ﺤﻤﻴﺔ ﻤﻌﻴﻥ ؟ -24
  ﻻ       ﻨﻌﻡ  
  ﻨﺕ ﺍﻹﺠﺎﺒﺔ ﻨﻌﻡ ﻤﻥ ﺃﻴﻥ ﺤﺼﻠﺕ ﻋﻠﻰ ﻨﻅﺎﻡ ﺍﻟﺤﻤﻴﺔ؟ﺇﺫﺍ ﻜﺎ
  ﺍﻷﻫل ﺃﻭ ﺍﻷﻗﺎﺭﺏ   ﻨﺸﺭﺍﺕ ﺘﻭﻋﻴﺔ ﺨﺎﺼﺔ    ﻤﻥ ﺍﻟﺘﻤﺭﻴﺽ     ﻤﻥ ﺨﻼل ﻤﻘﺎﺒﻠﺔ ﺍﻟﻁﺒﻴﺏ   
  .............................................................ﻏﻴﺭ ﺫﻟﻙ ﺤﺩﺩ    
 
 
 
  ﻫل ﺃﻨﺕ ﻤﻠﺘﺯﻡ ﺒﻤﻭﺍﻋﻴﺩ ﺯﻴﺎﺭﺓ ﻁﺒﻴﺏ ﺍﻟﻌﻴﺎﺩﺓ ﻜﻤﺎ ﻫﻭ ﻤﺤﺩﺩ ﻟﻙ ؟ -34
  ﻻ        ﻨﻌﻡ  
 ﺇﺫﺍ ﻜﺎﻨﺕ ﺍﻻﺠﺎﺒﻪ ﻻ ﻓﺎﺫﻜﺭ ﺍﻟﺴﺒﺏ 
  ﺍﻟﺨﻭﻑ ﻤﻥ ﺃﻋﺭﺍﺽ ﻨﻘﺹ ﺍﻟﺴﻜﺭ ﻋﻨﺩﻱ  ﻤﺩﺓ ﺍﻹﻨﺘﻅﺎﺭ ﻁﻭﻴﻠﺔ     ﺍﻟﻌﻼﺝ ﻏﻴﺭ ﻤﺘﻭﻓﺭ  
  ﺍﻟﻁﺒﻴﺏ ﻻ ﻴﻌﻴﺭﻨﻲ ﺍﻫﺘﻤﺎﻤﻪ ﺒﺸﻜل ﺠﻴﺩ          ﺍﻟﻁﺒﻴﺏ ﻗﺩ ﻻ ﻴﺄﺘﻲ ﺩﺍﺌﻤﺎﹰ                    
  .............................................................ﺃﺴﺒﺎﺏ ﺃﺨﺭﻯ ﺤﺩﺩ  
 
  ﻫل ﻴﻭﺠﺩ ﻤﻀﺎﻋﻔﺎﺕ ﻋﻨﺩﻙ ﻨﺘﻴﺠﺔ ﺍﻟﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ؟ -44
  ﻻ ﺃﻋﺭﻑ                ﻻ       ﻨﻌﻡ  
 ﺇﺫﺍ ﻨﻌﻡ ﺤﺩﺩ
  ........................................ﺍﻟﻌﻴﻭﻥ  
  .........................................ﺍﻟﻜﻠﻰ  
  .........................................ﺍﻟﻘﺩﻡ  
  (ﺘﺼﻠﺏ ﺍﻟﺸﺭﺍﻴﻴﻥ ﺍﻟﺘﺎﺠﻴﺔ)ﻨﻭﺒﺔ ﻗﻠﺒﻴﺔ        ﺇﻋﺘﻼل ﺍﻷﻋﺼﺎﺏ ﺍﻟﺤﺴﻴﺔ                 
  ..........................ﺍﺨﺭﻯ   (ﺘﺼﻠﺏ ﺍﻟﺸﺭﺍﻴﻴﻥ ﺍﻟﺩﻤﺎﻏﻴﺔ)ﻓﺎﻟﺞ ﺩﻤﺎﻏﻲ  
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  ؟ (ﺍﻟﺠﻠﻭﻜﻭﻤﻴﺘﺭ)ﻫل ﺘﻘﻭﻡ ﺒﻔﺤﺹ ﻤﺴﺘﻭﻯ ﺴﻜﺭ ﺍﻟﺩﻡ ﺒﻨﻔﺴﻙ ﻋﻥ ﻁﺭﻴﻕ ﺠﻬﺎﺯ ﻓﺤﺹ ﺴﻜﺭ ﺍﻟﺩﻡ  -54
  ﻻ       ﻨﻌﻡ                 
  :ﺴﻜﺮ ﰲ ﺍﻟﺪﻡﻓﻬﻞ ﺗﻘﻮﻡ ﺑﻔﺤﺺ ﻣﺴﺘﻮﻯ ﺍﻟ,ﺍﺫﺍ ﻛﺎﻧﺖ ﺍﻻﺟﺎﺑﺔ ﻧﻌﻢ
............................. ﺍﺨﺭﻯ      ﺸﻬﺭﻴﺎ       ﺃﺴﺒﻭﻋﻴﺎ        ﻴﻭﻤﻴﺎ                  
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 ﻣﻌﻠﻮﻣﺎﺕ ﻣﻦ ﻣﻠﻒ ﺍﳌﺮﻳﺾ 
   
  : .............................ﺍﻟﺴﻜﺭ ﺭﻗﻡ ﻤﻠﻑ
  ...........................(:ﺒﺎﻟﺴﻨﺔ)ﺍﻟﻤﺩﺓ....................  ﺴﻨﺔ ﺍﻜﺘﺸﺎﻑ ﺍﻟﻤﺭﺽ 
....................................................................   :ﺍﻟﺨﻁﺔ ﺍﻟﻌﻼﺠﻴﺔ
  
......................................................................................
 .....................................................................................
  :ﻤﻥ ﺘﺎﺭﻴﺦ ﺍﺨﺭ ﺯﻴﺎﺭﺓ ﻟﻌﻴﺎﺩﺓ ﺍﻟﺴﻜﺭ   )SBF(ﺁﺨﺭ ﻗﺭﺍﺀﺘﻴﻥ ﻟﺘﺤﻠﻴل ﺴﻜﺭﺍﻟﺩﻡ ﺍﻟﺼﻴﺎﻤﻲ 
  ....................  ld/gm      ..................ld/gm     
 
ﻓﻲ ﺍﻟﺩﻡ ﺨﻼل ﺴﻨﻪ ﻤﻥ ﺘـﺎﺭﻴﺦ ﺍﺨـﺭ (  clAbH )ﺁﺨﺭ ﻗﺭﺍﺀﺘﻴﻥ ﻟﺘﺤﻠﻴل ﻤﺨﺯﻭﻥ ﺍﻟﺴﻜﺭ 
  :ﺯﻴﺎﺭﺓ ﻟﻌﻴﺎﺩﺓ ﺍﻟﺴﻜﺭ
 ...........................   ........................
 ﻓﻲ ﺍﻟﺩﻡ ﺨﻼل ﺴﻨﻪ ﺘﺤﻠﻴل ﻤﺴﺘﻭﻯ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻭ ﺍﻟﺩﻫﻭﻥ ﺍﻟﺜﻼﺜﻴﻪﻟ ﺁﺨﺭ ﻗﺭﺍﺀﺘﻴﻥ
                ld/gm………GT  .……:loretselohc latoT
              ld/gm ………GT  .……:loretselohc latoT  
          
  (ﺍﺭﺒﻊ ﻗﺭﺍﺀﺕ ﺨﻼل ﺍﻟﺴﻨﻪ)ﻗﻴﺎﺱ ﻀﻐﻁ ﺍﻟﺩﻡ 
    gHmm               ………PB  ………PB  ………PB   ……   PB
  .................... gk    : ﺍﻟﻭﺯﻥ
 ......................mc  : ﺍﻟﻁﻭل
  ................... 2m/gk: IMB
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Non – Compliance in type 2  Diabetes 
Patient – questionnaire 
 
Data from patients Questioning 
 
1- Sex     Male    Female  
 
2- Marital Status   single   Married 
Widow   Divorced 
 
3-    Age …………………….. 
 
4-    Address ……………………. 
 
5-    Occupation   work    Didn’t work 
• If work: 1- Profesional (physician , lawyer, accountant,chemist.….) 
     2- Managerial (manager, headmaster, teacher, … ) 
    3- Marcher. 
    4- Skilled worker (chief worker, chief, groceryer, printer 
…). 
    5- Partly skilled (telephone worker, fruit worker, …). 
    6- Unskilled worker (cleaner). 
    7- Unemployed. 
        8- House wife. 
6- Years of education …………………………………………………... 
 
7- Number of family members………………………………………….. 
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8- Family income 
< 1000 NS    1000-2000 NS 
> 2000 NS    Refuse the answer 
9- Consanguinity 
        First degree    Second degree   No 
10- Have any one in your family ever had diabetes? 
   Yes    No 
• If yes: 
Father   Mother   Brother/sister 
Son/daughter  uncle    grandfather 
11- Smoking 
  Yes    No 
                    Stop smoking (for more than 6 months). 
• For smokers: - No. of cigarette ……………… 
                  - Duration …………………….. 
12- Associated chronic diseases 
  Yes    No 
* If yes: 
 Hypertension 
 Ischemic Heart Disease. 
 Respiratory Diseases. 
 Endocrine Disease. 
 Stroke. 
 Others. 
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13- How did you start your treatment? 
 Diet   Doanil  Insulin  Mixed 
14- What is your treatment now? 
 Diet   Doanil  Insulin  Mixed 
15- Are you compliant ( the patient was asked to mention his/her 
management plan, and it was compared with the management plan which 
had been written in his/her file). 
  Yes    No 
• If compliant, go to question 17 
16- Why not compliant? 
Forgetfulness     yes             No 
Drug is not always available   yes    No 
 Feel better without treatment          yes No 
           Polypharmacy                                yes No 
           Could not understand the               yes No 
           management plan. 
          Fear from drug side-effect             yes No 
          Others                                             yes No 
17- Do you have information about the medicines you are using and their 
side effects? 
  Yes    No 
*If yes: From Where did you get this medicine information? 
Physician    pharmacist 
Relatives    Neighbors 
Media    Others. 
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18- From where do you get your medicine (the anti – diabetic drug)? 
 UNRWA.                                  Governmental health center 
 Others. 
19- Is the anti-diabetic drug you are using available at the health center 
(Governmental) 
Yes always   Yes, some times       Not available 
20- If not available, where do you get the drug from? 
 another health center.  
 private pharmacy. 
 I use drugs from relatives. 
 I remain with out treatment. 
 Others. 
21- Do you use drugs for diabetes that has been prescribed to relatives or 
neighbors? 
 Yes, always.  
 Yes, sometimes. 
 NO. 
22- Are you taking drugs for other chronic diseases? 
  Yes    No 
23- Do you take the anti diabetic drugs regularly as prescribed? 
 Yes    sometimes   No 
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24- If you miss a dose of anti diabetic drugs, do you take them later on? 
 Yes, immediately. 
 Yes, with the next dose. 
 Yes, at bed time. 
 I don’t take it. 
25- How do you remember the time for drugs administration? 
self reliance   Relying others 
using an alarm   No particular method 
26- In case of improvement (from DM), you? 
 Continue taking the drug 
 Decrease the dose 
 Stop the drug. 
 Consult the physician. 
 Others ……….. 
27- Do you feel that you do not like to take the drug? 
 Yes    sometimes   No 
28- Do you belief that you need the treatment? 
 Yes    sometimes   No 
• If yes, what is the cause? 
Because of drug side-effects. 
 Fear from drug side-effect in future. 
 Fear of dependence. 
 No confidence with medicines. 
 Others ……….. 
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29- Do you feel that you want to take a period of rest from medicine? 
  Yes    No 
30- Do you take Insulin? 
  Yes    No 
• If No, shift to question no. (36) 
31- Who give you the injection? 
myself    member of the family 
I go to pharmacy   go to the health center 
others 
32- Are you trained for insulin injection?  
  Yes    No 
• If yes, who trained you? 
I had trained in the center. 
 I had trained by other member in the family. 
 Others . 
33- If a member of your family give you the injection, is he trained? 
  Yes    No 
• If yes, who trained him 
In the health center. 
 Others. 
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34- Do you think, it is necessary to eat after insulin injection? 
  Yes    No 
35- If yes:  
 De you eat directly after the injection. 
 Do you eat after an hour. 
 More than an hour 
36- Diabetes is: 
 A curable disease 
 Partially curable disease. 
 I don’t know 
37- Do you depend on traditional remedies?  
 Yes 
 Yes, in the past. 
 Never use it. 
38- In case of depending on traditional remedies, do you stop treatment? 
  Yes    No 
39- Do you think that practicing exercise is useful for the control of 
diabetes?  
  Yes    No 
40- Do you practice any exercise? 
  Yes    No 
41- How often do you practice exercise? 
 >= 3days / week 
 < 3days / week 
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42- Do you follow any diet regimen? 
  Yes    No 
43- Do you respect your clinic appointment? 
  Yes    No 
* If no, mention the cause 
 Drug is not available 
 Increase waiting time 
 Fear of hypoglycemia 
 Physician don’t come regularly 
 Physician don’t give me his care. 
 others 
 44- Do you have any complication?  
 Yes    No    I don’t know 
• If yes, 
Retinopathy . 
 Renal disease. 
 Diabetic foot. 
 Neurological disease. 
 IHD. 
 Stroke. 
 Others. 
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45- Do you measure your blood sugar by your self? 
  Yes    No 
• If yes, how often 
Daily     Weekly 
Monthly    Others 
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Information from Patient file 
  
a. No. of file ………………… 
b. Date of diabetes discovery ………………… 
c. Duration ……………….. 
d. Management plan ………………………………………… 
- Last two reading of FBS during the last year 
………………….. mg/dl   …………………... mg/dl  
- Last  two reading of (HBAIC) during the last year 
 ………………………………………………………… 
Last two reading of total cholesterol and triglyceridemia during the last 
year  
Chol …………….   TG ………………… 
Chol …………….   TG ………………… 
- BP ………… ……………. ……………….. …………… 
- weight: ……………… 
- Hight ………………... 
- BMI ……………….... 
 
  
 
 186
 
 
 
 
